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Abstract 
 
The United Kingdom Asian Diabetes Study (UKADS) is a large community based 
cluster randomised controlled trial designed to evaluate a culturally sensitive 
intervention to reduce cardiovascular risk in south Asians with type 2 diabetes. The 
study was conducted over a 2 year period and involved 21 General Practices in 
Coventry and Birmingham. Two major components of the UKADS trial –the clinical 
intervention (chapters 2,3 and4 ) and the genetic characterization for type 2 diabetes 
susceptibility genes (chapters 5 to 8) are presented in this thesis.  
 
Over a 2 year period there were significant improvements in mean arterial and diastolic 
blood pressures in the intervention group that included additional practice nurse time, 
asian link workers and specialist diabetes nurse input. The intervention, however, had 
no effect on total cholesterol or glycaemic control. Prescription of statins and anti-
hypertensives increased significantly during the study period with a greater proportion 
of subjects in both groups achieving General Practice targets for blood pressure and 
cholesterol.  
 
Genetics studies for association with type 2 diabetes showed a strong association with 
the common polymorphisms of the TCF7L2 gene. Studies for associations with other 
susceptibility genes with small effect sizes (PPARG, PPARG1A, CALPAIN10 ) were 
not adequately powered to detect possible associations. 
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Chapter 1: Introduction to Diabetes 
 
 
1.1 History of Diabetes 
 
 
The earliest recorded descriptions of ‘Diabetes’ as a metabolic disorder date back 
to 1550 BC(1). A polyuric condition that fits the modern day description of 
diabetes was recorded in Ebers Papyrus and the sweet taste of urine in patients 
with diabetes was described in the work of two Indian physicians, Charak and 
Susrut, around 500BC(1). Charak and Susrut also described two main types of 
diabetes- one that was ‘prevalent in obese and the indolent’ and the other ‘more 
serious condition that was difficult to treat’ and needed “nourishing diet”. The 
name ‘Diabetes’ itself is derived from the Greek word for ‘Siphon’ and the word 
‘Mellitus’( meaning ‘sweet’) was added subsequently to distinguish it from 
another polyuric condition, ‘Diabetes Insipidus’, in which the urine was tasteless. 
Much of our current understanding of diabetes, however, has progressed with 
various observations made since the beginning of the 17th century(1).  
 
Several periods could be identified as major landmarks in our understanding of 
diabetes. These include the description of hyperglycaemia by Matthew Dobson in 
1776 (2), glucose metabolism by Claude Bernard(3) and linking diabetes to the 
internal secretion of the pancreas by Osker Minkowski and Josef von Mering (4). 
A significant development was the discovery of islet cells by Paul Langerhans (5). 
This was followed by an intensive search for insulin, culminating in its discovery 
by Banting and Best in 1921(6) and the eventual identification of insulin sequence 
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by Frederick Sanger in 1955 (7). Over the last 50 years, there has been a better 
understanding of the epidemiology of diabetes, its classification and the role of 
hyperglycaemia in the causation of micro- and macrovascular complications of 
diabetes (8;9).  
 
Simultaneously, there have been major advances in the development of new oral 
agents, insulin analogues and drug delivery techniques for diabetes. Despite these 
developments, management of diabetes still remains a formidable challenge. 
 
1.2 Diagnosis of Diabetes 
 
 
The original criteria for diagnosis of diabetes were recommended by the World 
Health Organisation (WHO) in 1965 and a cut-off value of fasting blood glucose 
greater than 7.2mmol/L was used for diagnosis(10). This criterion was revised 
subsequently in 1980, 1985 and in 1999(11). In addition to the criteria proposed 
by WHO, a separate diagnostic criterion was proposed by the National Diabetes 
Data Group in 1979 (12), which also introduced the terms “non-insulin dependent 
diabetes mellitus” (NIDDM) and “insulin dependent diabetes mellitus” (IDDM) to 
distinguish the two main types of diabetes, along with the category “impaired 
glucose tolerance”. In 1997, the American Diabetes Association (ADA) revised 
the criteria for diagnosis of diabetes and lowered the cut-off for fasting blood 
glucose to 7mmol/L from previous 7.8mmol/L and also introduced a new category 
called “impaired fasting glucose” (IFG) for those with fasting glucose between 6 
and 6.9mmol/L(11). In 2003, the ADA lowered the cut-off value of IFG to 
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5.6mmo/L based on Pima Indian, San Antonio, Mauritius and Hoorn study data 
(13). This recommendation was, however, not accepted by the WHO, which kept 
the cut-off level for IFG at ≥ 6.1mmol/L. On the whole, the current criteria for 
diagnosis of diabetes as recommended by the WHO and the ADA are similar, 
although ADA appears to place greater emphasis on the fasting blood sugar 
(Table1.1). 
 
 The current WHO recommendations for the diagnosis of diabetes are: 
Fasting glucose > 7mmol/L (126mg/dL)     OR 
2 Hour glucose >  11mmol/L ( 200mg/dL) with symptoms or confirmed on a 
repeat measurement (on OGTT) in the absence of symptoms. 
 
The intermediate groups at risk of diabetes were defined as 
     a) Impaired Glucose Tolerance (IGT) when the 2 hour glucose value is 
>7.8mmol/L and <11mmol/L      AND 
    b)  Impaired Fasting Glucose (IFG) when fasting glucose is between 6.1 
mmol/L and 6.9mmol/L 
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Table 1.1: Diagnostic criteria for Diabetes, IFG and IGT as per WHO and 
ADA. 
 
 WHO 1999    ADA 2003 
Diabetes 
Fasting glucose 
2 hr glucose 
 
≥ 7.0 mmol/L    or 
≥ 11.1mmol/L 
 
≥ 7.0mmol/L or 
≥ 11.1mmol/L 
IGT 
Fasting glucose 
2 hr glucose 
 
< 7mmol/L (if measured) 
and 
 ≥ 7.8 and < 11.1mmol/L 
 
Not required 
≥ 7.8 and < 11.1mmol/L 
IFG 
Fasting glucose 
2 hr glucose 
 
6.1 to 6.9mmol/L 
             --- 
 
5.6 to 6.9mmol/L 
         ------ 
 
 
1.3 Diabetes Classification 
 
 
In 1980, the WHO published the first classification of diabetes mellitus. This was 
subsequently modified in 1985(14). Both the 1980 and 1985 classifications 
included clinical classes and two statistical risk classes. In the 1980 classification, 
two major classes of diabetes were introduced and named “Type 1 diabetes” or 
“IDDM” and “Type 2 diabetes” or “NIDDM”. The terms “Type 1” and “Type 2” 
were omitted in the classification in 1985 and a new class of diabetes- 
malnutrition related diabetes mellitus (MRDM)- was introduced. Both 
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classifications included gestational diabetes and impaired glucose tolerance. The 
new classification of diabetes was proposed in 1998 following collaboration 
between the WHO and ADA expert groups(13;15). Diabetes is classified into four 
major groups – Type 1 diabetes, Type 2 Diabetes, other specific types and 
gestational diabetes (Table 1.2).  Of these Type 1 diabetes accounts for nearly 5% 
of the cases while a greater proportion of the remainder (85-95%) is Type 2 
diabetes(13).  
 
Type 1 diabetes mellitus (IDDM or juvenile diabetes) is characterized by 
autoimmune beta cell destruction resulting in absolute insulin deficiency. The 
onset is usually acute, with symptoms progressing over a period of a few days to 
weeks(13). Over 95 percent of persons with type 1 diabetes mellitus develop the 
disease before the age of 25, with an equal incidence in both sexes and 
proportionately more common in the white population. 
 
Type 2 diabetes mellitus (NIDDM, type II or adult-onset diabetes) is characterized 
by beta cell dysfunction and insulin resistance. This is the most common form of 
diabetes mellitus and is highly associated with a family history of diabetes, older 
age, obesity and lack of exercise(13). The aetiology of type 2 diabetes mellitus is 
complex and involves both genetic and environmental factors.  
 
“Other specific types” includes diabetes mellitus of various known etiologies 
grouped together(14). This group includes persons with genetic defects of beta-
cell function (MODY or maturity-onset diabetes in youth) or with defects of 
insulin action; persons with diseases of the exocrine pancreas, such as pancreatitis 
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or cystic fibrosis; persons with dysfunction associated with other endocrinopathies 
(e.g., acromegaly); and persons with pancreatic dysfunction caused by drugs, 
chemicals or infections. 
 
Table 1.2  Aetiological classification of diabetes mellitus 
I. Type 1 diabetes (β-cell destruction, usually leading to absolute 
insulin deficiency) 
 
A. Immune  mediated 
B. Idiopathic  
 
II. Type 2 diabetes (may range from predominantly insulin 
resistance with relative insulin deficiency to a predominantly 
insulin secretory defect with insulin resistance)  
 
III. Other specific types 
 
A. Genetic defects of  β-cell function 
B. Genetic defects in  insulin action 
C. Diseases of the  exocrine pancreas 
D.Endocrinopathies 
E. Drug- or chemical-induced 
F. Infections  
G. Uncommon forms of  immune-mediated diabetes 
H. Other genetic  syndromes sometimes associated with diabetes 
 
IV. Gestational diabetes mellitus (GDM) 
 
Gestational diabetes includes a spectrum of conditions ‘with any degree of 
glucose intolerance with onset or first recognition during pregnancy’. Individuals 
with type 1 diabetes or type 2 diabetes detected first during pregnancy are 
therefore also classified as gestational diabetes. Other important changes were the 
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deletion of terms NIDDM and IDDM. The new classification encompasses both 
clinical and aetiological classifications and is widely accepted(14).  
 
Figure 1.1 
 
Adapted from reference 14. 
 
 
1.4 Global prevalence of diabetes 
 
 
Epidemiological trends indicate that the world prevalence of diabetes has 
increased steadily over the last few decades(16;17). Although increases in both 
type 1 and type 2 diabetes have been observed, much of this increase is 
attributable to type 2 diabetes. In 1998, King et al predicted global prevalence (in 
adults over 20 years of age) to increase to 154 million by the year 2000. 
Subsequent data have shown that these figures were an underestimate(17-19). In 
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the year 2000, the global prevalence was 171million. Recently published 
projections suggest that diabetes prevalence is set to double over the next 2 
decades and reach an alarming 366 million by 2030(17). The greatest relative 
increases are expected to occur in the Middle Eastern crescent, sub-Saharan 
Africa and India while the greatest absolute increase will be in India. India, China 
and the United States retain the top three spots for the greatest number of people 
with diabetes.  
 
Currently, there are an estimated 31.7 million people with diabetes in India and 
this is expected to increase to 79.4 million by 2030(17). The age-related 
prevalence of diabetes varies between developing and developed countries, with 
the majority of those with diabetes in developing countries being in the age group 
45 to 64 years and those in developed countries being >64 years. Gender-specific 
prevalence shows similar estimates for men and women overall but the prevalence 
is greater in men in the age group less than 60 years and in women over 60 years. 
The increasing prevalence of diabetes can be attributed to rising rates of obesity, 
sedentary lifestyles and improved survival rates across the globe. Rapid changes 
in lifestyles following globalisation have contributed to the increased prevalence 
observed in urban populations. Increased life expectancy and the proportion of the 
elderly population is thought to be contributing to the rise in prevalence in the 
developed nations(18). While the estimated increase in prevalence is likely to 
occur even if obesity rates remain constant, the observed increase in the 
prevalence of obesity may suggest that the true prevalence may far exceed 
predictions. From a public health perspective, the impact of diabetes and its 
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complications is likely to place a huge demand on health care resources and a 
greater emphasis on preventative measures is required to tackle this problem(17). 
 
1.5 Complications of diabetes 
 
1.5.1 Acute complications 
 
Disturbances in glucose metabolism as a result of relative or absolute insulin 
deficiency can be associated with acute complications(20). These can be broadly 
differentiated into those associated with hyperglycemia and hypoglycaemia. Acute 
complications associated with hyperglycemia include diabetic ketoacidosis (DKA) 
and non-ketotic hyperosmolar coma (HONK). DKA often occurs in subjects with 
type 1 diabetes and can also be the initial presentation. It occurs rarely in type 2 
diabetes. It is characterized by normal or elevated blood sugars, dehydration and 
ketosis, which results in severe metabolic acidosis. HONK, on the other hand, 
occurs in type 2 diabetes and is characterized by very high blood sugars, 
dehydration and shock. Both these are potentially serious and require aggressive 
management with fluids and insulin replacement(20).  
 
Although hypoglycaemia is regarded as an acute complication of diabetes, it is 
frequently iatrogenic and occurs in subjects treated with glucose lowering 
agents(21). Milder degrees of hypoglycaemia are often associated with increased 
autonomic symptoms and are easily correctable. Severe degrees of 
hypoglycaemia, however, may require assistance and can be associated with 
severe morbidity particularly in children and the elderly(21-23). 
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1.5.2 Chronic complications of diabetes 
 
 
Although there are epidemiological differences between the two major types of 
diabetes, the long term exposure to hyperglycemic states results in significant 
microvascular and macrovascular damage. Diabetes is now the leading cause of 
blindness in the working population (retinopathy), end-stage renal disease and 
non-traumatic amputations(24). The pathogenesis of these microvascular 
complications (retinopathy, nephropathy and neuropathy) is complex and involves 
several pathways leading to accumulation of advanced glycation end products and 
eventual end organ damage (25). These complications are often progressive and 
irreversible.  Increased awareness and advances in understanding of the 
pathogenesis and screening techniques have allowed early detection and the 
development of interventions to slow the progression of these complications.   
 
 
1.1.5.1. Nephropathy 
One of the major microvascular complications is diabetic nephropathy. This is the 
most common cause of renal failure in the developed world (26). It is estimated 
that approximately 25-30% of patients with diabetes develop some degree of 
nephropathy (27). Certain ethnic groups, for example, South Asians, appear to be 
at an even higher risk (27). Diabetic nephropathy progresses through a series of 
stages, which can be defined by measuring the excretion of albumin in the urine as 
an indicator of microvascular and endothelial cell damage. Sub-clinical disease 
progresses to a state of microalbuminuria (defined as a urinary albumin excretion 
rate of greater than 30mg per day but less than 300mg per day), which is the 
earliest point of detection of renal disease. In some individuals this may progress 
11 
 
to overt nephropathy (macroalbuminuria, defined as a urinary albumin excretion 
rate greater than 300mg per day), with accompanying renal dysfunction, and may 
eventually progress to end-stage renal disease (28). 
 
 
1.1.5.2. Retinopathy 
Diabetic retinopathy is the most common cause of acquired blindness in the 
western world (27;29;30). Retinopathy also progresses through recognizable 
stages. Initially there are early non-proliferative changes, which appear in almost 
all individuals with type 1 diabetes within about 20 years of disease onset, as well 
as a significant percentage of those with type 2 diabetes. This may develop into 
pre-proliferative retinopathy, followed by proliferative retinopathy and macular 
oedema. At this stage, there is a risk of retinal detachment and vitreous 
haemorrhage. The later stages of retinopathy can be sight-threatening. 
Approximately 20% of patients with diabetes have some evidence of retinopathy 
at diagnosis of the disease, but the prevalence increases with age (27). There is a 
close link between diabetic retinopathy and nephropathy (31). 
 
 
1.1.5.3. Neuropathy 
This is the most common chronic complication of diabetes (27). Neurological 
disturbances in diabetes are caused by changes in the blood supply to the nerves 
or degeneration of peripheral nerves due to an overproduction of neurotrophic 
factors in response to hyperglycaemia. Neuropathy refers to a complex group of 
conditions that can take many different forms. These fall into two major 
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categories; focal and generalised (32). Examples of focal neuropathies include 
femoral neuropathy and peroneal nerve and cranial nerve palsies (33).  
 
The most common generalised neuropathy is sensorimotor polyneuropathy, which 
often first presents as peripheral neuropathy. This can lead to foot ulceration, poor 
healing and gangrene. As a result  patients with diabetes have an approximately 
15-fold higher risk of non-traumatic lower limb amputation compared with the 
non-diabetic population (27). The autonomic nervous system is also commonly 
involved, resulting in cardiac dysfunction, gastroparesis, bladder dysfunction and 
erectile dysfunction (34). Neuropathy can result in poor blood flow to the feet, 
causing foot problems through a number of mechanisms; a) diabetic patients with 
neuropathy find it difficult to know if they have a foot injury, causing a delay in 
treatment, b) neuropathy reduces the rate of healing of foot injuries due to poor 
blood flow, and c) neuropathy is associated with an increased risk of foot ulcers.  
 
In the UK, foot problems are the most common reason for hospitalisation of 
patients with diabetes and good foot care can greatly reduce the risk of amputation 
(27;35). Patients with diabetes are actively screened for signs of neuropathy, as a 
means of prevention of foot ulcers and other complications (36). 
 
 
1.1.5.4 Macrovascular complications 
 
Both type 1 and type 2 diabetes are associated with increased risk of 
macrovascular complications. The co-existence of other risk factors for 
macrovascular disease often such as obesity, hypertension, dyslipidaemia and 
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hypercoagulable state with type 2 diabetes is frequently responsible for the excess 
cardiovascular risk associated with type 2 diabetes(37). The risk of coronary heart 
disease, peripheral vascular disease and stroke are all increased in individuals with 
diabetes. Epidemiological studies have shown that the risk of cardiovascular 
disease is three times greater in individuals with type 2 diabetes and is 
proportionate to that observed in those who have already had a cardiovascular 
event(38). Diabetes increases the rate of atheroma progression and in pre -
menopausal women in particular may offset the cardiovascular protection derived 
from estrogens. Epidemiological studies have shown a ‘J’ shaped relationship 
with glycaemia with risk of cardiovascular disease increasing with blood sugars 
above the diabetes range. Despite this, there is inconsistent evidence to suggest 
that lowering blood glucose actually reduces cardiovascular risk (39;40). Recent 
evidence, however, suggests that tight glycaemic control in early years of type 2 
diabetes can indeed be associated with significant risk reduction(41). Effective 
management of cardiovascular disease in diabetes therefore requires both tight 
glycaemic control as well as control of other risk factors.  
 
 
1.6 Management of diabetes- risk factor control 
 
1.6.1 Effects of glycaemic control 
 
 
The fact that tight glycaemic control is essential for minimising the consequences 
of diabetes was recognized early in the post-insulin era. E.P Joslin in his book 
stated the importance of glycaemic control and urged for this to be pursued with 
“missionary zeal”(42). Despite this recognition, it was only in the late 1990’s that 
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the  importance of tight glycaemic control in the management of type 1 and type 2 
diabetes was firmly established(8;9). 
 
1.6.1.1 Microvascular disease 
 
The first definitive evidence that tight glycaemic control reduced the risk of 
microvascular complications came from the results of the Diabetes Complications 
and Control Trial (DCCT) in 1994(8).  The DCCT trial was in patients with type 1 
diabetes and compared intensive treatment with conventional management. 
Significant reductions in microvascular complications were observed in the 
intensively treated group with a relative risk reduction of 60% in retinopathy and 
neuropathy and 39% reduction in microalbuminuria. Given that the epidemiology 
and pathogenesis of type 2 diabetes is considerably different to type 1 diabetes, it 
was important to verify the benefits of intensive glycaemic control in patients with 
type 2 diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) was 
designed to answer this specific question. The UKPDS was a large prospective 
trial in newly-diagnosed patients with type 2 diabetes(9). Patients were 
randomised to intensive glucose control or conventional therapy. After a median 
follow up of 10 years, the intensive group was shown to have significant 
reductions in diabetes-related end points, all-cause mortality and microvascular 
end points. Reduction in HbA1c (glycated haemoglobin) of 0.9 % was associated 
with 12% relative risk reduction for any diabetes-related end point, 6% reduction 
in all- cause mortality and 25% reduction in microvascular end points. 
Interestingly, patients allocated to intensive control with metformin had better 
reductions in all these end points than other intensive therapies. Patients on 
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metformin had a 32 % risk reduction in diabetes-related end points, 42% reduction 
in diabetes-related death and 36% reduction in all-cause mortality. The results of 
the UKPDS had a major impact on management of patients with type 2 diabetes 
and led to the setting of targets for glycaemic control. Following the success of the 
UKPDS there has been much debate about the lowest possible target for glycemic 
control. Recent studies suggest that targets as low as HbA1c of 6.5% can be 
associated with significant reductions in microvascular complications but may be 
hampered by the risk of hypoglycaemia(43).  
 
1.6.1.2 Macrovascular disease 
 
There is strong epidemiological evidence to suggest a link between the risk of 
cardiovascular disease and hyperglycaemia. However, unlike microvascular 
complications, where the risk increases beyond a certain level of blood sugar, 
there is no threshold below which the risk of macrovascular disease becomes 
negligible(44;45). The relationship between blood glucose and cardiovascular risk 
therefore appears to be linear. Type 2 diabetes increases the risk of cardiovascular 
disease and mortality from cardiovascular disease is nearly 3 times more common 
in diabetic subjects than in individuals without diabetes(38). Despite this 
association between blood glucose and cardiovascular disease, there is some 
degree of uncertainty about the benefits of intensive glycaemic control to reduce 
cardiovascular disease. In the UKPDS, the risk of myocardial infarction in the 
intensive group was 16% less compared to the conventional treatment group. This 
result was, however, not statistically significant. Recently, three major trials – the 
ADVANCE,VADT and the ACCORD trials - reported that intensive glycaemic 
control is associated with no cardiovascular benefit (VADT )(43) and may in fact 
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be associated with increased cardiovascular mortality ( ACCORD) (40). At the 
same time, a 10 year post-study follow-up of patients in the UKPDS study 
suggested that the benefits of early intensive treatment offered significant 
cardiovascular protection even after the intensive control worsened(41). While the 
uncertainty about the benefits of intensive glycaemic control for cardiovascular 
risk reduction continues, it is now widely accepted that, in newly-diagnosed 
patients at least, intensive treatment is useful.  
 
1.6.2 Effects of blood pressure and lipid control 
 
 
There is now substantial evidence to show that blood pressure and lipid control is 
associated with significant reductions in cardiovascular risk. Although most of 
these trials have been in the general population, many have included subjects with 
diabetes. In addition to the reduction in cardiovascular events, blood pressure 
control is associated with a decreased risk of microvascular events in patients with 
diabetes. In the UKPDS, intensive control of blood pressure, resulting in a 
reduction of 10 mmHg  systolic blood pressure, was associated with 24% relative 
risk reduction in diabetes-related end points, 32% reduction in diabetes-related 
death and 44% reduction in microvascular end points(46). The benefits were 
attributed to the reductions in blood pressure rather than the agents used. 
Subsequent trials have shown that certain agents, such as ACE inhibitors and 
angiotensin receptor blockers, may have additional benefits over and above that 
expected from blood pressure lowering alone, particularly in the context of 
diabetic nephropathy. Unlike glycaemic control, however, the benefits of good 
blood pressure control can be lost unless the control is sustained(47). 
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Dyslipidaemia is another frequent cardiovascular risk factor associated with 
diabetes and is characterised by high or normal LDL cholesterol, low HDL 
cholesterol and elevated triglycerides. Lowering of cholesterol (LDL) has been 
shown to be associated with major reduction in cardiovascular events(48).  While 
initial statin trials established the benefits of cholesterol lowering on 
cardiovascular outcomes, subsequent trials (some diabetes-specific) have shown 
that relative risk reduction in diabetes patients may be substantial. In the CARDS 
study, a 1 mmol/L reduction in LDL cholesterol was associated with 37% relative 
risk reduction in cardiovascular events(49). Given the high risk of cardiovascular 
disease in diabetes patients, lower treatment targets of <4 mmol/L of total 
cholesterol or < 2mmol/L of LDL cholesterol are recommended.  The role of 
therapies targeted at elevating HDL cholesterol or reducing triglycerides are not 
well established and is at present considered in those with severe dyslipdemia not 
managed on statins alone(50). 
 
 
1.6.3 Multiple risk factor intervention 
 
 
Although there is now sufficient evidence to suggest that control of single risk 
factors reduces long term complications, few trials have examined the cumulative 
benefits of multiple risk factor intervention in type 2 diabetes. In the STENO 2 
trial, involving 160 patients with type 2 diabetes, the additive benefits of intensive 
multiple risk factor treatment was compared against conventional 
treatment(51;52). Over a follow-up period of 7.8 years, there were significantly 
fewer cardiovascular events and microvascular complications such as nephropathy 
and retinopathy. A post-study follow-up of these patients for a further 5.5 years 
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showed that these benefits persisted with significantly decreased rates of death 
from any cause, cardiovascular deaths and microvascular disease in the group who 
were originally intensively treated(53). These results support a role for targeted 
and intensive multiple risk factor intervention in patients with diabetes.  
 
 
 
1.6.4 Secular changes in diabetes management-the Quality and 
Outcomes Framework (QOF) 
 
 
The realization that intensive risk factor control can reduce the burden of long 
term complications has led to a greater emphasis on treating to lower targets. 
Despite minor differences, there is general agreement between the different 
international bodies regarding these targets.  In general, it is recommended that 
the targets for glycaemic control are  HbA1c of 6.5 % or 7%, blood pressures of 
130/80 mmHg systolic and LDL cholesterol levels of less than 2 mmol/L(54;55).  
 
An important secular change in the UK in recent years has been the introduction 
of the Quality and Outcomes Framework (QOF) initiative by the UK Government 
in 2004(56).  This links physician pay to performance against 146 quality 
indicators relating to 10 chronic diseases. The QOF program incurred an 
additional government expenditure of £1.8 billion over a three year period. A key 
feature of this has been the linking of physician performance to targets achieved 
both in clinical and organisational areas. Management of diabetes as a chronic 
disease is linked to 99 points and includes specific targets for blood pressure 
(≤145/85mmHg), HbA1c (≤ 7% in >50% of patients) and total cholesterol (≤ 
5mmol/L), amongst many other parameters. Although evidence-based targets for 
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these risk factors are lower than those recommended in the QOF, initial data 
suggest that in general there has been an improvement in the standards of care 
received by patients(57). 
 
In addition to the QOF initiative, the general increase in awareness of the risk 
factors, evidence from clinical trials and availability of effective therapeutic 
agents have led to a greater involvement of the primary care physicians in the 
management of diabetes patients. While these changes have no doubt been 
encouraging, there is still need for intensification of treatments. Moreover, current 
treatment targets are based on studies in white European populations and do not 
take into account ethnic differences. Given that the risk of disease and its 
complications varies between ethnic groups, there is an argument for ethnic-
specific targets. At present, however, there is no evidence to support such an 
approach. 
 
 
 
1.7 Diabetes in the south Asian Diaspora 
 
Effects of migration 
 
 
Over the past 50 years, there have been significant changes to the world 
population. Political turmoil and economic changes and demand for skilled labour 
with increasing industrialization have resulted in migration of people from poorer 
and developing countries to developed countries. Migration of south Asians to 
Europe occurred in two phases(58). The first wave of migration from the Indian 
sub-continent occurred in the post-Second World War era, following increased 
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labour demands. A further wave of migration occurred in the 1960s and 70’s 
because of the political turmoil in East Africa. More recently, technological 
progress and the need for skilled labour has resulted in migration to different parts 
of the world, including the United States Canada and Australia. The term ‘South 
Asian’ broadly refers to people of Indian, Pakistani and Bangladeshi origin, but 
those from Sri Lanka and Nepal are also commonly included. Although there is 
considerable heterogeneity between these sub groups, they share many socio-
cultural factors and characteristically high susceptibility to type 2 diabetes and 
cardiovascular disease(58).  
 
1.7.1 Diabetes prevalence and risk factors 
 
It is estimated there are over 25 million people of south Asian origin living 
outside the Indian subcontinent. Prevalence of diabetes in this community is 
particularly high and is rising at a faster rate than in any other ethnic group (16). 
In the UK, south Asians constitute about 4% of the total population and are the 
largest ethnic minority group. The majority live in inner city areas and have a very 
high prevalence of diabetes. One of the first indications for the high prevalence of 
type 2 diabetes in south Asians was the publication of the Southall diabetes survey 
in 1985 (59).  This revealed that prevalence of type 2 diabetes in south Asians was 
three times that in white Europeans and five times more in those aged between 40 
and 69 years. According to recent estimates, diabetes prevalence in south Asians 
living in the UK is around 20% (60) compared to 9% in urban India and 4% in 
rural India (61;62) (Figure 1.2).  This figure is much higher than in native 
countries suggesting migration to affluent societies has been a key factor in the 
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rise of type 2 diabetes in the population. High rates of prevalence amongst south 
Asians have also been reported in other countries in Europe, the United States and 
Canada(18). Diabetes also occurs around 10 years earlier compared with white 
Caucasians and is often associated with established complications at diagnosis. 
Prevalence rates also vary within the different sub groups of south Asians, with 
figures being particularly high amongst those of Bangladeshi and Pakistani 
origin(60). 
 
 
 
Figure 1.2: Prevalence of type 2 diabetes amongst UK ethnic groups. 
 
Adapted from reference:(60) 
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1.7.2 Genes or Environment? 
 
The complex aetiology of type 2 diabetes is influenced both by genetic and 
environmental factors(63).  There is little doubt that environmental changes have 
been the primary reason for the increase in the levels of type 2 diabetes seen 
globally. Moreover, the fact that type 2 diabetes is disproportionately high in 
migrant south Asians suggests a vital role for environment. Cultural and social 
values and differing lifestyles invariably affect the susceptibility to diseases such 
as type 2 diabetes and there is evidence to suggest that these factors predispose to 
increased susceptibility to type 2 diabetes(64).  
 
Diets rich in saturated fat and reduced levels of physical activity have been noted 
in migrant south Asians and contribute to the increased levels of obesity, insulin 
resistance and diabetes(58). Increased BMI, central adiposity and higher 
prevalence of diabetes in migrant south Asians has been reported in comparative 
studies involving natives and migrants. The susceptibility to diabetes therefore 
appears to be proportionate to the degree of environmental exposure.  
 
Environmental factors alone, however, cannot fully explain the increased 
susceptibility to type 2 diabetes in South Asians compared with other ethnic 
groups. Even amongst south Asians who share the same environment, there are 
considerable differences in disease risk. There is also familial clustering of 
diabetes, suggesting that susceptibility to type 2 diabetes may be partly genetically 
determined. Until recently, genetic studies in south Asians have been relatively 
few and the considerable heterogeneity within this group adds to the difficulties in 
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characterising this population(65).Studies published so far have merely replicated 
the findings in other ethnic groups and, although subtle differences have been 
reported, as yet no gene specific to this ethnic group has  been identified(66). The 
increased prevalence of diabetes may therefore be due to more individuals sharing 
susceptibility genotypes rather than a novel gene itself. The genetic basis of type 2 
diabetes and the studies in south Asians are discussed in Chapter 6 in the latter 
part of this thesis. 
 
1.7.3 Macrovascular disease  
 
 
People of south Asian ethnicity have the highest rates of cardiovascular disease 
worldwide and are expected to account for nearly 40% of the global burden by 
2020. Standardised mortality rates from cardiovascular disease in UK south 
Asians are 150 % of those observed in the local white European population(67). 
Diabetes is thought to contribute significantly to this excess risk, with death rates 
in UK south Asian diabetic individuals being 3 times greater than in the white 
diabetic population(68). Similarly, higher rates of cardiovascular disease have 
been reported in immigrant south Asians in other countries(69). This increased 
propensity to cardiovascular disease is thought to be due to a higher burden of 
known risk factors and a greater predisposition to insulin resistance and 
diabetes(70). South Asian ethnicity itself has been suggested as a possible 
independent risk factor but the role of ethnicity remains unclear.  
 
The relationship between diabetes and CHD can be further explored through 
studies of the ‘Metabolic Syndrome’. Originally described by Reaven in 1988 
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(71), this syndrome comprises the co-existence of insulin resistance, hypertension, 
raised triglycerides and low HDL in a single individual. Several alternative 
definitions of the metabolic syndrome have since been proposed(72;73)( Table1). 
Subtle differences exist between the definitions but increased waist 
circumference/BMI, hypertension, dyslipidaemia and glucose intolerance are 
common to most of them. The prevalence of metabolic syndrome is considerably 
higher amongst South Asians than in Europeans using both the WHO and the 
ATPIII criteria(74). In another study using the ATPIII criteria, the prevalence of 
metabolic syndrome was reported to be as high as 41% in urban Indians with the 
figures rising to over 70% in those with diabetes(72). This potentially ominous 
combination of diabetes and the metabolic risk factors in an individual thus 
predisposes to the high risk of CHD observed in this population.  
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Table 1.3. The IDF and ATPIII definitions of Metabolic Syndrome. 
IDF  Definiton of Metabolic Syndrome using ethnic specific values for South 
Asians 
 
 
 
The diagnosis of Metabolic Syndrome in a person using IDF criterion requires 
 
The presence of central obesity defined as waist circumference > 90cm in males 
and > 80 cm in females     
 
plus any two of the following 
 
Raised Triglyceride level : >150mg/dl (1.7 mmol/L) or specific treatment for this 
lipid abnormality 
 
Reduced HDL cholesterol : <40mg /dl (1.03mmol/L) in males and 
<50mg/dl(1.29mmol/L) in females or specific treatment for this lipid abnormality 
 
Raised blood pressure: systolic blood pressure >130 or diastolic blood pressure 
>85mmHg, or treatment of previously diagnosed hypertension 
 
Raised fasting plasma glucose (FPG) >100mg/dl (5.6mmol/L), or previously 
diagnosed type 2 diabetes 
 
 
 
ATP III criterion for the diagnosis of Metabolic Syndrome 
 
The diagnosis of Metabolic Syndrome using the ATP III (2001) criterion in a 
person requires at least three of the following 
 
Central Obesity : Waist circumference >102cm (male) ,>88cm (female) 
 
Dyslipidaemia    :  Triglycerides >1.695mmol/L (150mg/dl) 
 
Dyslipidaemia   :   HDL cholesterol <40mg/dl (male) ,<50mg/dl (female) 
 
Blood pressure   : >130/85 mmHg 
 
Fasting plasma glucose : >6.1mmol/L (110mg/dl) 
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1.7.4 Role of traditional risk factors 
 
 
The contribution of conventional risk factors to the excess cardiovascular risk in 
South Asians has been investigated in several epidemiological studies. Most of 
these have compared migrant South Asians with local white Caucasians. Other 
studies have included comparisons between the migrant and indigenous South 
Asian populations. These have highlighted important differences between the 
ethnic groups.  
 
1.7.4.1 Blood pressure 
 
Studies comparing the prevalence of hypertension in white Caucasians and South 
Asians have shown varying results(75-78). While some studies have reported 
higher blood pressures in South Asians, others have reported lower values. A 
review of the cross-sectional data on blood pressure in South Asians found that 
there was considerable variation in the blood pressure values reported(77). In 
men, seven of twelve studies reported a lower mean systolic blood pressure, while 
six of nine studies reported a lower systolic blood pressure in women. Relatively 
higher diastolic pressures were reported in both South Asian men and women 
compared with white Caucasians. A multiethnic comparison of risk factors 
amongst patients recruited to the United Kingdom Prospective Diabetes Study 
(UKPDS) showed that South Asians had lower blood pressures compared with 
Afro-Caribbeans, but similar values to those observed in white Caucasians(78). In 
general, however, it is accepted that the blood pressure values in South Asians are 
slightly lower or similar to those observed in white Caucasians. Despite this, 
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South Asians have a much higher prevalence of microalbuminuria and 
nephropathy (79).  
 
The relationship between blood pressure and cardiovascular risk is continuous and 
a higher blood pressure in south Asians already known to have a high burden of 
other risk factors may further increase the risk of cardiovascular events(80). 
Moreover, there is some evidence to suggest that markers of cardiovascular risk 
such as microalbuminuria may be detected in south Asians even with blood 
pressures considered to be within the ‘normal’ range (81). This may be an 
argument to have lower thresholds for intervention and to aim for lower blood 
pressure targets in South Asians.  
 
1.7.4.2 Dyslipidaemia 
 
Despite the reportedly lower or similar levels of total cholesterol, South Asians 
have a more atherogenic lipid profile than white Caucasians. Higher levels of 
triglycerides and lower HDL levels have been observed amongst South Asians-
features frequently associated with insulin resistance and the metabolic 
syndrome(82). This pattern of dyslipidemia appears to be further exaggerated in 
migrants, suggesting a strong environmental influence (83). South Asians also 
have smaller and denser LDL particles and altered apoprotein B /apoprotein A1 
ratio, which may help explain their propensity for early atherosclerosis (84). 
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1.7.4.3 Smoking 
 
Overall rates of smoking in South Asian migrants are comparable to those seen in 
white Europeans. Smoking in south Asians, however, appears to be more common 
in men than in women(70;85;86). Smoking rates as high as 82% have been 
reported in Bangladeshi men living in East London, while smoking rates are lower 
in Indian and Pakistani men(87). Although the rates of smoking are lower, under 
reporting of smoking status in south Asian women may be common. In addition 
tobacco chewing has also been reported to be common in south Asians and may 
contribute to excess cardiovascular risk(88). 
 
1.7.4.4 Physical activity 
 
Moderate physical activity has been shown to be associated with significant 
benefits in cardiovascular risk reduction, improvement in glycaemic control and 
prevention of diabetes(89;90). Several studies that have compared physical 
activity levels in different ethnic groups have shown lower levels of activity in 
south Asians(91). Within the south Asian population, there is considerable 
heterogeneity with Bangladeshi women in particular having the lowest level of 
physical activity(60). In the Health Survey of England 2004, physical activity 
levels in south Asians was lowest compared to other ethnic groups. Only 11% of 
the Bangladeshi women and 14% of Pakistani women met the criterion for at least 
30 minutes of moderate physical activity for five days a week. Low levels of 
physical activity were also seen in 51% of the Pakistani and Bangladeshi men and 
68% Bangladeshi women and 52% Pakistani women(60). Similarly low levels of 
physical activity were reported in south Asians by Fischbacher et al and Hayes et 
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al(91;92). Although physical activity in south Asians was generally lower than in 
white Europeans, these differences were more apparent in the older age 
groups(92). There is limited data on the physical activity levels in native south 
Asians but results from the INTERHEART study suggest that low physical 
activity levels are comparably lower amongst native south Asians than in other 
ethnic groups(70).  
 
Until now, very little research has been undertaken to understand the barriers to 
physical activity in south Asians. Available evidence suggests that there is a 
complex interaction of social, cultural and economic reasons contributing to 
this(88;91;93). Lack of time, commitment to family needs, language barriers and 
the weather has all been quoted as reasons for lack of exercise. Cultural and 
religious factors, such as using a unisex swimming pool, may dissuade south 
Asian women from using such facilities(94).  There is also lack of awareness of 
the benefits of exercise and a fatalistic attitude towards life that makes south 
Asians not attach much importance to exercise. Despite these barriers, it may be 
possible to promote physical activity in south Asians. A HTA report suggested 
more south Asian women were willing to undertake exercise if offered on 
prescription (95). Such initiatives have, however, not been evaluated on a bigger 
scale.  
 
Methodological differences in studies reporting physical activity levels and the 
fact that not all studies have taken into account both the leisure time activities and 
household work may have underestimated true activity levels in south 
Asians(91;92). Very few studies have used objective measures of physical activity 
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but even these studies have reported low levels of activity in south Asians(92;96). 
Nevertheless, the common message from all studies is that lower physical activity 
levels in south Asians is of concern and needs to be addressed if the risk of 
diabetes and cardiovascular disease in this population is to be reduced. 
 
1.7.4.5 Dietary factors 
 
 
It is not entirely clear what aspects of the south Asian diet predispose to increased 
risk of type 2 diabetes(88).  There is considerable dietary heterogeneity within the 
south Asian groups making it difficult to make generalisations. Moreover, 
vegetarianism is also common in some south Asian sub groups. In an uncontrolled 
trial, traditional south Asian vegetarian diet induced higher and prolonged rises in 
plasma glucose than a traditional European meal(97).  South Asian diet is also 
considered to have more carbohydrates, less protein and more fibre than 
indigenous European diets. Cooking practices also vary considerably and notably, 
involves the use of Ghee or clarified butter particularly in the Northern Indian 
diets(98).  
 
There is some variation in the reports concerning fruit and vegetable intake. In the 
Health Survey of England, the average consumption of fruit and vegetables was 
greater amongst south Asians compared to other ethnic groups with more than a 
third of south Asians meeting the ‘five a day’ recommendation(60). Other studies, 
however, report that the average consumption of fruit and vegetables to be lower 
in south Asians. It is also common practice in south Asian cooking to over cook 
the vegetables thus depriving of the essential vitamins. Cultural practices may also 
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influence dietary habits. South Asian men are less likely to take part in meal 
preparation and in general south Asians consume traditional sweets rich in fat and 
sugar(88). 
 
1.7.4.6 Obesity 
 
 
The rise in prevalence of diabetes is closely linked to the rising rates of obesity. 
South Asians have a lower average BMI than their European counterparts. Even at 
lower BMI, however, South Asians have been found to have a higher percentage 
of visceral fat and features of insulin resistance(99) . The cut-off values for 
obesity in South Asians have therefore been revised by the WHO, with a BMI 
greater than 27.5 kg/m2 considered obese in this group and greater than 23 kg/m2 
as overweight (100). Recent data from India, however, suggest that the 
appropriate cut off for defining obesity in those from the Indian sub continent 
would be a BMI > 23 for overweight and BMI > 25 for obesity (101). In the 
Health Survey of England (2004) (60) the prevalence of obesity (BMI>30kg/m2) 
in South Asian men was around 14% and in women was 20%, with considerable 
heterogeneity within the sub groups. Interestingly, in the same report the 
proportion of South Asians aged over 35 years and with BMI > 25 was 53% for 
men and 55% for women (60). Thus if the lower cut off values for obesity were to 
be applied for South Asians, the prevalence could be much higher. As the risk of 
type 2 diabetes increases with increasing degrees of obesity there is a need for 
interventions targeted towards reducing obesity in this ethnic group. 
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1.7.4.7 Novel risk factors 
 
The fact that the excess cardiovascular risk observed in South Asians may not be 
fully explained by traditional risk factors has led to increased attention on novel 
risk factors. These include adipocytokines, prothrombotic factors and 
inflammatory markers and some of these are of particular interest. Adiponectin is 
an adipocytokine known to have insulin-sensitising, anti- atherogenic and anti-
inflammatory properties. Low levels of adiponectin are associated with insulin 
resistant states and strongly correlate with visceral adiposity. Studies comparing 
adiponectin levels in white Caucasians and South Asians have shown consistently 
low levels of  adiponectin in the latter(102). There also appears to be a correlation 
between low HDL levels and adiponectin(103). These features are present even in 
patients with impaired glucose tolerance and may explain the propensity of South 
Asians to early cardiovascular disease(103). Similarly, higher levels of C reactive 
protein, homocysteine, plasminogen activator inhibitor and fibrinogen and 
impaired endothelium-dependent vasodilatation have been reported in South 
Asians(104;105). While there is considerable interest in these novel risk factors, 
they have not been evaluated in prospective studies and their potential role in the 
pathogenesis of cardiovascular disease is not fully established.  
 
1.7.4.8 Socio-cultural factors 
 
 
‘Culture’ can be defined in several ways. It is a set of ‘distinct features that 
includes amongst other things lifestyles, value systems, traditions, and beliefs of a 
society or social group(106).  There is considerable evidence to suggest that South 
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Asians in the UK have distinct dietary and lifestyle habits. Some of these 
influence cultural practices and may act as barriers to healthy lifestyle. Diet and 
exercise are an important part of diabetes management and cultural practices 
therefore have a huge effect on the life of an individual with diabetes.  
 
The health needs of the migrant population are unique and differ significantly 
from those of the native country and the host country. Migration is associated with 
major changes in the socio-cultural environment which often influence health 
status(64). The conflict of adherence to old cultural values and the process of 
integrating with the society in the new country can be stressful and challenging. 
Differences in lifestyle habits of south Asians and white Europeans are well 
recognised(88). Traditional cooking practices, attitudes and barriers to exercise, 
large families, strictly defined gender roles and communication difficulties are all 
known to contribute directly and indirectly to increased risk of diabetes(58;88).  
Lack of effective communication is another major barrier in delivering quality 
health care. A significant proportion of south Asians who have migrated to the 
UK have poor knowledge of the English language. This often leads to 
communication problems and difficulties for both the individual and the health 
professionals(94). Physicians may have difficulty in understanding patient 
symptoms and making an accurate diagnosis. Often advice given in English is not 
well understood by the patients. As a result there is misunderstanding of the 
instructions, poor adherence to treatments and missed appointments. There is also 
a tendency to involve other family members in decision-making, even when it is 
about one’s own health. This results in making shared treatment decisions 
difficult. In addition to the above, South Asians have a different attitude to health. 
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They often have a fatalistic attitude to illness and seek help much later, leading to 
delay in diagnosis.  There is also a reliance on alternative or complimentary 
therapies, frequently leading to poor compliance with medication. 
 
1.8 Summary 
1.8.1 Why do we need an intervention in the south Asian 
population with diabetes? 
 
 
Despite the high prevalence of diabetes and cardiovascular disease, there have 
been very few randomised controlled trials in the South Asian population 
(107;108). Representation of South Asians in clinical trials has also been 
poor(108). Consequently, many of the treatments are based on evidence from 
other ethnic groups. While ethnic differences may be subtle, risk between ethnic 
groups varies and it is important to have a strong evidence base that is ethnic-
specific. This is particularly important as some of the targets for treatment based 
on studies in white Europeans may underestimate the risk in south Asians. Further 
there are likely to be differences within an ethnic group as well as between groups 
and identifying these differences is essential to develop more effective treatments. 
The precise reasons for poor representation of South Asians in clinical trials are 
not clear. Studies looking at recruitment of south Asians in clinical trials suggest 
that they have the same attitudes towards research as other ethnic groups(109). 
There are, however, identified barriers to participation in research(110;111). 
These include fears and misconceptions about research, but also relate to the 
attitudes of researchers (example: difficulties in consenting and interpretation) 
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(112;113). Others factors include language barriers, poor understanding of the 
research processes and discriminatory practices(112). 
 
The impact of culturally sensitive care models has previously been evaluated in 
other ethnic groups with some success.  Studies in Mexican Americans showed 
that by using an integrated care package that met the needs of the immigrant 
population, substantial benefits could be achieved(114). Significant improvements 
in HbA1c and blood pressure were seen using culturally sensitive methods. A 
similar approach in south Asians in the UK using community link workers was 
shown to be beneficial(115). None of these methods have been evaluated in a 
randomised controlled trial, however, and the cost effectiveness of such models of 
health care has not been established.  
 
Type 2 diabetes is a complex disease where there is a strong interaction between 
genes and environment(63). Although until recently, success in genetic studies has 
largely been confined to monogenic forms of the disease, recent advances in 
genetics have allowed characterization of the more ‘common’ form of type 2 
diabetes(116). Most of these studies have been in white Caucasians and, despite 
the high prevalence of diabetes, there have been very few attempts to characterize 
genetic susceptibility in south Asians. Understanding of the pathogenic 
mechanisms is essential to identify any potential differences between the ethnic 
groups and could have wider implications for disease management. 
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1.9 Aims and objectives of this thesis 
 
 
The United Kingdom Asian Diabetes Study (UKADS) is designed to evaluate the 
effectiveness of a culturally sensitive health care delivery model in south Asians 
with type 2 diabetes. Consistent with the design of complex interventions, a pilot 
trial (described in chapter 2) was completed and results published in 2004. The 
definitive trial, involving a larger cohort of general practices, was commenced to 
evaluate the intervention over a 2 year period. The study had several components 
including clinical, economic evaluation, genetic characterisation and psycho-
social aspects involving south Asians with type 2 diabetes. At the time of 
commencement of my research, the recruitment for the trial was underway and the 
intervention had commenced in some of the practices recruited to the trial. 
Recruitment of white Europeans and the control samples for the genetics arm of 
the study was in progress. With both the baseline and the two year data likely to 
be available during the period of my study, the objectives for my thesis included:  
 
? Description and comparison of the baseline characteristics of both the 
ethnic groups 
? Assessment of clinical outcomes after the two year culturally sensitive 
intervention that included a brief economic evaluation 
? Genetic characterisation of the south Asian cohort for known type 2 
diabetes susceptibility genes 
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1.9.1 Ethnic comparison of clinical characteristics at baseline 
 
 
Although the UKADS intervention was in south Asians with type 2 diabetes, the 
plan was to recruit white Europeans from the same practices to be able to compare 
the two ethnic groups and identify any disparities. I was involved in the strategy 
and planning for recruitment of white Europeans to the study. I was also involved 
in the collection of data, running data queries and checking the data for errors for 
both south Asians and white Europeans. I also performed the data analysis for the 
comparison of baseline characteristics, with the help from the group statistician, 
and interpretation of the data.  
 
1.9.2 Clinical outcomes after 2 year culturally sensitive 
intervention in south Asians with type 2 diabetes 
 
 
This constituted the main focus of my work. At the time of commencement of my 
research, recruitment of south Asians was in progress and I assisted in the 
recruitment process by ensuring an adequate number of participants for each 
group and adherence to the inclusion/exclusion criteria. Patients were recruited 
from practices in Coventry and Birmingham and part of my responsibility was to 
co-ordinate with project managers at both sites on a weekly basis to ensure 
progress of the trial and adherence to timelines. During the course of the study, I 
provided clinical support, supervised the conduct of the research clinics, co-
ordinated timely data collection, checked for data errors and reviewed progress of 
the trial at research group meetings. I was responsible for the collection of the data 
at the end of two years and was involved in the data analysis and interpretation 
with the help of the group statistician. 
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1.9.3 Genetic characterisation of the south Asian cohort for 
known type 2 diabetes susceptibility genes 
 
 
The genetics work constituted the main part of my laboratory work. All subjects 
who participated in the clinical arm of the UKADS trial were also invited to be a 
part of the genetics arm of the trial. Their participation was, however, voluntary 
and involved a separate consenting process. The overall aim was to create a DNA 
resource from the UK Mirpuri/Punjabi south Asian population to facilitate 
genetics studies in this ethnic group. The goal is to recruit 3000 south Asians with 
type 2 diabetes and the same number of control subjects. I was involved in the 
initial stages of DNA collection and recruitment of control subjects. This was 
done through GP practices, community clinics and organising Diabetes 
Awareness Days in the community. My laboratory work involved looking for 
associations between common polymorphisms of the genes previously associated 
with type 2 diabetes in white Caucasian populations and the disease in the South 
Asian cohort. All of my laboratory work was performed at Prof. Barnett’s 
laboratory at the University of Birmingham Medical School, under the 
supervision of Dr. Ann Kelly. I performed the genotyping for all the genes 
included in my thesis as well as the data collection, interpretation and statistical 
analysis. 
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Chapter 2 
The United Kingdom Asian Diabetes Study: UKADS 
 
2.1 Background  
 
The task of translating the successes of clinical trials in practice is a major 
challenge. Patients in primary care often present with complex problems. 
Understanding the health risks and needs of the population is essential for 
successful delivery of health care. Health care delivery to various groups may be 
further complicated by the differing social and cultural needs and requires an 
integrated approach(58). In the UK, traditionally, diabetes specialist nurses have 
been hospital based and have concentrated their efforts on insulin-dependent or -
treated patients. Practice nurses with an interest and training in diabetes, and 
working with primary care physicians, play a major role in the care of patients 
with type 2 diabetes. Application of the findings of major clinical trials, such as 
the UKPDS, to type 2 diabetes patients is therefore likely to require a structured, 
protocol-driven, nurse educator-led multi-professional approach. Such a multi-
professional approach is likely to be successful if the language, religious and 
cultural needs are incorporated. The constraints in professional manpower and the 
language and cultural needs of the south Asian population have given rise to the 
use of diabetes link workers as a key resource in improving education, screening 
and compliance. The United Kingdom Asian Diabetes Study was designed to 
evaluate the effectiveness of a health care delivery model that addressed some of 
these needs of the south Asian community living in the UK(58). 
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2.2 Hypotheses 
 
 
The UKADS hypotheses were a) that the introduction of structured care for 
diabetes, tailored to the needs of the Asian community, can improve surrogate 
endpoints in a cost-effective manner for diabetic complications (and by 
extrapolation, morbidity and mortality) in Asian patients with type 2 diabetes; b) 
that the optimal intervention will include input from South Asian link workers, 
community-based Diabetes Specialist Nurses (with a focus on care for South 
Asian patients working across the primary/secondary care interface) and practice 
nurses, with protected time and an enhanced role, working to a joint protocol with 
clearly defined targets. 
 
2.3 The UKADS pilot  
 
2.3.1 Study design and methods 
 
 
Keeping in with the framework for complex interventions, the first phase of the 
UKADS  included a pilot study, involving 401 south Asian patients with type 2 
diabetes recruited from 6 general practices in Coventry and Birmingham, 
UK(117). For the purposes of the study, South Asian ethnicity was defined as all 
patients in UK census ethnic origin categories of Indian, Pakistani and 
Bangaldeshi. Patients eligible were of South Asian ethnicity, with type 2 diabetes 
plus at least one of three defined risk factors: elevated blood pressure, 
systolic>140 mmHg or diastolic >80 mmHg, HbA1c > 7%, total cholesterol > 5.0 
mmol/l. Practices were randomised to intervention (enhanced care- comprising 
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additional practice nurse time, link worker assistance and specialist nurse input) 
and control (standard care). Both groups received the same treatment protocols for 
blood pressure, cholesterol and HbA1c. Patients in intervention practices were 
seen at weekly research clinics. The practice team was encouraged to follow 
protocols for glycaemia, lipid and blood pressure control, to achieve targets of 
HbA1c < 7.0%, cholesterol < 5.0 mmol/l and blood pressure < 140/80 mmHg if no 
microvascular complications and < 130/80 if microalbuminuria or proteinuria was 
present. Control practices received the same guidelines to achieve targets, but 
used existing practice resources for managing their patients with diabetes. 
Microalbuminuria for this study was defined based on values at the reference 
laboratory of Birmingham Heartlands Hospital; albumin/creatinine ratio (ACR) of 
> 3 mg/mmol and < 15 mg/mmol. Albuminuria was defined as ACR of >15 
mg/mmol (values are mg of albumin per mmol of creatinine). The primary study 
outcomes were blood pressure, HbA1c and lipid control after one year of follow-
up. Baseline data were collected during February to April 2001 in Coventry, and 
May to June 2001 in Birmingham, with follow-up data collected during the same 
months one year later. 
 
Whilst the unit for randomisation in this study was the cluster (general practice), 
the statistical analyses were planned at the individual level. The rationale for this 
approach was that only six clusters were to be used as a proof of concept, with 
insufficient power to detect differences if adjusted for cluster effects. The 
intention was to design a full study if there was evidence to suggest that the 
intervention was effective.  
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2.3.2 Outcomes after 1 year intervention 
 
 
361 of the 401 patients eligible on the basis of the presence of risk factors 
consented to take part and were included in the study. All six practices 
randomised completed one year of follow-up and analyses were on the basis of 
intention to treat. The study showed high retention rates, with 90% of the eligible 
participants completing one year follow-up. At baseline, between 50 and 60% of 
intervention and control patients had elevated blood pressure (systolic > 
140mmHg or diastolic >80 mmHg) or total cholesterol > 5 mmol/L, and over 60% 
had HbA1c above 7.0%, suggesting a major proportion of these patients had 
poorly controlled risk factors. 
 
After one year intervention, there was a significant difference between both 
groups for blood pressure and cholesterol(117). Systolic blood pressure decreased 
by a mean 6.7 mm Hg in the intervention group against a reduction of 2.1 mm Hg 
in the control group (difference 4.6 mmHg) (Table 2.1). After adjusting for 
confounding factors, intervention status remained statistically significant for 
follow-up diastolic blood pressure and was of borderline significance for systolic 
blood pressure. The difference in total cholesterol reduction was no longer 
significant. Interestingly, there was no overall reduction in HbA1c and no 
significant difference between the intervention and control groups. 
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Table 2.1: Risk factor change over one year of follow-up in the pilot study 
 
 
Note: All values presented are after adjusting for confounders between groups. 
 
Over the one year study period, albumin:creatinine ratios deteriorated for 32 
patients (13%) and improved for 47 patients (19%). Deterioration of 
albumin:creatinine ratio was associated with those with less (or no) improvement 
in mean systolic blood pressure over the year. 
 
There were substantial and statistically significant differences between 
intervention and control groups with respect to numbers of patients progressing 
through treatment protocols. More intervention than control patients started 
insulin (6% vs. 3%) or increased their dosages or number of oral antidiabetes 
agents used (50% vs.  32). Similarly, more patients started or increased doses of 
anti-hypertensives (35% vs. 25%), angiotensin converting enzyme (ACE) 
 Intervention Mean 
Control 
Mean 
Difference between 
intervention and 
control 
95% Cl p value
 change change    
Systolic BP 
(mmHg) -6.7 -2.1 -4.6 
-8.8 to -
0.3 0.035
Diastolic BP 
(mmHg) -3.1 +0.3 -3.4 
-5.7 to -
1.2 0.003
Total 
Cholesterol 
(mmol/l) 
-0.51 -0.12 -0.38 -0.65 to -0.12 0.005
HbAlc (%) -0.23 -0.20 -0.03 -0.36 to + 0.30 0.866
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inhibitors (41% vs. 28%),  angiotensin receptor blockers (22% vs.11%) and statins 
(50% vs. 27%) in the intervention than control group.  
 
2.4 Relevance of the pilot study outcomes 
 
 
The success of the pilot study was essential for the commencement of the larger 
study to evaluate the effectiveness of the culturally sensitive enhanced care 
intervention. Results of the pilot study confirmed two important things. Firstly, it 
showed that the intervention strategy was feasible and could be implemented in 
UK primary care. Secondly, it proved that by engaging and employing link 
workers from the same community, it was possible to recruit and retain an ethnic 
group in a clinical trial that was hitherto considered difficult. This pilot phase 
confirmed the feasibility of applying the enhanced care intervention strategy in 
primary care and showed significant reductions in risk factors. The estimated 
additional reduction in 10 year absolute risk for CHD due to the intervention in 
the UKADS pilot study was 5%. The baseline data also produced important 
insights into the nature of the prevalence of complications, cardiovascular risk and 
obesity in this group, confirming their high susceptibility to cardiovascular 
disease. However, although the reductions in the risk factors were encouraging, 
lack of improvement in HbA1c was still disappointing. It was also not clear if the 
results achieved could be reproduced in a larger cohort and whether the benefits 
could be sustained. It was also important to establish if the intervention was cost 
effective if it were to be implemented in UK general practice. A larger trial 
involving a greater number of practices and a longer follow-up period was 
therefore felt necessary. 
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2.5 UKADS- Main study 
2.5.1 Project outline and Aims 
 
 
The feasibility of the novel approach both in the project’s ability to work with 
general practices in deprived areas and to recruit and retain a large number of type 
2 South Asian diabetic patients was demonstrated in the pilot study. It was 
therefore proposed to extend the study to provide definitive testing of this 
healthcare intervention in a wider practice population, using surrogate outcomes 
of cardiovascular and microvascular risk reduction over a two year period. The 
West Midlands is an ideal place for such a large scale study to evaluate this new 
approach, with its high concentrations of South Asian patients. In the longer term, 
if the delivery of health care can be improved for this important group of patients, 
this innovation should make a significant impact on the morbidity and mortality 
associated with this disease. 
 
The intervention strategy used in the pilot study was retained but a few additional 
components were included, keeping in view the larger cohort size. Accordingly, 
the definitive UKADS trial had four major components- Clinical, Economic, 
Genetic and Qualitative.  
 
The aim of the UKADS is to provide reliable evidence on the clinical- and cost-
effectiveness of a novel delivery strategy to improve the management of South 
Asian patients with type 2 diabetes, and to provide evidence that this intervention 
can be delivered on a wider scale. 
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To support this overall aim, the study has a number of specific objectives: 
 
i) to test the feasibility of implementing a strategy of risk reduction to reduce 
blood pressure, lipids, microvascular progression and improve glycaemic 
control in an Asian population with type 2 diabetes; 
ii) to measure changes in clinical endpoints associated with the introduction of 
this strategy for patients with type 2 diabetes;  
iii) to measure the costs of the strategy, including healthcare and patient costs 
and to compare costs and short-term outcomes to current practice. 
iv) genetic characterisation of South Asians with type 2 diabetes  
v) to provide qualitative data on the processes of care 
 
2.5.2 Methods 
 
2.5.2.1 Patient selection 
 
To achieve these aims, the study was extended to involve 18 practices from 
Coventry and Birmingham, each recruiting about 100 South Asian patients (total 
1800). The extension phase included all adult patients of South Asian ethnicity 
with type 2 diabetes. In order to make ethnic comparisons in respect to known 
cardiovascular risk factors an additional 500 White Caucasian patients with 
diabetes were recruited from the same practices. Patients were excluded if they 
had previously diagnosed type 1 diabetes or impaired glucose tolerance.  The pilot 
study included patients with at least one known modifiable cardiovascular risk 
factor other than diabetes.  
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The results from the pilot study indicated that the benefits seen in the intervention 
group were offset in part by progression of risk factors in those initially not 
recorded as hypertensive or dyslipidaemic. Therefore, in the definitive study, all 
adult South Asian patients with type 2 diabetes were eligible. Eligible participants 
from each practice were invited to participate in the study. The response rate for 
the study for both the sites was just over 60%.  
 
 
2.5.3 Intervention 
 
The intervention in the UKADS comprised three essential components -enhanced 
practice nurse time, link worker support and specialist nurse supervision. These 
roles are described below:  
 
(i) Practices were randomised to provide either the ‘active’ UKADS 
package of care or 'conventional care'. Practice nurses in the active 
group received additional training to be able to deliver the UKADS 
care package. Each practice nurse had protected time (4 hours a week) 
to provide an additional intensive control clinic for diabetes care. Each 
patient randomised to active intervention was seen monthly in the 
intensive control clinic until the targets  were met and two to three 
monthly thereafter for maintenance. Practice nurses worked with 
primary care physicians to implement the protocol and encourage 
appropriate prescribing, provide face-to-face patient education in a 
clinic setting and achieve targets for blood pressure, lipid and 
glycaemic control.  
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(ii) The Asian link workers were recruited from the same community and 
spoke the same languages (Urdu, Mirpuri and Punjabi) as the patients. 
All link workers attended a workshop for diabetes and received 
training from the nurse co-ordinator. Link workers contacted each 
patient before and in between appointments to ensure clinic 
attendance. The link workers attended the research clinics along with 
the practice nurses and provided interpretation and face to face 
education and lifestyle advice.   
 
(iii) The Diabetes Specialist Nurse attended some of the research clinics in 
the active group and provided additional educational support as well as 
clinical advice to patients. In addition the Diabetes Specialist Nurse 
supervised the practice nurses and link workers.  
 
Both the intervention and control practices were provided with common treatment 
algorithms. The control practices did not receive any additional support and 
managed with their own resources. 
 
2.5.4 Sample Size estimation 
 
The results of the pilot study suggest that improvements in blood pressure and 
cholesterol can be achieved over one year. Over a longer follow-up period, and 
with patients from the whole spectrum of diabetes, more substantial gains may be 
possible. In our original design we allowed for 25% drop-outs and refusals. The 
actual drop-out rate in the pilot study was only around 10%. We observed a mean 
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decrease in systolic blood pressure of 6.7 mmHg, and 0.5 mmol/l total cholesterol.  
 
No significant difference was observed in HbA1c levels. However, given that the 
main trial would be for a longer duration and to reflect the changes in targets in 
UK primary care, expected a 0.75% change in HbA1c over the two year period. 
Using these differences, plus standard deviations and estimates of intra-cluster 
correlation from our pilot data (0.0352 (SD 21.25) for systolic blood pressure and 
0.0597 (SD 1.1) for total cholesterol and 0.75 (SD 2.1) for HbA1c) we estimated 
that we will need 18-20 clusters of 70-90 patients each. Allowing for 10% drop-
outs, we estimated that 18 clusters of 80-100 patients would be sufficient to give 
us power of 80% (at a significance level of 0.05). 
 
Data from the UKPDS baseline suggest that 40% of patients may have elevated 
blood pressure. In our sample of South Asians this may be closer to 50%. In the 
pilot study we were able to achieve a 12% change, from 55% to 43%. Over a 
longer period a change of 15% would seem reasonable and to achieve this would 
require 152 patients per group, which allowing for the cluster design effect and 
10% drop-outs, translates to 16 clusters of 80-100 patients. 
 
2.5.5 Outcome measurements 
 
A number of clinical outcomes were identified for the main study. 
 
Primary outcomes were:  
Changes in blood pressure, lipids and HbA1c at 2 years 
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Secondary outcomes were changes in: 
i) cardiovascular risk  (Framingham) 
ii) waist circumference 
iii) diabetes knowledge scale, quality of life measures 
iv) albumin/creatinine ratio 
v) plasma creatinine + urea 
 
2.5.6 Evaluation of the process of care 
 
The effectiveness of the new process of care will be assessed by comparing the 
active and conventional care practices with respect to the proportion of patients 
achieving target values for the cardiovascular risk factors as well as absolute 
reductions in blood pressure, total cholesterol and HbA1c. Comparisons will also 
be made with risk factors in White European patients recruited from the 
conventional care practices. Patient satisfaction with care will be assessed by 
Health Related Quality of Life (HRQOL) questionnaire. Assessments of the above 
parameters will be made at baseline and then annually. The research team in each 
area will travel to general practices to ensure high patient compliance and assist 
each practice with the annual assessment process. 
  
Preliminary data from the pilot study suggests that the relationship between 
hypertension and microalbuminuria in this population is different to that seen in 
White Europeans. Further follow-up of this population will therefore, also provide 
novel data on the efficacy of risk factor control and of the relationship between 
risk factors and development of complications in this population.  
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2.5.7 Economic evaluation 
 
a) Costing study: 
The study measured intervention and treatment costs in both patient groups. All 
costings were subject to sensitivity analysis. The costing study involved a broad 
societal perspective and sought to estimate the difference in the cost of the 
resources used by patients in the two arms of the study. This enabled costs and 
consequences to be compared from a societal perspective (including patient costs) 
as well as from a health care perspective. The latter is likely to be of more interest 
to NHS decision makers if such structured interventions were to be introduced in 
primary care and delivered by PCTs. 
 
Intervention costs: The cost of providing the intervention included staff time, 
capital (including accommodation and any equipment necessary), overheads and 
consumables. The use of services will be costed from a variety of sources, 
including detailed local rates of pay, rent etc provided by the finance departments 
of the hospitals and services concerned and national sources. Intervention costs 
will be calculated to exclude research protocol costs (e.g. annual outcome 
measurement) unless these normally occurred as part of the intervention. Costs to 
patients in terms of personal, out-of-pocket expenses will be obtained from a 
questionnaire administered to a sample of participants. 
 
Treatment costs: An initial overview will be used to identify areas of treatment 
cost difference for patients in the two groups. The resource consequences of each 
area will be estimated using costing approaches similar to those outlined above. 
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Where appropriate, costs will be discounted to adjust for the distribution of costs 
incurred over time using annual discount rates. 
 
b) Comparison of costs and consequences: 
An initial economic evaluation will be performed based on a comparative 
assessment of the marginal costs and outcomes of the intervention introduced. 
This will be performed both from a societal perspective (including patient costs) 
and from a health care perspective. An initial cost consequence analysis will be 
conducted in order to map any resource consequences and measurable benefits. 
In addition, if significant differences in clinical outcomes are observed in the two 
groups a cost-effectiveness analysis using the EQ5D (EuroQol) index will be 
performed. A standard EQ-5D questionnaire will be administered to all trial 
participants to facilitate this. A careful analysis of the sensitivity of any findings 
will also be undertaken.  
 
c) Decision-modelling analysis 
A decision-modelling approach will be used to model costs and benefits. Short 
term outcomes measured in this study will be coupled with research evidence on 
the distribution of treatment modality effectiveness and disease progression in 
specific groups. The study findings will provide an analysis for PCTs, strategic 
health authorities and clinicians to indicate whether, and in what way, such a 
protocol-driven, multi-disciplinary intervention could be worthwhile for South 
Asian patients with type 2 diabetes. 
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Chapter 3 
Comparison of cardiovascular risk factors between south 
Asians and white Europeans with type 2 diabetes 
 
3.1 Introduction  
 
Cardiovascular disease is a major cause of morbidity and mortality worldwide. 
Like diabetes, however, the prevalence and susceptibility to cardiovascular 
disease varies significantly between ethnic groups. Reported mortality from 
cardiovascular causes is disproportionately higher in south Asians compared to 
other ethnic groups and contributes to nearly 40% of the global burden of 
cardiovascular disease. On its own, diabetes produces a two- to threefold increase 
in cardiovascular events and mortality(38) and, for South Asians there is a further 
50% increase (68). A higher burden of known risk factors has been suggested as a 
reason for the increased susceptibility to cardiovascular disease seen in south 
Asians. The known major risk factors, however, do not completely explain this 
increased risk. South Asian ethnicity may be associated with other risk factors or 
potentiate the effect of known risk factors. 
 
Many studies have compared the risk profiles of South Asians (SA) with white 
Europeans (WE) -  (78;87;118), but only a few have examined the effects of 
ethnicity on these risk factors in people with type 2 diabetes(119). South Asians 
typically have more visceral fat at a given BMI(99), lower HDL cholesterol and 
higher triglyceride levels and commonly develop type 2 diabetes at a younger age 
than white Europeans(78). Rates of smoking, particularly in south Asian women, 
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on the other hand, are significantly lower. The relative contribution of individual 
risk factors to the overall cardiovascular risk is different for South Asians(70), but 
it is not clear if these differences are sufficient to explain the risk or are amenable 
to change.  Risk factors operate in a continuum(120) and while a risk factor such 
as blood pressure recorded in south Asians resident in the UK may be within the 
“normal range” based on studies in Western urbanised populations, it may not be 
normal when compared to the indigenous blood pressures in rural South Asia (83) 
.Therefore, thresholds for intervention based on studies in other populations may 
not be relevant to the South Asian population.   
 
The aim of this study is to describe the cardiovascular risk factors in a south Asian 
population with type 2 diabetes and draw comparisons with a white European 
(WE) control population, examining the effect of ethnicity on individual risk 
factors, and explore differences using the Framingham(121) and United Kingdom 
Prospective Diabetes Study ( UKPDS)(122) risk engines.  
 
 
 
3.2 Methods 
 
The UKADS study design and details of patient selection have been described in 
the earlier chapter (Section 2.5). Briefly, 1486 South Asian (SA) subjects were 
recruited from 21 general practices in Coventry and Birmingham, UK, as a part of 
the main UKADS intervention study between May 2004 and April 2005. An 
additional 492 white European subjects were recruited from 4 general practices 
within the same area during the same period. The white European patients were 
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not part of the intervention and were recruited only for comparison of baseline 
characteristics.  
 
Detailed clinical history, diabetes onset, duration and current medication, plus 
anthropometric data, were collected for all patients at the time of entry to the 
study. Anthropometric measures included height, weight (from which BMI was 
estimated), and waist circumference. Ethnicity-specific BMI categories were used;  
for SA, normal <23 kgm-2, overweight 23-<25 kgm-2, obese >=25 kgm-2, and for 
WE, normal <25 kgm-2, overweight 25-<30 kgm-2 and obese >=30 kgm-
2)(100;101). Blood pressure was measured using an ‘OMRON’ electronic blood 
pressure measuring device and the average of 3 consecutive readings recorded. 
 
 
Laboratory: Serum electrolytes, HbA1c, total cholesterol, HDL cholesterol and 
triglycerides were measured in all patients. Lipid profile, Electrolytes and urea 
were measured by colorimetric method (Roche diagnostics) and HbA1c was 
measured using high performance liquid chromatography (HPLC-Tosoh inc.) 
method. Urinary albumin excretion (microalbuminuria) was estimated from one 
single measurement using an early morning urine sample. The albumin:creatinine 
ratio (ACR) was estimated in chemical pathology laboratories following 
measurement of urinary albumin by an immunoturbidimetric assay and urinary 
creatinine using a kinetic Jaffe assay. Proteinuria and microalbuminuria were 
defined as ACR>=30.0 mg/mmol for both males and females and ACR 2.5 – 30.0 
mg/mmol for males and 3.5- 30.0 mg/mmol for females respectively, with values 
below these thresholds indicating normal albuminuria.  
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10 year CHD risk was estimated for patients using both the Framingham and the 
UKPDS risk engines. In analysing CHD risk scores the Framingham age limits 
were applied, including patients aged 30 to 74 years and with no previous history 
of cardiovascular disease (CVD-including CHD, stroke, peripheral vascular 
disease) only. Risk scores were stratified for men and women separately into 10 
year age bands.  
 
3.3 Statistical methods 
 
Data measured on a continuous scale were compared between groups using 
Students t-test and Wilcoxon non-parametric tests as appropriate, while 
categorical variables were compared using the chi squared test. To investigate 
individual risk factors,(blood pressures, total and HDL cholesterol, triglycerides 
and HbA1c), taking confounding and the potential clustering effects of General 
Practice into account, multi-level mixed models were used. In all models, terms 
for age at diagnosis, duration of diabetes and gender were included, with further 
terms for other risk factors and their treatment assessed with respect to changes in 
the ethnicity effect observed. Smoking was coded “current” vs. “non smoking” for 
logistic regression analyses and odds ratio (OR) and 95% confidence intervals 
(95% CI) for SA vs. the WE ethnicity group adjusted for age, gender and other 
factors estimated. To allow comparison of Framingham and UKPDS 10 years 
CHD risk scores between ethnicity- defined groups, stratified data analyses were 
performed for women and men separately, using age bands 30-44, 45-54, 55-64 
and 65-74 years.  
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3.4 Results  
 
 
Risk factor data were collected for all patients in both ethnicity-defined groups 
(Table 3.1). South Asians were significantly younger than white Europeans (57 
vs. 65 years) and had a longer duration of diabetes (7.8 vs. 6.3 years). There were 
significantly more women in south Asian cohort compared to white Europeans 
(p=0.0150).The mean waist circumference and BMI were significantly lower in 
south Asians (Table 3.1). When ethnicity-specific cut-offs for obesity were 
applied, however, 92% of SA vs. 82% WE were either obese or overweight.  
 
Unadjusted comparisons showed significant differences between the groups in 
blood pressure, HbA1c and lipid profiles (Table 3.1). Mean systolic blood 
pressure (SBP) was 4mmHg lower in South Asians but diastolic blood pressure 
(DBP) was similar in both groups. Total cholesterol and triglyceride levels were 
significantly higher, and HDL cholesterol levels lower, in SA compared to WE 
(Table 3.1). HbA1c was significantly higher amongst SA than in WE (8.2% v 
7.2%) and these differences were observed across both genders.  
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Table 3.1: Comparison of risk profiles in South Asian (SA) and white European (WE) patients.,  
 SA 
N=1486 
WE 
N=492 
Statistical test result 
p 
 
Age 
 
57.0 (11.9) 
 
64.8 (11.6) 
 
<0.0001 
Duration 7.8 (6.7) 6.3 (7.0) <0.0001 
BMI (Kg/m2) 28.6 (5.5) 31.0 (7.2) <0.0001* 
Waist Circumference (cm)  101.7 (11.8) 105.5 (14.2) <0.0001* 
SBP (mmHg) 140.1 (20.8) 143.9 (19.7) 0.0004 
DBP (mmHg) 83.3 (11.0) 82.4 (10.7) 0.1400 
Total Cholesterol (mmol/l)  4.7 (1.1) 4.3 (0.9) <0.0001* 
Triglycerides (mmol/l) 2.5 (1.9) 2.0 (1.2) <0.0001* 
HDL (mmol/l) 1.3 (0.5) 1.5 (0.5) <0.0001 
HbA1c (%) 8.2 (1.9) 7.2 (1.4) <0.0001 
BMI (Kg/m2)categories # 
Normal 
Overweight 
Obese 
 
131 (  9) 
231 (16) 
1123 (76) 
 
89 (18) 
150 (31) 
252 (51) 
 
<0.0001 
Smoking status 
Current 
Ex- 
Never 
 
221 (15) 
128 (  9) 
1135 (76) 
 
75 (15) 
186 (38) 
231 (47) 
 
<0.0001 
Gender 
Females 
Males 
 
709 (48) 
776 (52) 
 
203 (41) 
287 (59) 
 
0.0150 
CVD history  268 (18) 105 (21) 0.1041 
Diabetes treatment 
Insulin 
Tablets 
Diet only 
 
290 (20) 
1020 (69) 
176 (12) 
 
65 (13) 
285 (58) 
142 (29) 
 
<0.0001 
Prescribing:    
Statins  711 (48) 350 (71) <0.0001 
Anti-hypertensives 817 (55) 336 (68) <0.0001 
ACE/ARB 567 (38) 258 (52) <0.0001 
Values shown are Mean ( Standard Deviation) and N (%) for categorical values. Missing data: SA 
duration diabetes (n=7), BMI (n=1), waist (n=39), systolic and diastolic BP (n=2), total cholesterol 
(n= 28), triglycerides (n=55), HDL cholesterol (n=100), HbA1c (n=68)  
WE age (n=3), duration diabetes (n=2), BMI (n=1), waist (n=6), total cholesterol (n=3), 
triglycerides (n=12), HDL cholesterol (n= 8), HbA1c (n=17)  
Notes:* statistical test is non-parametric (Wilcoxon)# BMI (Kg/m2) categories are ethnicity-
specific, SA normal <23, overweight 23-<25, obese >=25, WE normal <25, overweight 25-<30, 
obese >=30 
59 
 
After adjusting for confounding factors and clustering effects, there were no 
differences between the ethnic groups for SBP or DBP (Table 3.2). Whilst there 
was no significant difference in total cholesterol or triglycerides after adjustment 
for clustering and confounding, HDL cholesterol was significantly lower and 
HbA1c significantly higher in the SA ( Table 3.2).  
 
Table 3.2: Ethnicity effect (SA vs. WE) after adjustment for confounding plus 
clustering: 
 
Risk factor: Effect size:  SA – WE P value 
Systolic BP 
Diastolic BP 
HbA1c  
Total cholesterol 
HDL cholesterol 
Triglycerides  
-1.34 (-4.19 to 5.12) 
-0.30 (-1.97 to 1.36) 
0.50 (0.22 to 0.77) 
0.13 (-0.03 to  0.28) 
-0.09 (-0.17 to -0.01) 
0.14 (-0.10 to 0.39) 
P=0.3587 
P=0.7221 
P=0.0004 
P=0.1039 
P=0.0266 
P=0.2488 
 
 
 
Missing data for SA and WE inclusive:  
 
Systolic BP (n=21), diastolic BP (n=21), total cholesterol (n=49), HDL 
cholesterol (n=124), triglycerides (n=85), HbA1c (n=102)  
Confounding factors – all estimates are adjusted for age at diagnosis, 
duration of diabetes, gender, any diabetes treatment, statin treatment, 
obesity status (ethnicity-specific), history of CHD, hypertension, area and 
smoking status.  
 
 
60 
 
Current smoking prevalence was similar comparing SA to WE (Table 3.1). 
However, whilst there were 349 (24%) current or ex-smokers in the SA group, vs. 
261 (53%) WE, a greater proportion of WE were ex rather than current smokers 
(Table 3.1). In logistic regression analysis, adjusting for potentially confounding 
factors, including area (Birmingham vs. Coventry), diabetes treatment (insulin vs. 
diet, tablets vs. diet), treatment with statins and anti-hypertensives (No vs. Yes), 
CVD history (No vs. Yes), ethnicity-specific obesity (Normal vs. obese, 
overweight vs. obese) and age, a significant interaction between ethnicity and 
gender was identified. Repeating the adjusted multiple logistic regression for 
women and men separately, showed SA women were significantly less likely to 
be current smokers (OR= 0.35 [0.20 to 0.62], p<0.0003) while no significant 
difference was observed in men. 
 
There was a significant difference in albuminuric status comparing ethnicity 
groups; the prevalence of microalbuminuria was higher in the WE group than in 
SA (24% vs. 20%; P=0.354) but the combined prevalence of microalbuminuria 
and proteinuria was greater in SA (Table 3.3). SA had a significantly higher 
prevalence of proteinuria,( 7% vs. 2%, P<0.0001). In both ethnic groups there was 
a significant association between albuminuric status and increasing duration of 
diabetes, systolic blood pressure and HbA1c (Table 3.3) . 
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Table 3.3  Association of albuminuria status with ethnic background and other factors 
 Albuminuria status:  
 Normal 
(1350)              
Microalb-
uminuria 
(390) 
Proteinuria 
(112) 
Total 
(1852) 
 
P-value 
Ethnicity: 
SA 
White 
 
1007 (73) 
  343 (74) 
 
  281 (20) 
  109 (24) 
 
  101 ( 7) 
    11 ( 2) 
 
1389 
  463 
 
P<0.0001 
DM Duration: 
< 5 years 
5-9 
10-19 
20 + 
Systolic BP: 
<120  
120-139 
140-159 
160-179 
180+ 
HbA1c bands: 
<7.0% 
7.0-<8.0 
8.0% + 
 
  618 (77) 
  373 (74) 
  282 (68) 
    72 (56) 
 
  246 (83) 
  505 (75) 
  436 (73) 
  125 (60) 
    37 (49) 
 
  502 (80) 
  314 (76) 
  481 (65) 
 
  152 (19) 
   102 (19) 
   104 (25) 
    33 (24) 
 
    40 (14) 
  136 (20) 
  126 (21) 
    65 (31) 
    23 (30) 
 
  107 (17) 
    79 (19) 
  189 (24) 
 
    30 (  4) 
    26 (  6) 
    31 (  7) 
    23 (20) 
 
    10 (  3) 
    30 (  5) 
    35 (  6) 
    19 (10) 
    16 (21) 
 
    18 (  3) 
    22 (  5) 
    65 (10) 
 
  800 
  501 
  417 
  128 
 
  296 
  671 
  597 
  209 
    76 
 
  627 
  415 
  735 
 
P<0.0001 
 
 
 
P<0.0001 
 
 
 
 
P<0.0001 
 
 
 
 
* Missing data: age (n=3), duration DM (n=6), systolic BP (n=3), HbA1c (n=75). 
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1140 (77 %) SA and 317 (64%) WE fulfilled the Framingham age criterion and 
had no previous CVD history. Framingham 10 years CHD risk scores were 
estimated for 1064 (93%) SA and 308 (97%) WE. UKPDS 10 years CHD risk 
scores were estimated for 1022 (90%) SA and 296 (93%) WE. Mean 10 year CHD 
risk (Framingham) in SA was 11.7% in males and 7.3% in females, vs. 11.7% for 
males and 6.5% for females in the WE group. The estimated mean 10 years CHD 
risk using the UKPDS risk engine was 21.9% and 10.8% for SA males and 
females respectively and 22.6% and 10.1% for WE males and females 
respectively. In age band stratified analysis of 10 year CHD risk, statistically 
significantly raised risk scores for SA vs. WE were observed for age bands 55-64 
and 65-74 years. (Table 3.4). A history of CVD was recorded for 371 (19%) 
patients; 18% of the SA group and 21% of the WE group.  
 
 
 
 
Major differences in treatments were observed between the groups (Table 3.1). 
Compared with WE, SA were less likely to be prescribed statins (48% v 71%) and 
ACE inhibitors/ Angiotensin Receptor Blockers (38% v 52%) than WE. On the 
other hand, SA were more likely to be receiving oral anti-diabetes agents or 
insulin treatment (89 % v 71%) compared to WE (Table 3.1).  
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Table 3.4: All, plus age band-specific, Framingham equation and UKPDS 10 
years CHD risk scores divided by ethnicity and gender: 
 
 South Asian 
Mean (sd) 
White European 
Mean (sd) 
Test result 
p 
Framingham 10 years CHD risk scores: 
Females (30-74) 
All 
30-44 
45-54 
55-64 
65-74 
 
7.3 (6.2) 
1.8 (2.1) 
5.3 (3.9) 
9.4 (5.7) 
11.9 (7.4) 
 
6.5 (4.2) 
1.3 (2.0) 
5.3 (4.9) 
7.0 (3.6) 
7.4 (4.0) 
 
0.8648* 
0.5335 
0.9533 
0.0195* 
<0.0001* 
Males (30-74) 
All 
30-44 
45-54 
55-64 
65-74 
 
11.7 (8.8) 
4.7 (4.5) 
9.1 (6.6) 
13.5 (7.5) 
19.7 (7.4) 
 
11.7 (9.7) 
2.9 (2.9) 
8.6 (7.4) 
11.1 (8.0) 
15.4 (11.0) 
 
0.9631 
0.1451 
0.6891 
0.0468 
0.0039 
UKPDS 10 years CHD risk scores: 
Females (30-74) 
All 
30-44 
45-54 
55-64 
65-74 
 
10.8 (8.8) 
4.0 (2.3) 
7.2 (4.2) 
12.0 (6.4) 
21.1 (10.9) 
 
10.1 (5.7) 
3.7 (2.1) 
6.0 (2.7) 
8.8 (3.2) 
13.7 (6.1) 
 
0.2657* 
0.7533 
0.3059* 
0.0010* 
<0.0001 
Males (30-74) 
All 
30-44 
45-54 
55-64 
65-74 
 
21.9 (14.3) 
10.7 (5.9) 
16.2 (9.5) 
25.1 (11.4) 
37.0 (14.7) 
 
22.6 (13.8) 
10.0 (15.6) 
14.7 (9.0) 
19.4 (8.4) 
30.9 (14.7) 
 
0.5970 
0.0815* 
0.4220 
0.0006* 
0.0063 
Test results are from t-test, except: 
* variances unequal, P-values from non-parametric Wilcoxon test. 
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3.5 Discussion 
 
Strength of this large study is that the SA and WE subjects were recruited from 
the same community from inner city practices and both groups shared a common 
health care system and socio-economic environment.  The cohort reflects current 
UK experience and compared to the United Kingdom Prospective Diabetes Study 
(UKPDS) cohort, subjects in our study were older, had higher blood pressure, but 
lower HbA1c and total cholesterol. These differences in cholesterol and HbA1c 
reflect the secular trends in the management of patients with diabetes and 
dyslipidaemia over the last decade and the fact that in the UKPDS, subjects were 
selected at diagnosis. 
 
Comparison of the risk factors between the two ethnic groups showed significant 
differences in cardiovascular risk profiles. Typically, south Asians were younger 
and had lower BMI, waist circumferences and lower overall smoking rates (in 
women) than white Europeans. Systolic blood pressure and HDL cholesterol 
levels were lower, but triglycerides and HbA1c were higher in South Asians. 
These differences are consistent with those observed in previous 
(69;78;123)studies. Despite these major differences in risk profiles of SA and 
WE, after adjusting for confounding variables a significant ethnicity effect 
remained only for lower HDL cholesterol, much lower smoking and much higher 
HbA1c in the South Asians. These results suggest that the effect of South Asian 
ethnicity itself on the overall cardiovascular risk is modest and is probably 
mediated through increased predisposition to insulin resistance.  
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While SA in our study were younger, with a longer duration of diabetes compared 
to WE, as seen in other studies (78;123), the situation with regard to body 
composition is more complicated.  BMI and waist circumference were both 
significantly lower in SA than in WE. The majority of SA individuals would be 
classified as non-obese by using standard cut-offs for BMI. Studies suggest that 
for a given BMI, SA have more visceral fat than WE(99) and that it is not the 
absolute BMI value but fat distribution (particularly excess visceral fat) that best 
defines risk associated with obesity(124). To account for body build differences, 
ethnic-specific cut-offs should be used to define obesity(125) .  Applying these 
cut-offs showed overweight/obesity to be higher in SA than WE. 
 
Many earlier studies have reported similar or lower levels of cholesterol in South 
Asians compared to WE. The mean total cholesterol levels in South Asians in this 
study were interestingly higher than in WE. This is more likely to be due to the 
fact that fewer SA were on statins or lipid-lowering treatment compared to WE 
rather than a true difference. Epidemiological studies have consistently reported 
lower levels of HDL cholesterol in South Asians(70;126) and while we confirm 
this, the absolute difference in HDL is small and its clinical relevance (when total 
cholesterol is not different) is questionable. Studies have shown that SA have 
much more adverse lipid profiles and measuring total cholesterol alone may in 
fact be misleading. Instead, measuring the ApoB/ApoA ratio has been suggested 
as a better marker of dyslipidemia in south Asians(70). The utility of measuring 
ApoB/ApoA in routine clinical practice, however, is still not established.  
 
66 
 
SA in this study had poorer glycemic control than WE. The difference in HbA1c 
remained significant even after adjusting for duration of diabetes. The fact that 
this was so, despite the fact that a significantly greater proportion of SA were on 
glucose-lowering therapies (including insulin) than WE, is of great concern. 
While the poorer glycaemic control in SA in comparison to WE is likely to be a 
major factor in the high prevalence of microvascular complications, its 
relationship to cardiovascular disease may be more complicated(41;127).  There is 
a clear epidemiological link between HbA1c and cardiovascular morbidity and 
mortality and the assumption is that this is causal and the current strategy for type 
2 diabetes is to try to normalise blood sugars and reduce HbA1c(54).  Recent 
studies suggest that this is difficult to achieve in SA(123;128;129).  Furthermore 
the cardiovascular protection offered by current treatment strategies to tighten 
glycaemic control remains uncertain and may indeed do harm in older, long 
duration patients(39;40).   
 
Overall, rates of smoking in SA have been reported to be lower than in 
WE(58;60). While this was true in SA women, the rate of smoking in SA males in 
our cohort was comparable to that in WE. Further, compared to WE, the 
proportion of ex-smokers was significantly less in SA. Significant decline in the 
rates of smoking and CHD has been observed in most western populations in 
recent years following public health measures(130-132). The finding from this 
study raises concerns about the effectiveness of these measures in the SA 
population. 
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An interesting observation in this study is that the overall prevalence of 
microalbuminuria was similar in both ethnic groups. No difference in the 
prevalence of microalbuminuria between ethnic groups was observed in the 
UKPDS and our results support this, even though the subjects in our study had a 
longer duration of diabetes than in UKPDS. In contrast, significantly higher rates 
of microalbuminuria in south Asians have been reported in many earlier studies, 
including one from our own group(133;134). This variance may have arisen due 
to methodological differences and the fact that some of these studies were in 
smaller cohorts. On the other hand, the prevalence of overt proteinuria was 
significantly higher in south Asians. The reasons for this are not known. Given 
these contrasting results, more work studying microalbuminuria and proteinuria in 
south Asians needs to be done.  
 
To compare the CHD risk in both groups we used a general (Framingham) and a 
diabetes-specific (UKPDS) risk engine. The predicted risk scores for both groups 
were considerably lower than previously reported(135) and may reflect the 
widespread use of statins in recent years. Both the Framingham and the UKPDS 
risk engine predicted equal risk for South Asians and WE. This appears to be at 
variance with the prognosis we and others document(136;137).  However, age is 
the most important determinant of CHD risk and, as the mean age of SA was 
lower than WE, the reality of our finding is that SA have the same risk as WE 
who were seven years older.  As a rule of thumb, adjusting existing risk engines 
by ten years appears justifiable(138) but, if risk scores are to be used in routine 
practice, to provide valid estimates of risk, ethnicity-specific risk engines, based 
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on longer follow up of cardiovascular morbidity and mortality, are urgently 
needed. 
 
It may be particularly relevant here that SAs were less likely to be prescribed 
statins and inhibitors of the rennin-angiotensin system than WE. Despite the 
reported increase in statin prescriptions in recent years, the overall rates of statin 
prescriptions in SA are still lower than recommended(128). Even a small 
reduction in cholesterol is associated with significant cardiovascular 
protection(139)and it is difficult to justify denying statin treatment to a population 
that is  at high risk.  
 
3.6 Conclusion 
 
 
Cardiovascular disease and mortality risk are both potentially modifiable(140), 
but earlier detection of diabetes, impaired glycaemia and cardiovascular disease 
are the essential prerequisites  if health inequalities are to be rectified.  The 
practicality and potential benefits of systematic screening for diabetes and 
cardiovascular disease in South Asians at high risk remains a challenge for future 
study.  Furthermore, even in those where the condition is detected, there remains 
much work to be done to define and implement targets of risk factor reduction for 
blood pressure, lipids and glycaemic control.  Enhanced and ethnic-specific 
targets for obesity, hypertension, lipids and glycaemia, combined with more 
sensitive and focused healthcare delivery, have great potential to reduce these 
inequalities.
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Chapter 4 
The United Kingdom Asian Diabetes Study (UKADS): 
outcomes after 2 year culturally sensitive intervention. 
  
4.1 Introduction  
 
 
Many clinical trials have shown that effective risk factor control reduces both 
microvascular and macrovascular complications in patients with type 2 diabetes. 
Implementing the findings of these trials in clinical practice, however, is a major 
challenge. Prevalence of diabetes and the risk of its complications vary 
significantly between ethnic groups and are also influenced by social, economic 
and cultural factors. An integrated approach that addresses the specific needs of a 
community is therefore essential to achieve better health outcomes. Culturally 
sensitive models of health care in some ethnic groups have been shown to 
improve outcomes. Such models of health care delivery, however, have not been 
evaluated in randomised controlled trials and in particular in the South Asian 
population. 
 
 The United Kingdom Asian Diabetes Study (UKADS) is a cluster randomised 
controlled trial to evaluate a culturally sensitive intervention tailored to the needs 
of the South Asian population with type 2 diabetes. Following the success of the 
pilot trial (described in chapter 2) a definitive trial was undertaken between 2004 
and 2007.  
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The timing of the trial coincided with the introduction of the Quality and 
Outcomes Framework (QOF), a new initiative by the U.K Government to improve 
standards in primary care, and provided an opportunity to evaluate the impact of 
this initiative on diabetes care in our study population. In this chapter, the results 
of the two year culturally sensitive intervention are described and the clinical and 
economic implications discussed. 
 
4.2 Methods 
 
 
Twenty-one General Practices (seven in Coventry and fourteen in Birmingham, 
UK) with a very high proportion (>80%) of South Asians were included in the 
study. All the practices were approached individually with an aim to recruit 18 to 
20 clusters. Response rate from the practices was 100% with all the practices that 
were approached agreeing to participate in the study. 10 of the 21 practices were 
group practices while remaining 11 were managed by a single practitioner. 
Number of patients registered with these practices ranged from 3600 to 5000 for 
single GP practices and 10,000 to 14000 for the group practices. Nine practices 
were randomised to enhanced (intervention) and twelve to conventional (control) 
care; a common treatment algorithm was provided ( Appendix 1 to 3).  All adult 
patients with type 2 diabetes were eligible for inclusion in the study (Figure 4.1). 
 
 
 
 
71 
 
4.2.1 Protocol and targets 
 
 
Enhanced care included an additional practice nurse session per week supported 
by link workers and a community diabetes specialist nurse. Patients in the 
intervention group were followed up on average every two months in weekly 
clinics run by the practice nurses.  
 
Practice nurses worked with primary care physicians to implement the protocol 
and encourage appropriate prescribing, provide face-to-face patient education in a 
clinic setting and achieve targets for blood pressure, lipid and glycaemic control. 
Each patient was contacted by a link worker before and between appointments to 
encourage clinic attendance. In addition, link workers provided interpretation and 
additional educational input to the patients in the community setting in local 
languages to improve compliance and understanding and to encourage dietary and 
lifestyle change. The community diabetes specialist nurse attended some of the 
research clinics and provided additional educational and clinical support, 
including insulin initiation, to the practice teams. All staff had formal training in 
diabetes care and were experienced in delivering diabetes care in the practice 
setting.  
 
Practices were encouraged to adhere to treatment protocols and to achieve targets. 
The study targets followed internationally accepted norms and were HbA1c 7.0%, 
total Cholesterol  4.0 mmol/l (160mg/dl) and blood pressure 130/80 mmHg if no 
microvascular complications (as recommended by the Joint British Societies and 
international bodies)(48;141;142) and 125/75 mmHg if microalbuminuria or 
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proteinuria were present.  Control practices received the same treatment protocols 
and the practices managed patients with their existing resources.  
 
The study protocol was approved by East Birmingham and Coventry Primary 
Care Trust Ethics Committees. Graphical representation of components and 
timings of the complex intervention are outlined in figure 4.1(143). 
 
Primary outcomes were follow-up measurements for blood pressure, total 
cholesterol and HbA1c, with secondary outcomes of waist circumference, body 
mass index (BMI) and Framingham 10 years Coronary Heart Disease (CHD) risk 
score(121), microalbuminuria and plasma creatinine. 
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Figure 4.1: Graphic representation of the complex intervention trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timeline Intervention Control 
Month 0 
Randomisation of 
practices  
 
F C C,F  
Months 1-8 
Recruitment of 
patients and baseline 
data collection 
 
B, C, D 
E,G 
B,F,E 
G 
2 monthly research 
clinic appointments 
 
B, C, D 
A  
F 
 A, F 
Research 
monitoring  meetings-
(2-3 months apart) 
 
G, C, D G, C 
Months-12-32 
Outcomes assessed 
 
B, C, D 
E 
B, C 
E 
A Prescribing algorithms - algorithms for blood pressure, blood glucose and 
lipid control (Appendix 1-3) 
 
B Practice Nurse  - protected time to run research diabetes clinic in 
intervention practices. Dietary advice and implementation of protocols. 
Practice nurses were formally trained in diabetes and had 1:1 observed 
sessions in DSN run clinics. For control practices, data collection only. 
 
C Specialist Nurse - clinical input including insulin initiation and 
educational role. Attendance at some, but not necessarily all, research 
clinics. Two specialist nurses were responsible for all 21 practices in the 
trial, one based in Coventry and one in Birmingham.  For control 
practices, data collection only. 
 
 
D Link Workers - educational, communication and facilitation role, 
promoting patients’ understanding and concordance. Link workers 
attended research clinics in intervention practices. A total of 5 link 
workers were employed, 3 in Birmingham (14 practices) and 2 in 
Coventry (7 Practices), with each responsible for 3 or more practices. All 
link workers attended a foundation course in diabetes management and 
also passed a long distance course for diabetes care technicians. 
 
E Questionnaires for patients – Quality of Life (EQ5D), and economic 
analysis data collection. 
 
F General Practitioners - overall responsibility for implementation of 
the study protocol within their practice. This was mainly devolved to the 
responsible Practice Nurse. GPs were involved in changing prescribing 
processes. 
 
G Research team - oversaw study processes. Meetings to monitor 
recruitment and data collection, to discuss and address issues of study 
conduct and management.  
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4.2.2 Sample size estimation and power  
 
 
This was a cluster randomized trial with General Practice the unit of 
randomization. Sample size estimations were made based on the observed 
differences and intra-class correlations (ICC-defined as between groups/ within 
groups variance) from the pilot study or an ICC = 0.05, which is derived from 
published estimates for primary care studies(144;145). In all estimations, power 
was set to 80%, and the probability value to P=0.05. Estimates were made for 
differences in changes in systolic blood pressure (7mmHg, with standard 
deviation (s.d.) 21.25 and ICC=0.035), total cholesterol (0.45mmol/l, s.d.=1.1, 
ICC=0.05) and HbA1c (0.75, s.d=2.1, ICC= 0.05). All estimates from above data 
values resulted in 16-18 clusters of 80-100 patients being needed, allowing for 
10% drop-out rate, as observed  in the pilot study.  The rationale for these effect 
sizes was that they were similar to those observed in the pilot study, changes of 
this magnitude would be clinically significant and also they reflected prescribing 
algorithm targets. 
 
4.2.3 Statistical methods 
 
 
Data were analysed using the SAS software package. Baseline variables were 
compared between groups using χ2 tests of independence, with t-tests for 
continuous variables, which were first assessed for normality. Primary and 
secondary outcomes were continuous. In the main intervention evaluation, final 
measured outcomes were modelled, with grand mean centred baseline measures 
included as covariates. To adjust for clustering and potential confounding effects, 
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the SAS PROC MIXED procedure was used to fit hierarchical, combined fixed 
and random effects models(146;147). In all cases, mixed models included fixed 
effects for area (Birmingham vs. Coventry), gender, age at diagnosis of diabetes, 
duration of diabetes and corresponding grand mean centred baseline 
measurement. For HbA1c, treatment with insulin at baseline was included in final 
models. Terms for anti-hypertensive treatments, angiotensin-converting enzyme 
inhibitors (ACE) or angiotensin receptor blockers (ARB) at baseline were 
included in blood pressure models. For total cholesterol, statins and fibrates were 
included. Random effects were fitted, within a subject term for General Practice, 
allowing for different intercepts and regression slopes for each individual practice 
(random coefficients models) .  
 
Restricted maximum likelihood models (REML) were used to analyse data. The 
correlation structure used in reported results was “unstructured” in all cases; 
“variance components” structures were considered. SAS graphics options were 
used to plot and evaluate residuals and influential data points, which were then 
removed and models re-run; results presented do not exclude outliers. For the 
main intention to treat analysis comparing outcomes, all patients were included, 
with the exception of those who had died (n=48). For patients included in analyses 
but whose follow-up data were not available (Fig.4.2), data imputation using last 
observation carried forward (LOCF) was used; this was an interim value measured 
after one year for around 50% of cases, or the baseline value. Analyses using the 
same final models were performed using only subjects with complete data; whilst 
estimates of effect differed slightly, results and their interpretation were 
essentially the same.  
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Economic analysis and Quality of life data 
 
Detailed data on staff salaries, travel and subsistence, equipment costs, payment to 
practices, and prescribing were collected to estimate the net intervention cost over 
a 2 year period. Changes in quality adjusted life years between intervention and 
control groups were measured using the EQ5D questionnaire(148). An interim 
within trial cost effectiveness analysis was done using the above measures with a 
plan for long term decision modelling in due course. All the economic analysis 
and cost effectiveness evaluation was done by Prof. Ala Sczcepura and her team 
from the Warwick Medical School. The original study plan intended to collect 
Quality of Life measures in trial participants. However, due to logistics reasons 
and lack of resources, this data was not collected and a decision to not include 
these measures was made during the research group meeting at the start of the 
trial. 
 
4.2.4 Sub group analysis 
 
 
In order to evaluate the improvements in risk factors in patients whose risk factors 
at baseline were above the targets recommended by QOF (blood pressure ≥ 
145/85 mmHg, total cholesterol ≥ 5mmol/L and HbA1c ≥ 7.5% ), a post hoc 
analysis was carried out. Differences between the treatment groups were 
compared using similar methods and statistical techniques described above. A 
separate analysis was carried out to determine the proportion of patients achieving 
the UKAD study and the QOF targets. 
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4.3 Results 
 
4.3.1 Patient demographics and baseline risk factors 
 
1486 patients of South Asian ethnicity, with established type 2 diabetes, 
consented to take part and were included in the study; 500 (33.7%) from Coventry 
and 986 (66.3%) from Birmingham. Of these patients, final intention to treat 
analyses included 1438 (97%), excluding 48 who died during 2 years follow-up 
(Figure 4.2).  
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Figure 4.2 – Practice and patient recruitment and progress through the trial 
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Baseline risk factor profile, comparing the intervention and control groups, is 
shown in Table 4.1. Mean age for the whole group was 57.0 years, standard 
deviation (SD) 11.9 years. Differences observed between groups for gender, age, 
duration of diabetes and diabetes treatment modalities were not statistically 
significant. Current smoking prevalence (15%) was similar in both groups, but 
more control patients were ex-smokers. There were no differences in weight, body 
mass index (BMI) or waist circumference measurements. Significantly more 
intervention than control patients were treated with statins (Table 4.1)  
 
At baseline, 268 (18%) patients had evidence of existing CHD or prior 
cardiovascular events; angina, myocardial infarction, cardiovascular accident, 
coronary artery bypass graft or other heart problems; this group was comprised of 
150 (17%) intervention and 118 (19 %) control patients.  
 
Urinary albumin:creatinine ratio was measured for 1295 (87%) patients and 
microalbuminuria (defined as a ratio >2.5mg/mmol in males and >3.5 mg/mmol 
in females) was present in 268 (19%) patients. Significant proteinuria, defined as 
albumin:creatinine ratio of >30mg/mmol was detected in 114 patients (8%). The 
prevalence of combined microalbuminuria or proteinuria was 28%, with no 
difference between intervention and control groups.  Using the Framingham 
equation, mean (S.D) 10 year CHD risk score was 10.6 (8.8) with no difference 
between treatment groups (Table 4.1). 
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Table 4.1: Baseline characteristics of intervention and control subjects. 
 Intervention 
(N=868) 
Control  
(N=618) 
  Total 
Sex 
 
   
   Women 396 (46%) 313 (51%) 709 (48%) 
   Men 
 
472 (54%) 304 (49%) 776 (52%) 
Age ( years)    
  <45 131(15%) 84   (14%) 215 (14%) 
   45-64 467 (54%) 363 (59%) 830 (56%) 
  ≥ 65 270 (31%) 171 (28%) 441 (30%) 
Duration of Diabetes (years) 
 
   
   0-4 367 (42%) 222 (36%) 589 (40%) 
   5-9 230 (27%) 189 (31%) 419 (28%) 
   10-19 197 (23%) 161 (26%) 358 (24%) 
   ≥ 20  72 (8%)   41 (7%) 113 (8%) 
Treatment 
 
   
   Insulin 161 (19%) 129  (21%) 290 (20%) 
   Oral 591 (68%) 429 (69%) 1020 (69%) 
   Diet only 116 (13%)   60 (10%) 176 (12%) 
Smoking status 
 
   
   Current Smoker 135 (16%) 86 (14%) 221 (15%) 
   Ex-Smoker   59 (7%) 69 (11%) 128 (9) 
   Non-Smoker 
 
673 (78%) 462 (75%) 1135 (76%) 
Weight (kg) 
 
76.2 (14.6) 75.2 (14.6) 75.8 (14.5) 
Waist (cm) 
 
102.0 (11.5) 101.3 (12.3) 101.7(11.8) 
BMI  (kg/m2) 
 
28.5 (4.8) 28.6 (4.9) 28.5(4.9) 
Framingham 10 years CHD  
risk score 
 
10.5(8.8) 10.6(8.8) 10.6(8.8) 
Risk Factors 
 
   
Mean arterial pressure (mmHg) 101.7 (12.9) 102.9 (12.9) 102.2 (12.9) 
Systolic Blood Pressure (mmHg) 139.4(21.1) 141.1(20.3) 140.1(20.8) 
Diastolic Blood Pressure (mmHg) 82.9(11.0)  83.8 (11.1)  83.3 (11.0) 
Total Cholesterol (mmol/L)  4.7 (1.1) 4.7 (1.1)  4.7 (1.1) 
HbA1c (%) 
 
 8.2 (1.9) 8.2 (1.8)  8.2 (1.9) 
Prescribed drugs    
   All antihypertensives  475(55%) 342 (55%) 817 (55%) 
   ACE/ARB  321(37%) 246 (40%) 567 (38%) 
   Statins   438(50%) 273  (44%) 711 (48%) 
 
Data are number (%) or mean (SD). Missing data: duration of diabetes (n=7), smoking 
status (2), weight (2), waist circumference (5),BMI (10),total cholesterol (2) and HbA1c (13). 
Significant difference between groups for smoking (p=0.01) and statins (p=0.02).
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Effect of intensive control for 2 years  
 
During 2 years of follow-up, 48 (3%) patients died 24 (3%) intervention and 24 
(4%) control (P=0.972). New cardiovascular events were recorded for 97 (7%) 
patients, 62 (7%) intervention and 35 (6%) controls. None of these small 
differences between intervention and control groups were significant. Patients 
with CHD at baseline were more likely to die (18 [7%] vs. 30 [2%] of those 
without CHD), or to experience CHD events during follow-up (34 [13%] vs. 63 
[5%] of those without CHD), irrespective of treatment group. 
 
Results for comparison of outcomes between intervention and control groups are 
presented in Table 4.2; unadjusted differences compared with a t-test, plus results 
from multiple linear and mixed regression modelling are shown. Comparing 
treatment groups, after two years there was a reduction of 5.1 mmHg in systolic 
blood pressure and 4.6 mmHg in diastolic blood pressure for the intervention 
group vs. 4.6 mmHg and 2.9 mmHg respectively in the control group. T-tests 
showed significant differences in favour of the intervention group for diastolic BP 
and HbA1c. After adjustment for potentially confounding effects, diastolic BP, 
mean arterial pressure (MAP) and HbA1c showed significant advantages for the 
intervention group. In final models taking clustering effects into account, 
significant effects persisted for the intervention group for both MAP and diastolic 
BP (Table 4.2).  BMI was significantly increased in the intervention group. 
Differences between the groups in HbA1c, total cholesterol, waist circumference 
and CHD risk scores were small and not statistically significant after adjustment 
for confounding and clustering (Table 4.2). 
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Table 4.2. Outcomes, adjusted for potential confounding and for clustering: 
Outcomes: (A) Difference 
between means 
(P value) 
(B) Differences least 
squares means 
(P value) 
(C) Differences least 
squares means 
( P value) 
Primary: 
MAP 
 
Systolic BP 
 
Diastolic BP 
 
Total cholesterol 
 
HbA1c 
 
 
-1.28 (-2.60 to 0.03) 
(0.0560) 
-0.48 (-2.43 to 1.47) 
(0.6280) 
-1.68 (-2.89 to -0.48) 
(0.0060) 
-0.02 (-0.09 to 0.14) 
(0.7001) 
-0.18 (-0.34 to -0.01) 
(0.0040) 
 
-2.21 ( -3.30 to -1.11) 
(0.0001) 
-1.67 (-3.30 to 0.05) 
(0.0437) 
-2.46 (-3.48 to -1.46) 
(<0.0001) 
0.03 (-0.07 to 0.13) 
(0.5595) 
-0.13 (-0.28 to -0.02) 
(0.0825) 
 
-1.58 (-2.73 to -0.43) 
(0.0072) 
-0.56 (-2.69 to 1.56) 
(0.6027) 
-2.12 (-3.12 to -1.12) 
(0.0001) 
0.02 (-0.07 to 0.12) 
(0.6537) 
-0.16 (-0.34 to 0.01) 
(0.0680) 
Secondary: 
CHD risk (Fram) 
(n=1342)* 
Waist (cm) 
 
BMI 
 
 
0.08 (-0.55 to 0.71) 
(0.8030) 
-0.28 (-1.04 to 0.49) 
(0.4780) 
0.37 (0.19 to 0.55) 
(<0.0001) 
 
-0.11 (-0.64 to 0.43) 
(0.6899) 
-0.20 (-0.82, 0.43) 
(0.5396) 
0.39 (0.21, 0.56) 
(<0.0001) 
 
-0.002 (-0.58 to 0.58) 
(0.9944) 
-0.30 (-1.41, 0.82) 
(0.6017) 
0.40 (0.20, 0.60) 
(0.0001) 
* Note:- Framingham CHD risk only estimated for patients aged 30 to 74 yrs at baseline. 
Notes  
A - crude differences based on t-test comparison, no adjustment. 
B - differences based on fixed effects model, adjusted for confounding. 
C - differences based on mixed model, adjusted for confounding and clustering. 
Intervals presented in parentheses are 95% confidence interval (95%CI) 
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The percentage of patients with microalbuminuria or proteinuria increased from 
27% at baseline to 32% after 2 years, with no significant difference between the 
intervention and control groups. Patients at high renal risk, defined by plasma 
creatinine >120mmol for females and >150 mmol for males, increased from 3% at 
baseline to 4% after 2 years, with no difference between treatment groups.  
 
Combining all patients from intervention and control groups after two years, there 
was an overall decrease of 4.9 mmHg (4.0-5.9) in systolic blood pressure 
(P<0.001), 3.9 mmHg (3.3-4.4) in diastolic blood pressure (P<0.001) and 4.2 
mmHg (3.6-4.9) in MAP (P<0.001). Total cholesterol decreased by 0.46 mmol/L 
(0.40-0.52) (P<0.001). A very small and statistically non-significant increase was 
observed for HbA1c; 0.06% (-0.02 to 0.15), P=0.135. 
 
4.3.2 Prescribing changes at 2 years 
 
 
After two years follow-up, the proportion of patients treated with anti-
hypertensives had increased to 75% overall, with no difference between groups. 
Treatment with statins had increased and the difference between treatment groups 
disappeared, with 540 (64%) intervention vs. 389 (65%) controls treated. The use 
of ACE inhibitors or Angiotensin Receptor Blockers increased substantially from 
37% to 65% in the intervention group and 40% to 62% in the control group (no 
significant difference between groups). Similar proportions of patients were 
treated with insulin at baseline; 161 (19%) intervention and 129 (21%) control.  
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After 2 years, more intervention than control patients had started insulin therapy 
(47 [8%] vs. 23 [5%]), but this was not statistically significant (relative risk [RR] 
1.44 [0.89 to 2.34]).   
 
4.3.3 Sub-group analysis: patients at high risk  
 
 
In patients with blood pressures greater than 145/85 mmHg at presentation, the 
mean reduction in SBP was 12.8 mmHg in the intervention group and 10.4 mmHg 
in the control group Mean difference in SBP in these patients was 2.5mmHg 
(P=0.084). After adjustment for confounding and clustering factors the difference 
was only borderline signficance. For DBP the difference was 2.8mmHg (t=-3.41, 
P=0.001) and the difference between treatment groups remained significant after 
adjusting for confounders and clustering (Table  4.3).No significant differences 
between groups were observed for serum total cholesterol and HbA1c. 
 
In post-hoc analyses, the number of patients achieving the study targets for blood 
pressure was 310(36%) of the 868 in the intervention group versus 191(31%) of 
618 in the control group; for cholesterol, 411(47%) of 867 in the intervention 
group versus 311(50%) of 617 in the control group; and for HbA1c, 275(32%) of 
858 in the intervention group versus 165(27%) of 615 in the control group. For 
QOF targets, the corresponding numbers for blood pressure less than 
145/85mmHg was 575(66%) versus 346(56%); for cholesterol less than 5mmol/l, 
700(81%) versus 509(83%); and for HbA1c less than 7.5%, 377(44%) versus 240 
(39%). These are summarised in Table 4.4.  
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The proportion of patients in the intervention group achieving the study targets for 
blood pressure and HbA1c was greater in the intervention group but these 
differences were not statistically significant. 
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Table 4.3: High risk groups outcomes, adjusted for potential confounding 
and for clustering: 
Systolic BP analyses include only patients with systolic BP>145 mmHg at 
baseline 
Diastolic BP analyses include only patients with diastolic BP>85 mmHg at 
baseline 
 
 (A) 
Difference between 
means 
T-Test P value 
(B) 
Differences least 
squares mean* 
Fixed effects P value 
(C) 
Differences least 
squares mean** 
Cluster adjusted P 
value 
 
Systolic BP 
 
Diastolic BP 
 
 
-4.72 (-7.96 to -1.48) 
0.0044 
-1.73 (-3.44 to -0.01) 
0.0494 
 
-4.57 (-7.52 to -1.62) 
0.0024 
-2.21 (-3.83 to -0.59) 
0.0075 
 
-2.87 (-5.78 to -0.04) 
0.0527 
-3.41 (-5.27 to -1.51) 
0.0014 
Notes :   
 A - differences based on t-test comparison, no adjustment for confounding or clustering 
.B - differences based on fixed effects model, adjusted for confounding. 
 C - differences based on mixed model, adjusted for confounding and clustering. 
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Table 4.4: The proportion of patients in intervention and control groups 
achieving UKADS and QOF targets at 2 years. 
 
 Intervention 
 
 N (%) 
Control 
 
N(%) 
UKADS Targets 
 
  
  
Blood Pressure 
 ≤ 130/80 mmHg 
 
310 (36) 
 
191(31) 
Total Cholesterol 
≤ 4mmol/L 
 
411 (47) 
 
311(50) 
 
HbA1c 
  ≤ 7% 
 
275 (32) 
 
 
165(27) 
 
QOF Targets  
 
 
  
Blood Pressure 
 ≤ 145/85 mmHg 
 
 
575(66) 
 
346( 56) 
Total Cholesterol 
≤ 5mmol/L 
 
 
700 (81) 
 
509(83) 
 
HbA1c 
≤ 7.5% 
 
377 (44) 
 
240 (39) 
 
Missing data after 2 years: blood pressure (n=128), total cholesterol (n=134), 
HbA1c (n=135). 
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4.3.4 Cost of intervention and quality of life 
 
A detailed cost breakdown is presented in Table 4.5. The total cost of enhanced 
diabetes care over two years was £ 303,554 with over two thirds of this cost 
accounted towards the salaries of practice nurses, link workers and clinical time of 
specialist nurses. Over two years, the cost of intervention per patient was £434 
(£406 net service and £28 net prescribing costs). The net prescribing cost for non 
diabetic drugs was £16 and £12 for diabetes drugs. Overall quality of life in the 
studied subjects deteriorated over 2 years. In spite of that, the resultant net change 
in quality of life in the intervention over control group was positive, although 
small. The incremental cost-effectiveness ratio is calculated to be £28,933 per 
Quality of Life Year (QALY) gained. 
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Table 5. Intervention costs and incremental cost-effectiveness over 2 years 
 
Intervention costs (incremental cost between intervention & control) 
1. Staff salaries* £224,774
2. Payment to practices(incremental cost between intervention and 
control practices)** 
£50,000
3. Travel and subsistence £17,720
4. Clinical equipment £11,060
Total enhanced diabetes care service over 2 years £303,554
Per patient enhanced service cost over 2 years £406
Prescribing cost (incremental cost between intervention & control) 
Per patient net prescribing cost for non-diabetic drugs over 2 years £16
Per patient net prescribing cost for diabetic drugs over 2 years £12
Per patient net prescribing cost over 2 years £28
Total per patient incremental net cost of intervention over 2 years £434
Per patient quality adjusted life year (QALY) gain over 2 years 0.015 
Incremental cost per QALY gained £28,933  
 
* Staff salaries covered two specialist nurses’ and five link workers’ clinical time. 
The salaries included national insurance and pension contributions. 
** It is the net amount paid to nine intervention practices to implement the 
intervention over two years. 
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4.4 Discussion 
 
The achievement of targets set by national and international advisory 
bodies(48;55;141;142) in general practices in inner city areas with a high 
prevalence of socially diverse ethnic groups poses a major challenge. The twenty-
one practices included in our study represent those in areas with a large number of 
patients of South Asian origin. These areas generally have a higher prevalence of 
diabetes mellitus, impaired glucose tolerance and are socially deprived with high 
Townsend scores(141;149).  In keeping with previous reports, the  South Asian 
patients with type 2 diabetes described in our study were younger than the average 
age described in general practice and had a shorter duration of diabetes(78). 
 
At baseline, a large majority of our patients had HbA1c >7% (70%), BP >130/80 
mmHg (76%) and total cholesterol >4 mmol/l (70%); above targets recommended 
by international standards for diabetes care.  After two years in which secular 
changes included the pay for performance initiative, there were significant 
improvements in blood pressure and total cholesterol across the whole study 
population, but no change in HbA1c. Systolic blood pressure decreased by 4.9 
mmHg, diastolic by 3.9mmHg and mean cholesterol by 0.46 mmol/l. These 
reductions are both statistically and (if sustained) clinically highly significant 
given the population considered. Many studies have shown a direct relationship 
between blood pressure and cardiovascular risk with a reduction in blood pressure 
associated with rapid reduction in such risk(150-152). The relationship between 
blood pressure and cardiovascular risk is such that a reduction of 5 mmHg, if 
sustained would confer substantial protection from cardiovascular events(153).  
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The improvements in blood pressure and cholesterol in our study were associated 
with increased prescribing of anti-hypertensive agents and statins and are 
consistent with improvements reported by several others following introduction of 
the QOF initiatives (154). Overall cardiovascular risk estimated by the 
Framingham formula showed a small but significant improvement overall, but no 
difference between groups. 
 
The mortality observed during the study (3%), together with the baseline (18%) 
and follow-up (7%) frequency of cardiovascular events, confirm that the South 
Asian group we studied has a high cardiovascular risk and that substantial benefits 
could be obtained by aggressive risk factor reduction. The failure to prevent an 
increase in microalbuminuria, despite a 5mmHg reduction in blood pressure, is 
surprising and suggests that lower targets may be needed for this group.  
 
Comparing intervention and control groups after two years, significant differences 
were observed between groups for diastolic blood pressure and mean arterial 
pressure after adjustment for confounding factors and clustering. Systolic blood 
pressure was lower in the intervention group but this was not statistically 
significant. The reductions seen in diastolic pressure were comparable to those 
observed in our pilot study but the reduction in systolic pressure was less than 
previously achieved. It is possible that the relatively young age of onset and 
ethnicity may be a factor in this observation and it is interesting that a more 
pronounced diastolic effect has been reported in some other studies(155) .   
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In the control group HbA1c tended to rise, while in the intervention group it 
remained stable over two years. The lack of improvement in HbA1c may be due, 
at least in part, to the natural disease progression commonly seen in type 2 
diabetes(156).  It is disappointing, given the healthcare resources provided, that 
neither the QOF incentives nor our culturally sensitive enhanced care package 
impacted significantly on glycaemic control in these patients of South Asian 
ethnicity.  
 
Despite clear evidence of failure to reach target levels of HbA1c via diet and oral 
anti-diabetes therapy, only a small increase in the percentage of patients treated 
with insulin was observed in both groups (8% vs. 5% for intervention and control 
groups respectively). Even though the intervention included support from 
specialist diabetes nurses with experience of insulin initiation and enhanced time 
for patient education, this appears to have had only a limited effect in terms of 
behavioural change or patient acceptance of insulin.  
 
Initiating insulin in primary care in the UK is relatively new and building up 
confidence of both the health care team and South Asian patients may be as 
important as any financial incentives paid to the former. Changing patient 
behaviour through motivation and patient education might take longer than the 
two years follow-up in this study. Alternative methods of motivation, including 
structured patient education(157) and more aggressive insulin initiation, may be 
needed. To fully optimise adherence to treatment protocols, extending the role of 
the nurse to prescribe in primary care may improve patient outcomes. 
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 A small but statistically significant increase in BMI was noted in the intervention 
group. One likely reason for this could be the increased use of insulin in the 
intervention group but other factors such as poor adherence to lifestyle advice 
may have also contributed. Clearly, research is required into the barriers to 
therapeutic use in patients of South Asian origin with type 2 diabetes, as well as 
new methods to incentivise patients to accept sustained lifestyle change, anti-
diabetes drugs, and insulin treatment.  
 
One limitation of our study is the inability to assess the relative contributions of 
individual components of the intervention; such difficulties are inherent to 
evaluation of complex interventions. Interestingly, only a small proportion of 
patients achieved the study targets for cholesterol, blood pressure and HbA1c 
compared to those achieving the QOF targets. Neither the tight treatment 
algorithms, additional time input from the practice nurses and link workers nor the 
QOF initiatives had any impact on these outcomes suggesting that overall there 
was poor adherence to treatment protocols. The failure to meet the study targets 
suggests that there was reluctance on the part of health professionals to intensify 
treatments and aim for evidence-based targets rather than the arbitrary targets set 
by the QOF initiative. Other factors such as reduced patient motivation, reluctance 
of primary care staff to initiate insulin and resistance from patients might have 
impeded the achievement of better metabolic control. Such factors will not be 
exclusive to South Asians in UK primary care and may be relevant to other racial 
groups and healthcare settings. 
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The economic analysis showed that the financial investment required over two 
years (£434 per patient) did not produce sufficient health related quality of life 
gain to make such a nurse-led intervention clearly cost-effective. At £28,933 per 
QALY gained, compared to an indicative norm of £30,000 per QALY(158), wide-
scale implementation is not indicated without improvement in effectiveness.  
 
 
4.5 Conclusion 
 
 
Considerable difficulties in recruiting and retaining individuals of South Asian 
ethnicity have been reported previously by several investigators(109;110), which 
may account for the lack of large scale studies in this area(159).  However, our 
experience indicates that recruitment and retention is possible in this hard to reach 
group.  Our results suggest that small but sustained improvements in blood 
pressure can be achieved through the introduction of a culturally sensitive 
enhanced care package for South Asian patients in addition to improvements from 
the QOF financial incentives. Improvement in glycaemic control remains a major 
challenge and further work to enhance effectiveness of healthcare delivery in 
general practice and to improve motivation is clearly needed for this group if 
healthcare inequalities are to be reduced.  Thus while progress has been made, 
there remains a substantial challenge in achieving the more stringent targets 
required by national and international expert advisory bodies.
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Chapter 5 
Genetics of type 2 diabetes 
 
5.1 Introduction    
 
The prevalence and severity of diabetes varies significantly between 
populations(16). While environmental factors are known to greatly influence 
disease susceptibility they alone do not fully explain the differences between 
ethnic groups. Genetic factors often determine an individual’s response to the 
environment and recognising the role of these factors is essential to our 
understanding of the molecular mechanisms involved in the causation of the 
disease. 
  
5.2 Role of Genetics in Diabetes  
 
The role of genes in the pathogenesis of type 2 diabetes is supported by studies 
involving monozygotic twins and the familial clustering of diabetes. Studies in 
monozygotic twins have reported concordance rates for the disease of up to 70 % 
(160) compared to rates of 30% in dizygotic twins(160;161) .  The genetic basis of 
type 2 diabetes is further supported by familial aggregation. The life time risk of 
developing type 2 diabetes is about 40% if one parent is affected and this risk 
increases to almost 70% if both parents are affected(160;162). Diabetes 
prevalence also varies significantly between ethnic groups and certain ethnic 
groups, such as Nauru, Pima Indians and the South Asians, have much higher 
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rates of type 2 diabetes than white Europeans(16). Although environmental factors 
play a major role in these differences, genetic factors also appear to be important.  
Admixture studies involving different ethnic groups have shown an inverse 
relationship between the extent of interbreeding and diabetes prevalence, 
suggesting differences in genetic susceptibility determine the risk of disease(163).  
Type 2 diabetes, however, includes a wide spectrum of disorders with variable 
degrees of gene –environment interaction, including those with single gene 
defects and minimal environmental influence  and those that involve many genes 
and a greater environmental influence(63;164). This complex interaction between 
genes and the environment makes understanding of the pathogenesis of type 2 
diabetes challenging.  
 
5.2.1 Monogenic diabetes 
 
Monogenic forms of type 2 diabetes are predominantly due to single gene defects 
and account for less than 5% of all diabetes(63;165). They manifest early, have 
high phenotypic penetrance and are less influenced by environmental factors. 
Several sub groups of monogenic forms of type 2 diabetes are now recognized and 
include insulin resistance syndromes, mitochondrial diabetes and Maturity Onset 
Diabetes in the Young (MODY)(165).   
 
First described in 1965, MODY comprises a distinct group of monogenic forms of 
diabetes characterized by early onset, autosomal dominant inheritance, insulin 
independence, distinct extra- pancreatic features and a lack of association with 
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obesity. MODY can be differentiated from other forms of early onset diabetes 
based on genetic, clinical and associated features (Table 5.1)(165) 
 
 Type 1 
diabetes 
Early  
Type 2 diabetes 
MODY Genetic 
syndromes 
 associated 
with diabetes 
Inheritance Polygenic 
Strong HLA 
association 
 
Polygenic Monogenic, 
Autosomal 
dominant 
Variable 
Commonly-
recessive 
Number of 
parents 
affected 
0 
 
 
 
 
1 or 2 1 0 
Obesity Rare 
 
 
Common Rare Common 
Associated 
features 
Positive anti 
GAD and 
IAA 
antibodies 
Dyslipidaemia, 
acanthosis 
nigricans, 
Polycystic ovaries 
Dyslipidaemia 
Renal cysts 
Short stature 
Pancreatic 
agenesis 
Variable 
extra-
pancreatic 
features 
 
Table 5.1: Differentiation of MODY from other forms of early onset diabetes 
Adapted from: Textbook of Diabetes. Pickup and Williams.Third edition. Chapter 
24 (166). GAD : Glutamic acid decarboxylase.  IAA: Insulin auto antibody  
 
Early onset and high penetrance allowing detailed study of family pedigrees are 
the primary reasons for the success of genetic characterization of MODY. Unlike 
the common type 2 diabetes, MODY results from distinct mutations in genes 
associated with beta cell function. At least 6 different subtypes of MODY have 
been described thus far. MODY 2 is due to a mutation in the glucokinase gene 
while MODY 1(HNF4α), MODY 3 (HNF1α), MODY 4(IPF-1), MODY 5 
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(HNF1β) and MODY 6 (NEUROD1) are due to mutations in transcription 
factors(165;167). Each subtype of MODY is associated with distinct phenotypic 
features that are helpful in clinical characterisation (Table 5.2). Allelic 
heterogeneity is a characteristic feature of MODY and explains the phenotypic 
variation between MODY families. 
 
 
Subtype Gene Prevalence of 
individual 
subtypes within 
MODY in UK (%) 
Protein 
encoded 
Extra pancreatic 
features 
MODY1 HNF4 α 2 
 
 
Transcription 
factor 
 
MODY2 GCK 20 
 
 
Glucokinase  Reduced birth weight 
MODY3 HNF1α 64 Transcription 
factor 
Low renal threshold 
Sensitivity to 
sulfonylureas 
MODY4 IPF-1 1 
 
 
Transcription 
factor 
Pancreatic agenesis in 
homozygotes 
MODY5 HNF1β 1 Transcription 
factor 
Renal cysts, proteinuria 
Uterine and genital 
abnormalities 
MODY6 NEUROD1  0 
 
 
Transcription 
factor 
 
 
 
Table 5.2: The prevalence, protein encoded and extrapancreatic features of 
different MODY subtypes in the UK population.  
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5.2.2 Polygenic type 2 diabetes 
 
 
In contrast to the monogenic forms of diabetes, susceptibility to the more common 
form of type 2 diabetes is thought to be determined by several genes and a greater 
environmental influence(63). Diabetes can occur in individuals exposed to a 
diabetogenic environment even in the absence of genetic susceptibility and 
conversely, can be delayed substantially in those with genetic susceptibility in the 
absence of environmental influences. This complex relationship between genes 
and environment has been a major problem in identification of the causative 
genes. 
 
The genes associated with polygenic type 2 diabetes may be predominantly 
related to beta cell function, insulin resistance or a combination of both. To date, 
research has focused on identifying common variants of genes that are present in 
those with diabetes and in healthy individuals. The presence of these variants 
confers only a small risk to the individual but the effects could be much greater at 
a population level. Frequencies of these variants vary in different ethnic groups 
and  may explain the overall differences in disease susceptibility(168).  
 
 
5.3 Techniques/approaches for genetic studies in type 2 
diabetes 
 
 
Two major approaches have commonly been used in the search for type 2 diabetes 
genes-the candidate gene and the genome wide studies(164;169). In the candidate 
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gene approach, a gene whose physiological function is known and is thought to 
have a role in the pathogenesis of diabetes is selected and then systematically 
searched for sequence variations(164;168). Once the variations have been 
identified, the next step is to establish disease association. Currently, the preferred 
approach for establishing such an association is through population based case-
control studies, in which the frequency of the variant is compared between 
diabetic and non-diabetic groups. Population based case-control studies offer the 
advantage of large analytical power but on the other hand are disadvantaged by 
poor reproducibility, problems of population stratification and relatively large 
numbers needed to detect small effects(164). The PPARG, KCNJ11, TCF2 and 
WFS1 genes are some of those identified using the candidate gene approach.  
 
 An alternative approach to search for type 2 diabetes genes is the genome scan in 
which no prior assumptions are made (hypothesis free)(63;164).Genome scans 
have involved two basic approaches-the traditional linkage and genome-wide 
association (GWA) studies(116;170). Traditional linkage analysis involves 
looking for co-segregation between the disease and microsatellite markers in 
affected pedigrees or looking for linkage with microsatellite markers in affected 
sib pairs. Evidence of linkage with a particular microsatellite marker suggests that 
a disease susceptibility gene is likely to lie in close proximity to the marker. 
Further fine mapping studies are then required to define the exact location and 
identity of the gene. The first three MODY genes, CAPN10 gene and the TCF7L2 
gene are some of the successes using linkage studies(162). Completion of the 
Human Genome Project and the creation of SNP databases such as HapMap, 
listing all the sequence variants across the genome in different populations, now 
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allow us to directly search for polymorphisms associated with disease using case-
control studies. Between 2006 and 2008, large scale association and genome-wide 
association studies identified at least 16 loci with strong associations with 
susceptibility to type 2 diabetes(171-182), as well as confirming associations with 
PPARG and KCNJ11 (Table 5.3). Some of these loci are major susceptibility 
markers and associated with greater effects on disease risk than previously 
identified candidate genes. Identification of susceptibility variants, however, 
represents the initial step in establishing disease association. As the associated 
variants may be in linkage disequilibrium with true disease risk variants, further 
fine mapping and functional studies are needed to understand the role of genetic 
variants in the causation of type 2 diabetes.  
 
  
 
 
Table 5.3: Type 2 diabetes susceptibility genes/loci identified to date using the candidate 
gene, large scale association and genome wide association approaches. 
Gene/Locus Polymorphism Approach Effect (odds ratio) Risk allele Frequency 
PPARG rs 1801282 Candidate  1.14 0.87 
KCNJ11 rs 5215 Candidate 1.14 0.35 
TCF7L2 rs 7901695 Large scale association 1.37 0.31 
FTO rs 8050136 Genome wide association 1.17 0.40 
HHEX/IDE rs 1111875 Genome wide association 1.15 0.65 
SLC30A8 rs13266634 Genome wide association 1.15 0.69 
CDKAL1 rs 10946398 Genome wide association 1.14 0.32 
CDKN2A/2B rs 10811661 Genome wide association 1.20 0.83 
IGF2BP2 rs 4402960 Genome wide association 1.14 0.32 
HNF1β rs 4430796 Candidate/Large scale association 1.10 0.47 
WFS1 rs 10010131 Candidate/Large scale association 1.12 0.60 
JAZF1 rs 864745 Genome wide association 1.10 0.50 
CDC123/CAMK1D rs 12779790 Genome wide association 1.11 0.18 
TSPAN8/LGR5 rs 7961581 Genome wide association 1.09 0.27 
THADA rs 7578597 Genome wide association 1.15 0.90 
ADAMTS9 rs 4607103 Genome wide association 1.09 0.76 
NOTCH2 rs 10923931 Genome wide association 1.13 0.10 
KCNQ1 rs 2237892 Genome wide association 1.29 0.93 
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5.4 Genetic studies in South Asians 
 
 
Epidemiological studies have shown that the prevalence of type 2 diabetes 
amongst South Asians (people of Indian, Pakistani, Bangladeshi and Sri Lankan 
origin) is significantly greater than in many other ethnic groups and is up to four 
times greater than in white European populations(60). This increased 
susceptibility to diabetes is largely determined by environmental factors. Rising 
obesity, sedentary lifestyles, urbanisation and increased life expectancy have all 
been thought to contribute to the excess risk of diabetes in South Asians(18). On 
the other hand there are factors that suggest a possible genetic influence. Diabetes 
in South Asians occurs at a much younger age (5 to 10 years earlier than in white 
Europeans)(59). Distinct phenotypic characteristics such as visceral obesity and 
elevated triglycerides are more common in South Asians, as is familial clustering 
of diabetes(99). Studies comparing South Asians with white Europeans have 
shown that features of insulin resistance are manifest in South Asians as early as 
in infancy(183;184). More recently, studies in South Asian pregnant women have 
shown that nutritional deficiencies in the mother and the intrauterine environment 
influence insulin resistance in new born babies(185). These studies suggest a 
strong gene-environment interaction that indeed begins very early in South 
Asians.  
 
 
5.4.1 Monogenic type2 diabetes 
 
 
Much of our understanding of these disorders is from studies in white Europeans. 
Studies involving south Asians alone are rare and there is a considerable overlap 
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between MODY and ‘common’ type 2 diabetes (which has a very high 
prevalence and high familial clustering in this ethnic group),  making it difficult 
to estimate the true prevalence of MODY in this population. It is, however, 
reasonable to assume that the prevalence of these disorders in South Asians is not 
significantly different to that seen in white Europeans. In a South Indian study, 
the prevalence of MODY amongst those with type 2 diabetes was estimated to be 
around 4.8%(186) . 
 
 In another study the same group reported 7 novel mutations in the HNF1α 
(MODY 3) gene in 9.6% of all south Indian subjects with MODY(187). These 
studies, however, have not been replicated in any other sub group of south 
Asians. Considering that many of the genes involved in MODY are also 
candidate genes for polygenic type 2 diabetes, there is a need for more studies in 
south Asians.  
 
5.4.2 Polygenic type 2 diabetes 
 
 
In comparison with the number of studies in the European populations, genetic 
studies involving south Asians have been few. Most of these have been in the 
south Indian population. Studies involving south Asians have predominantly 
looked at type 2 diabetes susceptibility genes shown to have a strong association 
in other ethnic groups. These include the PPARG gene, PPARGC1A , KCNJ11, 
CAPN10 and TCF7L2 genes(186). Peroxisome proliferator activator receptor 
gamma (PPARG) gene is an important regulator of glucose and lipid metabolism. 
The common Pro12Ala polymorphism of this gene has been shown to be 
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protective against type 2 diabetes in white European populations(188). Studies in 
a south Indian population showed that this polymorphism was present at the same 
frequency in both diabetic and non-diabetic individuals and the presence of this 
polymorphism was not associated with either improved insulin sensitivity or 
decreased risk of type 2 diabetes(189). The Calpain10 gene was the first 
important gene associated with type 2 diabetes to be identified using the linkage 
mapping technique. A haplotype of three important polymorphisms (UCSNP 43, 
-19 and -63) of this gene was originally shown to be associated with increased 
risk of type 2 diabetes in a Mexican –American population(190). Replication of 
this study in other populations, has, however, shown mixed results with much 
lower frequencies of the risk haplotype in other populations(191-193). Studies in 
a south Indian population have shown that, while the haplotype does increase the 
risk of type 2 diabetes, its frequency in the background population is very low 
and its contribution to the risk of type 2 diabetes in this ethnic group is therefore 
likely to be small(194).  
 
The identification of the common variants of the TCF7L2 gene was by far the 
most significant discovery in the genetics of type 2 diabetes(195). First reported 
in Icelandic subjects, intronic variants of this gene were associated with the 
highest risk of susceptibility to diabetes reported to date(196). These associations 
have been replicated in several other populations including south Asians. In the 
two south Asian cohort studies, strong associations were reported with two SNPs 
( rs 7903146, rs12255372)(197;198). In another study involving north Indian 
Sikhs, 9 of the putative susceptibility variants identified in white Europeans by 
GWA were investigated)(199). A strong association with type 2 diabetes was 
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found with 4 of these; PPARG2 (rs 1801282), IGF2BP2 (rs 4402960), FTO (rs 
9939609) and TCF7L2 (rs 10885409).The cohort sizes in this study were small, 
however, and were not adequately powered to detect small effects. It was not 
therefore possible to rule out an effect of the other 5 loci on disease risk. Other 
type 2 diabetes susceptibility genes identified in south Asians include the PGC1 
alpha gene, adiponectin gene, UCP Ectoenzyme Nucleotide Polypeptide 
(ENPP1) gene, uncoupling protein genes (UCP2 and UCP3) and insulin receptor 
substrate (IRS-2) gene which were shown to have modest associations with type 2 
diabetes(198;200;201).  
 
 
5.4.2.1 Genetics of obesity 
 
 
Genome-wide association studies have also been useful in the identification of 
genes associated with obesity-a major risk factor for type 2 diabetes. Common 
variants of the fat mass and obesity associated gene (FTO) were shown to be 
associated with obesity in white European populations(202). Individuals with 
these variants were on average 3 kilograms heavier than those who did not 
possess them. Individuals were also at an increased risk of type 2 diabetes but 
this was secondary to the effects on obesity rather than a direct effect of the 
variants on the pathogenesis of T2D. In a recent study in south Asians, however, 
one polymorphism (FTO rs9939609) was associated with an increased risk of 
type 2 diabetes but this risk was independent of the effect on body mass index 
(203).  
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Another important gene identified in a study in south Asians and white 
Europeans living in the UK was the Melanocortin 4 Receptor (MC4R) gene(66). 
The study found that a variant of MC4R (rs12970134) was associated with 
increased risk of adiposity and insulin resistance. Individuals with the variant of 
this gene had a waist circumference ~2cm greater and insulin resistance (HOMA-
IR) ~10% greater than those who did not have it. As obesity is an independent 
risk factor for type 2 diabetes it is suggested that the MC4R gene may indirectly 
influence the risk of diabetes in individuals possessing the risk allele. These 
findings have also been replicated recently in Khatri Sikhs(204). The increased 
frequency of the risk allele in south Asians has been proposed as an explanation 
for the increased levels of type 2 diabetes in this population.  
 
 
5.4.2.2 Diabetic complications 
 
The predisposition to diabetic complications also varies significantly between 
ethnic groups. In general, the prevalence of diabetic nephropathy and retinopathy 
is higher in south Asians than in Caucasians(79;205). Risk of these 
complications, particularly nephropathy, is thought to be genetically determined. 
As such a search for genetic variants that predispose to these complications is an 
attractive proposition. Several potential genes associated with diabetes 
complications have been identified in other populations but studies in south 
Asians are few. Polymorphisms of the ACE1 gene and aldosterone synthase gene 
(for nephropathy) and the Vascular Endothelial Growth Factor (VEGF) gene (for 
retinopathy) (206-208)are some of the genes studied in south Asians but the 
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findings of these studies have been inconsistent and need verification in larger 
cohorts.  
 
5.5 Clinical significance of genetic studies 
 
Although our knowledge of type 2 diabetes has improved considerably over the 
last few decades, many of the processes involved in the pathogenesis remain 
unknown. Understanding the genetic basis is essential to define the molecular 
pathways involved in disease causation, prediction of disease susceptibility, 
disease prevention, and development of new therapeutic agents. South Asians 
have a disproportionately higher prevalence and earlier onset of diabetes 
(compared with many other ethnic groups) and a strong family history. 
Phenotypic features such as visceral obesity and insulin resistance are also more 
common in this ethnic group and are manifest very early in life thus pointing to a 
genetic predisposition. Despite such obvious differences there is generally a poor 
understanding of the genetics of diabetes in this population. Until now, most of 
the studies involving south Asians are replications of studies in other populations. 
Although these studies have improved our understanding to some extent, there 
are still many limitations. The term ‘South Asians’ includes several different sub 
groups and although they share many cultural and environmental factors, there 
are subtle phenotypic differences and marked genetic heterogeneity between the 
sub groups. The prevalence of diabetes between these sub groups is also 
different(60). Given these differences it would be difficult to generalise the 
results from one sub group to others. Most of the studies in south Asians have 
been in the south Indian population and north Indian Sikhs. Further, the cohort 
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sizes in most of these studies have been small, limiting our ability to detect any 
true associations. Experience from genetic studies in other populations has shown 
that larger cohorts are needed to demonstrate associations with risk variants that 
have the small effect sizes expected for T2D and exclude false positives and false 
negatives. Genetic characterisation of the different sub groups is therefore 
essential to understand these differences and verify true disease associations. 
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Chapter 6 
Common polymorphisms of the PPARG and the 
PPARGC1A genes and the risk of type 2 diabetes in a UK 
resident south Asian population 
  
 
6.1 Introduction 
 
 
The pathogenesis of type 2 diabetes involves defects in insulin secretion and 
insulin action. Although several candidate genes involved in both these 
aspects have been studied, to date few have been reproducibly associated with 
type 2 diabetes. Two of these genes-the KCNJ11 gene (primarily involved in 
regulation of insulin secretion) and the PPARG gene (associated with insulin 
sensitivity)- have generally been accepted to have an effect on the risk of type 
2 diabetes.  
 
6.1.1 The PPAR Gamma gene 
 
 
The Peroxisome Proliferator Activator Receptors (PPARs) belong to a family 
of nuclear receptors involved in lipid and glucose metabolism(209). There are 
three known members of the PPAR family – PPAR α, PPAR γ and PPAR δ. 
PPAR α was the first member of the family to be cloned and is expressed in 
liver, kidney, heart and skeletal muscle(210). PPAR α  is thought to have an 
important role in the regulation of fatty acid oxidation and is a target for the 
fibrate class of drugs(211). PPAR δ is expressed mainly in the brain, adipose 
tissue and skin(212).  
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The functional role of PPAR δ is less well understood although there is some 
evidence to suggest that it may be involved in cholesterol transport in 
macrophages(213;214). PPAR γ is expressed predominantly in adipose tissue 
and plays a critical role in adipogenesis and adipocyte differentiation, factors 
that influence insulin sensitivity (215)(figure 6.1).  
 
 
Figure 6.1: Various metabolic functions of PPAR gamma.  
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The PPAR γ gene (PPARG) is localised to chromosome 3 and encodes two 
distinct proteins, PPARγ1 and PPARγ 2. The PPAR γ2 protein has 28 
additional amino acids and is expressed highly in the adipose tissue(212). 
Transcriptional activity of PPAR γ is dependent on its binding to another 
transcription factor, RXR. The PPAR γ-RXR heterodimer complex then binds 
to a co-activator complex on the DNA binding site and in turn initiates the 
expression of target genes(216). Dominant negative mutations of the PPAR γ 
gene result in the heterodimer complex binding to a co-repressor complex 
resulting in inactivation of gene expression(217;218). PPAR γ is activated by 
both natural and synthetic ligands. Natural ligands for PPAR γ include 
polyunsaturated fatty acids and eicosanoids(219;220) while the common 
synthetic ligands include the thiazolidenedione class of drugs(209). 
 
6.1.2 PGC 1 alpha 
 
 
Peroxisome proliferators activator receptor γ co-activator alpha ( PGC-1α ) is 
an important member of a family of transcription co-activators involved in 
various biological processes(221). It plays a central role in cellular energy 
metabolism and is also thought to regulate the activity of PPAR gamma(222). 
PGC-1α is widely expressed in brown adipose tissue, skeletal muscle, and the 
heart and in low levels in the liver(223). In skeletal muscle, PGC-1α 
expression is associated with an increase in type 1 muscle fibre and increased 
energy expenditure(224). In the liver, PGC-1α expression is increased in 
response to fasting and is thought to promote gluconeogenesis through the 
activation of the phosphoenol pyruvate carboxykinase (PEPCK) 
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pathway(225). In the heart, PGC-1α facilitates oxidative phosphorylation in 
response to fasting(226). PGC-1α is also known to increase the expression of 
insulin-sensitive GLUT4 and indirectly facilitates insulin action(227). The 
role of PGC-1α in energy metabolism makes it an important target for 
therapies related to diabetes and obesity. 
 
 
6.1.3 Polymorphisms of the PPARγ (PPARG) and the PGC-1α 
(PPARGC1A) genes  
 
 
Given the important role for the PPAR in insulin resistance and the 
pathogenesis of type 2 diabetes, both PPARG and PPARGC1A have been 
candidate genes of interest. Both of these have been extensively studied in 
many populations and while there is reasonable evidence to support an 
association between variants of PPARG and diabetes, the evidence is much 
less convincing for PPARGC1A. 
 
Common polymorphism within the amino- terminus of the PPARγ2 protein, 
replacing alanine for proline at codon 12 (Pro12Ala), has been associated 
with protection against the risk of type 2 diabetes(188). The prevalence of 
this polymorphism in white Caucasian populations is thought to be 
approximately 12% but prevalence in other populations may vary(228). 
Although there has been some inconsistency about the role of this 
polymorphism in initial studies it is now widely accepted that the proline 
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allele of the Pro12Ala polymorphism is associated with risk of type 2 
diabetes(229;230)  
 
Two common polymorphisms of PPARGC1A – rs 8192678 (Gly482Ser) and 
rs 3736265 (Thr612Met) - have previously been studied in various ethnic 
groups(231-235). Increased risk of type 2 diabetes with the Ser482 
polymorphism has been reported in some but not all populations. 
Polymorphisms of PPARGC1A have been investigated in the south Indian 
population but not in any other south Asian groups (235). Given the role of 
this gene in energy metabolism and insulin resistance (perceived to be more 
common in south Asians) and its potential influence on the risk of type 2 
diabetes, it merits further investigation in the south Asian population.  
 
Although several candidate genes have been examined for association with 
type 2 diabetes, a majority of these have been linked to beta cell dysfunction. 
Genes associated with insulin resistance/ sensitivity on the other hand are 
rare. Both PPARG and PPARG1A genes have been shown to have an 
important role in energy metabolism and insulin sensitivity and 
polymorphisms of these genes have been shown to be associated with type 2 
diabetes in many different populations. Considering that insulin resistance is 
common in south Asians the possible role these two genes may have in the 
pathogenesis of type 2 diabetes is truly exciting. If such associations did exist 
it would also offer greater opportunities for treatment in this ethnic group 
especially as there are now therapeutic agents that specifically target are 
available.  
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The aim of this study was therefore to investigate the association between 
type 2 diabetes and common variants of the PPARG and PPARGC1A genes in 
the UK resident Punjabi/Mirpuri population. As both these genes share a 
common pathway they have been included in the same chapter. 
 
 
6.2 Methods 
 
6.2.1 Patient selection 
 
Type 2 diabetic subjects were recruited as part of the United Kingdom Asian 
Diabetes Study (UKADS) The UKADS cohort included subjects from a number 
of genetically diverse South Asian subgroups, the largest of which was of Punjabi 
origin. Subjects of Punjabi ancestry (N=831) were therefore selected to create a 
genetically homogeneous cohort for analysis. Ancestry was confirmed over three 
generations using data on family origin and self-reported ethnicity. The majority 
of the selected individuals originated from the Mirpur area of Azad Kashmir, 
Pakistan. Diabetes was defined using the WHO criteria(15). Ethnically-matched 
normoglycaemic control subjects (N = 436) were recruited from the 
Punjabi/Mirpuri populations of Birmingham and Coventry through community 
screening. Normal glucose tolerance was defined as fasting glucose <6mmol/l 
and 2 hr glucose <7.8mmol/l on a 75g OGTT. Where OGTT was not feasible, 
normal glucose tolerance was defined as random blood glucose <7mmol/l. 
Venous blood was collected from each subject after obtaining informed consent 
and genomic DNA extracted using an adaptation of the Nucleon® protocol 
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(Nucleon Biosciences, Coatbridge, UK)(see section 6.2.2).The study was 
approved by the East Birmingham Research and Ethics Committee.  
 
Control subjects were recruited over a period of two years between 2005 and 
2007. As recruitment for control subjects and DNA extraction for diabetes 
subjects was still in progress, Genotyping for PPARGC1A was performed in only 
516 diabetes and 134 control subjects recruited until the end of 2006. A further 
315 diabetes (total 831) and 302 control subjects (total 436) were included in the 
analysis for the Pro12Ala polymorphism of PPARG.  
 
 
6.2.2 DNA extraction 
 
 
Genomic DNA was extracted from 9ml of venous blood collected in an EDTA- 
coated vacutainer. After carefully decanting the blood from the vacutainer into 50 
ml pre-labelled centrifuge tubes, reagent A (Appendix 4) was added to bring up 
the volume to 40ml. Samples were mixed on a rotary mixer at 150rpm for 4 mins 
and then centrifuged at 840xg for 4mins to allow lymphocyte pelleting. The 
pellet was re-suspended in 15ml of reagent A after discarding the supernatant. 
The tubes were centrifuged for another 4 mins at 840xg and supernatant 
discarded. Lymphocyte pellets were stored at -800 C for at least 2 hours before 
DNA was extracted. 
 
After gentle thawing for 20-30 minutes, the lymphocyte pellets were fully 
suspended in 2ml of reagent B (described in Appendix 4) before being transferred 
to a pre-labelled 5ml cryovial. 500µl of sodium perchlorate (5M) (Sigma, 
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Poole,UK) was added and the tube was inverted 10 times to  mix. Ice-cold 
chloroform was added up to a volume of 4.5ml and the tube was inverted to mix 
10 times. The tube was centrifuged at 1310xg for 5 minutes, the upper layer was 
carefully transferred into a fresh 5ml cryovial and brought up to a final volume of 
4.5ml with ice-cold ethanol (100%). The tube was gently inverted 10 times and 
then placed at -20°C for 30mins to facilitate DNA precipitation. The DNA was 
pelleted by centrifuging at 1310xg for 10mins, after which the supernatant was 
removed. The pellet was then washed with 1ml cold 70% ethanol and centrifuged 
for a further 5mins at 1310xg. The supernatant was removed and the pellet left to 
dry at room temperature overnight. The DNA was resuspended in 100µl Tris-
EDTA (TE) buffer (10mM Tris.HCl, 0.1mM EDTA at pH 8.0, Appendix 4) at 
4°C for 2-3 days, before being transferred to a 1.5ml tube for long-term storage at 
-80°C. 
 
6.2.3 Genotyping methods 
 
 
Broadly, two methods of genotyping were used to study the SNPs described in 
this and the following chapters. Genotyping for the PPARGC1A Gly482Ser 
variant was done using the polymerase chain reaction- restriction fragment length 
polymorphism (PCR-RFLP) method. For all subsequent SNPs, Taqman 
genotyping assay supplied by Applied Biosystems (ABI, Warrington, UK.) was 
used. The rationale for this approach was that this would allow me sufficient 
exposure to the fundamental techniques involved in genotyping and familiarize 
myself with the laboratory processes involved in genetic analysis. A further 
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reason was that the PCR-RFLP method would be reasonable given the small 
sample sizes we had collected at the time of analysing the PPARG1A gene.  
 
 
Genotyping method PPARG1A 
 
Forward and reverse primer sequences for PPARGC1A were 5’-TGC TAC CTG 
AGA GAG ACT TTG-3’ and 5’ – CTT TCA TCT TCG CTG TCA TC-3’  
respectively. PCR amplification was undertaken in a 25µl volume containing 
100ng of DNA, 0.5µl of each primer (20mM) (SigmaGenosys, Suffolk ,UK), 
1.25µl of dNTP mix (4mM) (Pharmacia Biotech, Herts,UK), 1µl magnesium 
chloride (50mM), 2.5µl of 10X buffer and 0.25µl of Taq Polymerase 
(5units/µL)(BioLine,London, UK). Following initial incubation at 94oC for 5 
minutes, 30 amplification cycles were carried out with denaturation at 94oC for 
30 secs, annealing at 52oC for 30 secs and extension at 72oC for 30secs, followed 
by a final extension phase at 72oC for 10minutes.  
 
Digestion of the PCR product was done in a 10 µl reaction using 5 µl of the PCR 
product and 1 µl 10 X buffer, 0.5 µl Msp1 enzyme (20,000 units/ml, New 
England Biolabs, U.S.A), 3.5 µl water and incubated at 37 oC for 3 hours. 
Digestion products were subjected to electrophoresis on a 1% agarose gel 
(Geneflow Ltd. Staffordshire, UK) in 1x Tris-Borate EDTA buffer (89mM Tris-
Borate, 2mM EDTA, pH8.3) and visualised under ultraviolet light after staining 
with 0.5 µg/ml ethidium bromide (Promega, Southhampton, UK). The presence 
of the Msp1 restriction site (Glycine 482 allele) resulted in two fragments of 
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366bp and 245 bp and the absence of the restriction site (Serine 482 allele) 
resulted in a single fragment of 611bp. 
 
 
Genotyping of the PPARG  
 
Genotyping of the PPARG Pro12Ala polymorphism was performed using a pre- 
designed Taqman genotype assay supplied by Applied Biosystems (ABI, 
Warrington, UK.) A reaction mix of 775 µl  of water, 750 µl of PCR master mix 
(ABI,Warrington UK) and 75 µl of SNPmix (ABI Warrington,UK) was made up 
and 4µl was aliquoted into each well of a 384 well PCR plate. The reaction was 
started by the addition of 1 microliter of DNA (5ng/µL) to each well. 
Fluorescence was detected on an ABI 7900 prism sequence detection system. 
Genotyping was repeated in approximately 15% of the subjects to estimate error 
rate which was less than 1%. Genotypes were scored using the allelic 
discrimination software supplied by ABI. 
 
 
6.3 Statistical analysis 
 
No sample size estimations were made prior to the commencement of these 
studies. Based on previous reports in other populations it was recognized that 
large cohort sizes would be necessary to detect weak associations (for effect sizes 
<1.6). However, the sample sizes of our cohort were comparable to those 
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previously reported in other south Asian studies and were therefore thought to 
provide a comparison/verification of the findings reported by others.  
 
General characteristics of the diabetic and control groups were compared using 
the Mann-Whitney U test. For both diabetes and control subjects, conformity 
with Hardy-Weinberg equilibrium was verified using a chi square test ( 
significance set at p<0.05) and comparing the observed and expected genotype 
frequencies of homozygotes and heterozygotes. Genotype and allele frequencies 
between the groups were compared using binary logistic regression. Overall 
allele frequencies were used to calculate odds ratios (OR) after adjusting for 
confounders (age, waist circumference, family history of diabetes and gender). 
For each of the SNPs, odds ratios were calculated using additive, dominant and 
recessive models. The relationship between genotype and quantitative phenotypic 
characteristics was analysed using one way ANOVA and a ‘p’ value less than 
0.05 was considered significant. All statistical analysis was performed using 
SPSS16 software (SPSS Inc.,Chicago,U.S.A). 
 
 
6.4 Results 
 
Baseline characteristics of the diabetes and control subjects are summarized in 
tables 6.1 and 6.2.The control subjects genotyped for the PPARGC1A 
polymorphism were significantly older than the diabetes subjects (mean 
difference 1.98 years; p=0.005). In the Pro12Ala cohorts, compared with diabetic 
subjects, control subjects were younger (p=0.005) and had significantly lower 
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systolic blood pressure (p =0.001) and waist circumference (p=0.002). There 
were no significant differences in other phenotypic characteristics between the 
groups. Genotype frequencies for both the SNPs were in Hardy-Weinberg 
equilibrium. The minor allele frequencies for PPARGC1A Gly482Ser were 
similar (0.27 v 0.26) in both diabetic and non-diabetic controls. For PPARG, the 
common/minor allele frequencies of the Pro12Ala polymorphism in the diabetic 
and control subjects were 0.87/0.13 v 0.85/0.16 respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Clinical characteristics of diabetes and control subjects genotyped for 
the PPARGC1A Gly482Ser polymorphism * Data for BMI, waist circumference, 
blood pressure, cholesterol and HbA1c were available for only 42 of the 134 
control subjects. 
 
Diabetic 
subjects 
Control  
subjects 
n 516 134* 
Gender (M/F) 272/244 79/55 
Age at study (years) 55± 12 58± 10 
BMI (kg/m2)  28 ± 4          28 ± 4. 
Waist circumference (cm)      102 ± 10 99± 14 
Systolic blood pressure (mm Hg)       138 ± 20        140 ± 20 
Diastolic blood pressure (mm Hg)   83 ± 11 88± 12 
Total cholesterol (mmol/l) 4.8 ± 1 ND 
HbA1c (%) 8.3 ± 2 ND 
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Diabetic 
subjects 
Control  
subjects 
n 831 436 
Gender (M/F) 450/381 220/216 
Age at study (years) 56.9 ± 12.1 55.0 ± 11.8# 
Age at diagnosis (years) 49.6 ± 11.9 N/A† 
BMI (kg/m2) 28.3 ± 4.7      28.1 ± 4.9* 
Waist circumference (cm)   102.4 ± 10.7 99.8 ± 13.1 *# 
Systolic blood pressure (mm Hg)    140.5 ± 20.9    135.7 ± 20.4 *# 
Diastolic blood pressure (mm Hg) 84.1 ± 11.5 85.1 ± 12.1 
HDL cholesterol (mmol/l) 1.3 ± 0.5 ND 
HbA1c (%) 8.3 ± 1.9 ND 
 
Table 6.2: Clinical characteristics of diabetes and control subjects genotyped for 
PPARG Pro12Ala polymorphism. * BMI, waist circumference and blood 
pressure available in only 252 control subjects.  # Significant difference between 
groups for age (p=0.005), waist circumference ( p=0.002) and Systolic Blood 
pressure (p=0.001). 
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Table 6.3 shows the genotype distribution for both SNPs. This did not differ 
significantly between the diabetic and control groups for either SNP when 
analysed using dominant or recessive models.  
 
 
 
 
Gene/ 
Polymorphism 
Genotype Diabetes 
  N (%) 
Control 
  N (%) 
Odds ratio (95% 
Confidence Intervals 
 
PPARGC1A 
Gly482Ser 
 
 
 
 
 
 
GG 
 
GA 
 
AA 
 
272 (52.7) 
 
212 (41.1) 
 
32  (6.2) 
 
69 (51.5) 
 
59 (44.0) 
 
6   (4.5) 
 
 
OR= 0.580 (0.322 to 
1.046) ; p=0.07* 
Allele frequency 
 
0.73/0.27 0.74/0.26  
 
PPARG 
Pro12Ala  
 
 
 
 
 
 
 
CC 
 
GC 
 
GG 
 
626 (75.5) 
 
190 (22.9) 
 
13   (1.6) 
 
 
316 (73.0) 
 
107 (24.7) 
 
10 (2.3) 
 
 
OR= 0.774 (0.573 
to1.045) ; p=0.095** 
Allele Frequency                      0.87/0.13     0.86/0.14 
 
 
Table 6.3: Genotype frequencies and odd ratios for association with type 2 
diabetes for both SNPs. 
 
*adjusted for age, waist circumference, BMI and family history of diabetes 
** adjusted for age, waist circumference, BMI, family history of diabetes and 
gender 
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The relationship between the quantitative traits (blood pressure, age at diagnosis, 
BMI, waist circumference and cholesterol levels) and genotype was examined for 
both SNPs. No significant association was found for any of these traits and the 
genotypes for either SNP studied (Table 6.4). 
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Genotype Age at  
Diagnosis (yrs) 
BMI 
(kg/m2)  
Waist circumference 
        (cm) 
HDL 
(mmol/L) 
HbA1c 
   (%) 
Pro12Ala 
      CC                       51.2 (12.3)                      28.0 (4.6)                         101 (11.0)                         1.30 (0.5)                   8.3 (1.9) 
 
      CG                      51.7 (11.8)                      28.7 (4.9)                          102 (11.1)                        1.25 (0.3)                   8.0 (1.9) 
 
      GG                      54.7 (10.0)                      27.9 (4.6)                          99.7 (10.4)                       1.30 (0.2)                   7.9(1.6) 
 
Gly482Ser 
       GG                   49.8 (12.4)                       28.4 (4.7)                           101.9 (10.7)                  1.17 (0.2)                     8.4 (2.0) 
 
       GA                   50.6 (11.4)                       28.2 (4.5)                           102.1 (11.4)                  1.21 (0.2)                    8.2 (1.9) 
 
       AA                   51.7 (11.1)                       27.3 (3.7)                           100.5 (9.9)                    1.38 (0.9)                     8.1 (2.0) 
 
               
             Table 6.4 Association between the genotypes of the Pro12Ala and Gly482Ser polymorphisms  
             and the phenotypic   characteristics. 
 
             All values shown are mean (SD) and adjusted for duration of diabetes, gender, family history.
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6.5 Discussion 
 
The role of PPARG in the causation of type 2 diabetes has been the subject of 
investigation given the role of the PPARγ pathway in glucose metabolism(215). 
Initial studies looking for an association of the Pro12Ala polymorphism with type 
2 diabetes were inconsistent and were undermined by small cohort sizes and 
population stratification. The Pro12Ala polymorphism was first reported to be 
associated with type 2 diabetes by Yen et al in 1997(228). Deeb et al, in a study 
in a Finnish population, showed an association between the Pro12Ala 
polymorphism and type 2 diabetes and reported that the Ala allele was associated 
with lower BMI and fasting insulin levels(236). Studies that followed these initial 
publications, however, were less supportive of its role in the causation of type 2 
diabetes. No association was found in German(237), Italian and Polish 
populations(238;239). The inconsistency in the results of earlier studies reflects a 
common problem of lack of appreciation that large cohorts are needed to detect 
true associations with genes that have small effect sizes. It’s therefore likely that 
the early studies that found an association with Pro12Ala did so simply by 
chance, while those that failed to show an association were probably 
underpowered to detect such a small effect. A significant association with type 2 
diabetes and the Pro12Ala polymorphism was, however, confirmed in a study of 
family-based cohorts by Altshuler et al(188). The study reported that the more 
common proline allele was associated with a modest but significant risk of type 2 
diabetes that translated into a population attributable risk of 25%. This 
association has now been confirmed in subsequent genome-wide association 
studies and by meta analysis and PPARG remains one of the important genes 
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associated with type 2 diabetes identified originally using the candidate gene 
approach(188;240).  
 
The association between the Pro12Ala polymorphism and type 2 diabetes has 
been examined in at least two south Asian sub groups. In a study comparing 
south Indians  in Chennai, India with south Indians and white Europeans resident 
in Dallas, U.S.A, Radha et al found no association with the Pro12Ala 
polymorphism and type 2 diabetes in either of the south Indian cohorts(189). The 
frequency of the ‘protective’ alanine allele was comparable in diabetes and non-
diabetes subjects amongst south Indians while in white Europeans, the alanine 
allele was less frequent in the diabetics. The difference in prevalence of  the 
alanine allele has been suggested as a reason for the high prevalence of type 2 
diabetes in certain ethnic groups including south Asians. In a recent study in 
Khatri Sikhs, however, homozygosity for the ‘GG’ (alanine) genotype was 
associated with a significantly decreased risk of  type 2 diabetes(199). The results 
from the present study therefore appear to be in agreement with those reported in 
the south Indian population but at variance with those in the Sikh population even 
though the allele frequencies in our study are similar to those seen in Khatri 
Sikhs, as expected from close genetic relationship. It’s most likely that these 
disparate findings are due to chance. In white populations, meta-analysis suggests 
Pro12Ala has an odds ratio of 1.14, which is a very modest effect size(188). The 
size of the study cohorts in our study and the study of Radha et al were too small 
to conclusively exclude an association of this size, while the findings in Khatri 
Sikhs may have been purely due to chance. Two recent studies by the same 
groups, however, have shown that the Pro12Ala polymorphism in combination 
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with a risk haplotype may indeed be associated with type 2 diabetes risk in South 
Asians. Vimaleswaran et al reported that three variants of the PPARG gene ( -
1279G/A, Pro12Ala and His478His) had no effect on diabetes risk when assessed 
individually(241). However, a specific 2 locus haplotype and 3 locus genotype 
that included Pro12Ala were associated with risk of type 2 diabetes. In a separate 
study, Sanghera et al examined the relationship between type 2 diabetes and 14 
tagging SNPs of PPARG and found a strong disease association with Pro12Ala 
and a haplotype combination of two other SNPs ( rs11715073 and rs 3892175) 
plus Pro12Ala but no association with any of the other SNPs(242). Only the 
Pro12Ala polymorphism was investigated in the present study, but in the light of 
recent evidence, it would be interesting to replicate the findings of Vimaleswaran 
et al and Sanghera et al and this would be a subject for future study. 
 
Unlike the Pro12Ala polymorphism, the association between PPARGC1A 
polymorphisms and type 2 diabetes is less convincing. There are at least three 
variants of the PPARGC1A investigated for association with type 2 diabetes but 
the Gly482Ser variant has been the most frequently studied. A 1.32 fold increase 
in the risk of type 2 diabetes with the serine allele was reported in the Danish 
population(243). Similar association has been found in the Japanese 
population(232). These findings were supported by a meta-analysis of 9 
published studies which showed a modest association (OR=1.1) between the risk 
of diabetes and the serine allele(231). The Gly482Ser variant was also found to 
be associated with a 1.6-fold increased risk of progression from impaired glucose 
tolerance to diabetes in the STOP-NIDDM trial(244). No association between the 
Gly482Ser polymorphism and type 2 diabetes was found in French, Chinese and 
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Pima Indians(245-247), however. In another study in non-diabetic Dutch and 
German populations, no association between diabetes-related traits and 
Gly482Ser was found(234). Only one previous study examined the role of this 
polymorphism in south Asians. Association between three variants of the 
PPARGC1A gene and diabetes was examined in a south Indian population(235). 
No association was found between type 2 diabetes and the Gly482Ser 
polymorphism but the group reported an association with another variant, 
Thr194Thr (OR= 1.68; p=0.0004). In the present study association between the 
Gly482Ser variant and risk of type 2 diabetes was examined. The lack of 
association found in this study is consistent with the findings of the south Indian 
study. Also, the allele frequencies reported in the south Indian study are similar 
to those found in this study (serine allele frequency:  diabetes 0.28 v 0.27 and 
controls 0.28 v 0.26 in south Indian v Mirpuri/Punjabi populations respectively).  
These allele frequencies are lower compared to those reported in the white 
European populations (between 0.5 and 0.7) and may explain the differences in 
association reported between the ethnic groups(244). It must, however, be 
emphasized that even in the European populations, the effect on disease risk was 
weak (OR=1.1 as reported in the meta-analysis). The most likely reason for the 
lack of association in Asian cohorts is that they are too small and are 
underpowered to detect such a weak effect.  
 
In the Mirpuri/Punjabi population studied, there was no association between 
measures of adiposity or any other phenotypic characteristics (blood pressure, 
HDL cholesterol, age at diagnosis) and either the Pro12Ala or the Gly482Ser 
polymorphism. Association between the Pro12Ala polymorphism and phenotypic 
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features, particularly adiposity, has been examined in many studies. Largely, the 
alanine allele of the Pro12Ala polymorphism was associated with lower BMI and 
increased insulin sensitivity in many studies (230;236) but other studies have 
found no such association(237-239) suggesting responses to this variant may vary 
in different ethnic groups. No significant association with phenotypic measures 
has been observed with the Gly482Ser polymorphism(231;234) but the study in 
the south Indian population reported increased adiposity with the PPARGC1A 
Thr394Thr (G>A) polymorphism(248).  
 
The main limitation of this study is the small number of samples in both groups. 
Polymorphisms of both the PPARG and the PPARGC1A gene have been found to 
have small effect sizes (odds ratios of 1.1-1.14) in white populations. Given the 
allele frequencies observed in this study, our sample size would give only 23% 
power to detect an association of similar size for PPARG and only 11% for 
PPARGC1A. To be able to have 80% power to detect similar effects we would 
require over 3500 subjects with diabetes and an equal number of controls ( 
calculated using the  online  Genetic  Power  Calculator)(249). In the absence of 
larger trials it is difficult to establish a role for these polymorphisms in south 
Asians and larger studies are therefore needed. 
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6.6 Conclusion 
 
 
 
There is now substantial evidence to suggest that PPARγ plays an important role 
in glucose and lipid metabolism and metabolic disorders such as polycystic ovary 
syndrome and metabolic syndrome(215;230). The role of PPARγ in glucose 
metabolism is further supported by the fact that PPAR agonists are now an 
established part of type 2 diabetes treatment.  
 
The precise mechanisms by which the PPARG polymorphisms influence 
susceptibility to diabetes, however, are still poorly understood. It is possible that 
these polymorphisms are in linkage disequilibrium with other polymorphisms 
that may control important functions in the insulin pathway. The results of these 
studies also illustrate the difficulties of identifying genes that are strongly 
associated with type 2 diabetes. Polygenic nature of type 2 diabetes and the 
interaction between several genes themselves and the environment make it even 
more difficult to establish a direct causal relationship between the polymorphisms 
and disease. 
 
While the role for the polymorphisms of the PPARGC1A gene is less clear there 
is no doubt that this represents an area of great interest considering the role of 
PGC1α in energy metabolism. Functional studies in this area will hopefully 
unravel some of the missing links in this pathway and enhance our understanding 
of how these loci contribute to disease risk in South Asians. 
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Chapter 7 
Association between Calpain 10 polymorphisms and risk 
of type 2 diabetes in the UK south Asian population. 
 
 
7.1 Introduction 
 
 
Intensive search for type 2 diabetes genes using linkage mapping techniques led 
to the identification of a region on the long arm of chromosome 2 (NIDDM 1) 
that conferred disease risk in a Mexican American population(250). Subsequent 
positional cloning techniques resulted in the discovery of the Calpain 10 
(CAPN10) gene(190). Calpains belong to the superfamily of cysteine proteases 
which are enzymes activated by calcium(251;252). The Calpain heterodimer is 
comprised of a large 80K catalytic subunit and a smaller 30K regulatory sub unit. 
The 80K sub unit contains domains I to IV and 30K contains domains V to VI. 
There are at least 15 members of the Calpain family identified so far. 8 of these 
are typical Calpains , 6 atypical and 1 calpain sub unit(252;253) . Typical 
Calpains are composed of domains I to IV while some of the domains are 
replaced or deleted in the atypical Calpains. Atypical Calpains lack domain IV 
and cannot interact with the regulatory 30K sub unit. In humans, Calpains are 
ubiquitous and are involved in a variety of biological functions including cell 
proliferation, differentiation and intracellular signalling. Disturbances in Calpain 
function have been associated with many disease states(254). Calpains 1 and 2 
are associated with neurodegenerative disorders, Calpain 3 with limb girdle 
muscular dystrophy(255), Calpain 9 with gastric cancer (256) and Calpain 10 
with type 2 diabetes(190). Calpain 10 is an atypical calpain and lacks domain IV 
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but instead has a tandem linking domain 3(252). The gene for Calpain 10 is 
located on chromosome 2 and consists of 15 exons. Calpain 10 is expressed in 
many human tissues including the heart, pancreas, liver and the skeletal muscle, 
suggesting it may be involved in both insulin secretion and action(252;257).  
 
The association between type 2 diabetes and Calpain 10 was first reported in 
Mexican Americans by Horikawa et al(190). Individuals homozygous for the G 
allele at SNP43 who also possessed the specific haplotype 112/121(GRC/GRT) 
of SNP 43,-19 and -63 had a threefold increase in the risk of type 2 diabetes 
compared with individuals lacking this haplotype. These polymorphisms occur in 
the non-coding region of the Calpain 10 gene and are thought to affect calpain 
mRNA levels leading to lower calpain activity, up-regulation of protein kinase C 
and reduced insulin signalling. Subsequent studies in other populations have 
produced conflicting results with association reported in some but not all studies. 
Strong associations were reported by studies in Finnish/Botnians, Polish, African 
American and south Indian populations(194;258-260). No association between 
the original haplotype (112/121) and risk of type 2 diabetes was found in a 
British study(193).Similarly, no association was found in the Oji-Cree(261), 
Samoan(262), Japanese(191), Chinese(263), Finnish(264), Danish and Swedish 
populations(265). In a study in Pima Indians, no association was found between 
SNP43-GG genotype and diabetes but decreased rates of insulin- stimulated 
glucose turnover was reported in GG homozygotes with normal glucose 
tolerance(266). A possible association with another SNP (SNP44) was first 
described in a British population. SNP44 is only a few base pairs away from 
SNP43 and is in perfect linkage disequilibrium with a missense mutation 
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Thr504Ala (SNP110) (193). Independent association between SNP44 and 
diabetes was confirmed in a subsequent meta-analysis(267). In comparison with 
studies in those of European ancestry, the role of Calpain 10 polymorphisms in 
type 2 diabetes has not been extensively investigated in south Asians. In the only 
study involving south Asians, Cassel et al reported a fivefold increased risk of 
type 2 diabetes in individuals with the risk haplotype 112/121 in a south Indian 
population but the findings of this study were limited by the small cohort 
size(194). These findings, however, have not been verified in any other south 
Asian sub group. Given the genetic diversity of Calpain10 and the heterogeneity 
of the south Asian population, it is highly relevant to examine the role of these 
polymorphisms in other south Asian sub groups.  
 
The aim of this study was to examine the association between the two most 
commonly associated Calpain 10 SNPs, SNP43 (rs3792267) and SNP44 
(rs2975760), and type 2 diabetes in a UK-based south Asian population of 
Mirpuri ancestry. 
 
7.2 Methods 
 
7.2.1 Patient selection and Genotyping 
 
 
Details of patient selection and techniques of DNA extraction are described in 
chapter 6. Genotyping for Calpain 10 SNP43 (rs3792267) and SNP44 
(rs2975760) was performed using pre-designed Taqman genotyping assays using 
the protocol supplied by the manufacturer (Applied Biosystems [ABI], 
Warrington, UK.), using the same methods as described in section 6.2.3. 
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Genotyping was repeated in approximately 15% of the subjects to estimate error 
rate, which was less than 1%. Genotypes were scored using the allelic 
discrimination software supplied by ABI. 
 
7.2.2 Statistical analysis  
 
General characteristics of the diabetic and control groups were compared using 
the Mann-Whitney U test. Genotype and allele frequencies were compared 
between the groups using binary logistic regression and overall allele frequencies 
were used to calculate odds ratios (OR). For each polymorphism, association 
analysis was performed assuming additive, dominant and recessive models. The 
common ‘G’ allele was defined as the risk allele for SNP43. For SNP44, the 
minor ‘C’ allele was defined as the risk allele. Quantitative phenotypic 
differences between the genotypes were analysed using oneway ANOVA. A ‘p’ 
value less than 0.05 was considered statistically significant. All statistical 
analysis was done using SPSS 16 software (SPSS Inc.Chicago,U.S.A). 
 
7.3 Results 
 
 
The clinical characteristics of the diabetic and non-diabetic subjects are 
summarized in table 6.2,Chapter 6. Data were limited in control subjects and 
included only age, BMI, waist circumference and blood pressures. For diabetes 
subjects, age at diagnosis, HbA1c and lipid profiles were also available.  
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Allele and genotype frequencies for SNP43 and SNP44 are summarized in Table 
7.1  Overall allele frequencies for both the SNPs were similar in the diabetic and 
control subjects. Allele frequencies (G/C) for SNP43 were 80%/20% in diabetic 
subjects and 77%/23% in control subjects and this was not statistically 
significant. Minor differences in genotype frequencies were observed between 
the groups with proportionately more ‘GG’ homozygotes in the control group 
than in the diabetic group (64% v 56% respectively; p=0.001). Genotype 
frequencies in the control group, however, did not conform to Hardy-Weinberg 
equilibrium (X2 11.1p<0.0001). For SNP 44, the allele frequencies (T/C) were 
82%/18% in diabetic subjects and 80%/20 % in the control subjects respectively 
and this was not significantly different. Genotype frequencies for SNP44 were 
not in Hardy-Weinberg equilibrium in either diabetic (X2 16.4 p<0.0001) or 
control groups ( X2  14.9 p=0.02). 
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                   Table 7.1: Genotype and allele frequencies of SNP43 and SNP44 in subjects with diabetes and 
non diabetic controls. 
SNP Polymorphism                                               Genotype 
                           Diabetes  N(%)                                              Control  N(%)                        
SNP43 (rs 3792267) G/A                        GG     458 (56)                                               278 (64) 
                       GA     311(38)                                                121(28) 
                       AA       49 (6)                                                   35 (8) 
 Allele Frequency      0.80/0.20                                            0.77/0.23 
SNP 44 ( rs2975760) T/C                        TT        561 (68)                                             281(66) 
                       TC        217(26)                                              122(28) 
                       CC         40 (5)                                                 25(6) 
 Allele Frequency        0.82/0.18                                           0.80/0.20 
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To determine the association between the genotypes and diabetes risk, additive, 
dominant and recessive models were used in the analysis. A statistically 
significant association was found between ‘GG’ homozygosity at SNP43 and 
decreased risk of type 2 diabetes using the recessive model OR=0.71(0.562 to 
0.907); p=0.006. This relationship persisted even after adjusting for age, gender 
and family history of diabetes OR=0.732 (0.567 to 0.945); p=0.017. No 
association was found with additive or dominant modelling. In contrast, no 
association was found between the risk allele ‘C’ at SNP44 and diabetes risk in 
any of the three models studied, either before OR=0.83 (0.49 to 1.38); p=0.474 or 
after adjustment for co-variates OR=0.836 (0.482 to 1.452); p=0.525. (Table 7.3).  
 
 
 
 
 
Table 7.3: Association between the polymorphisms of the CAPN 10 gene (SNP43 
and SNP44) and the risk of Type 2 diabetes. 
 
 
Model SNP 43  
(rs3792267) 
OR ( 95% CI ) 
SNP44 
( rs2975760) 
OR ( 95% CI ) 
Additive 0.85 (0.705 to 1.033); p=0.104 0.893 (0.732 to 1.089); p=0.264 
Dominant 1.37( 0.878  to 2.160); p=0.164 0.87(0.68 to 1.12); p=0.295 
Recessive 0.71(0.562 to 0.907); p=0.006 0.83( 0.49 to 1.38); p=0.474 
 
 
 
 
There was no relationship between the quantitative traits (age at diagnosis, blood 
pressure, BMI and waist circumference) and the genotypes for either SNP (Table 
7.4). 
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               Table 7.4: Relationship between the genotypes and the phenotypic characteristics for SNPs 43 and 44 of the Calpain10 gene. 
 
 
 
 
 
  
 
SNP Genotype Age at diagnosis 
(years)  
Mean (SD) 
BMI 
(kg/m2) 
Mean (SD) 
Waist 
 Circumference (cm) 
Mean (SD) 
HbA1c (%) 
Mean (SD) 
Total Cholesterol 
(mmol/L) 
Mean (SD)  
HDL 
(mmol/L) 
Mean (SD) 
SNP43 
rs3792267 
 
GG 
GA 
AA 
51.8 (12.2) 
50.7 (11.9) 
51.3 (12.6) 
 
28.2 (4.8) 
28.1 (4.5) 
28.1 (4.3) 
101.5 (11.8) 
101.9 (10.2) 
100.7 (13.2) 
8.3 (1.9) 
8.2 (1.8) 
8.3 (2.0) 
4.7 (1.1) 
4.8 (1.1) 
4.8 (1.1) 
 
1.3 (0.4) 
1.3 (0.5) 
1.2 (0.4) 
SNP44 
rs2975760 
 
TT 
CT 
CC 
51.3 (11.9) 
51.7 (12.0) 
50.1 (11.6) 
 
 
28.2(4.5) 
28.2(5.0) 
27.7(4.7) 
101.6 (11.3) 
102.1 (11.0) 
  98.9 (12.0) 
8.3 (1.9) 
8.2 (1.8) 
8.2 ( 1.8) 
4.7 (1.1) 
4.7 (1.0) 
4.9  (1.2) 
 
1.3 (0.5) 
1.3 (0.5) 
1.3 (0.3) 
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7.4 Discussion 
 
In this study I examined the association between two variants of the Calpain 10 
gene –SNPs 43 and 44- and the risk of type 2 diabetes in a Punjabi/Mirpuri 
population. A significantly decreased risk of type 2 diabetes was observed with 
homozygosity for the ‘GG’ genotype at SNP43. There was no association between 
SNP44 and the risk of type 2 diabetes. These findings contrast with those of a 
previous study of South Asians which reported a strong association with SNP43 
(with a specific haplotype combination 1112/1121) and the risk of type 2 diabetes 
in a group of South Indian ancestry. Association between increased diabetes risk 
and Calpain 10 polymorphisms has generally been attributed to specific haplotype 
combinations involving three or more SNPs(190;194;259;260;268). In contrast, 
the evidence for association between individual SNPs of the Calpain 10 gene and 
type 2 diabetes is much weaker. Significant association between the individual 
SNP43 and type 2 diabetes was reported in African-Americans(260). In a 
subsequent meta-analysis that included 21 population studies and 5 family studies, 
a significant association was found between SNP43 and the risk of type 2 diabetes 
(269). In the studies showing association with type 2 diabetes and SNP43 (either 
individually or in combination with the risk haplotype), the excess risk was 
attributed to the ‘GG’ genotype. A possible role for SNP43 is further supported by 
quantitative phenotypic studies in various populations. Homozygosity for the ‘G’ 
allele has been associated with decreased insulin sensitivity and preferential 
oxidation of fat, increased first phase insulin secretion and decreased skeletal 
muscle mRNA expression of Calpain10(266). Such support, however, is not 
consistent with several other studies reporting no association with disease risk, 
141 
although several of these may have been limited by small sample size 
(193;264;270).  
 
In the present study, I found that homozygosity for the ‘G’ allele at SNP43 was 
associated with decreased risk of type 2 diabetes in the Punjabi population. These 
findings are clearly at variance with those of earlier studies in different 
populations. Although the 121 haplotype in Japanese(271) and 111/221 haplotype 
combination in Europeans(268) have been associated with reduced risk of disease, 
no previous studies have reported a protective effect of the ‘GG’ genotype. These 
results therefore require careful interpretation. Although the results from this 
study suggest that the ‘GG’ genotype may have a protective effect on the risk of 
type 2 diabetes it is difficult to place too much emphasis on this. On the contrary, 
the statistical effect observed may be due to the departure from Hardy-Weinberg 
equilibrium seen in the control group. The excess of ‘GG’ homozygotes in the 
control group raises the possibility of genotype error. However, this is unlikely as 
genotyping in 15% of the samples was repeated with an error rate of less than 1%. 
Rather a more likely reason for the excess homozygotes would be consistent with 
the increased rates of consanguinity in the Mirpuri population(272), although why 
this is not seen in the diabetic subjects is unclear. Nevertheless this anomaly in 
genotype distribution makes it difficult to interpret our findings. 
 
 Unlike for SNP43, I did not find any association between SNP44 and diabetes in 
this population. As for SNP43, studies looking for association between SNP44 
and type 2 diabetes have been inconsistent in their findings. Independent 
association between the minor  ‘C’ allele at SNP 44 and the risk of type 2 diabetes 
was first reported in the British/ Irish population(193). Replication of these initial 
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findings have reported only modest associations with the ‘CC’ genotype in some 
populations and no association in other populations. Odds ratios reported in 
different studies have also varied significantly, with ratios as high as 2.13 in 
Mexican Americans(190) and only 0.83 in the Finnish population(258). A meta-
analysis of 10 published studies, however, reported a strong association between 
SNP44 and diabetes risk(267). There is considerable variation in the frequency of 
the minor allele ‘C’, ranging from 6% in Mexican Americans, 16% in the 
British/Irish and up to 25% in Botnians(267). The minor allele frequency in the 
present study was 18%, which was similar to that observed in the British 
population (193) and the south Indian population(194). It is interesting that 
despite a reasonably high frequency of the minor allele neither of the South Asian 
studies found any association between this SNP and diabetes risk.  The absence of 
disease association could be due to small sample sizes in both South Asian 
studies, making it difficult to detect weak associations. Additionally, the fact that 
the genotype frequencies in our cohort were not in Hardy-Weinberg equilibrium 
could have also contributed to our inability to demonstrate a disease association 
with SNP44. 
 
Significant associations between CAPN10 genotypes and BMI and waist/hip 
ratios have been reported in earlier studies. ‘GG’ homozygosity was  associated 
with increased BMI and waist/hip ratios in Chinese and Pima Indians (266;273) 
but no association was observed in the Mexican American population(190). In the 
south Indian study, however, the GG genotype was associated with lower BMI 
and waist/hip ratios(194). SNP 44 on the other hand has been associated with 
measures of glucose intolerance (274) and PCOS(275). In this study I did not find 
any association between the phenotypic characteristics of the subjects with either 
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of the SNPs studied. This may be due to environmental differences specific to the 
population studied or may simply reflect the fact that the role of these SNPs is 
modest in influencing phenotypes and our dataset was underpowered to detect 
these small effects. 
 
A distinct feature of Calpain10 studies has been the genetic heterogeneity between 
ethnic populations. Even when associations have been found, the greatest risk was 
associated with specific haplotype combinations rather than with individual SNPs. 
Most studies have compared associations between the original haplotype 
combinations of SNP43, -63 and -19 and diabetes and some have included SNP44 
as well. Two of these four commonly studied SNPs were included in the present 
study as strongest associations were reported with these SNPs both in individual 
studies and in meta-analyses. SNP-63 was found to be strongly associated with 
type 2 diabetes in a south Indian study but the allele frequency for this SNP was 
too small to attribute much significance at a population level. An obvious 
limitation of my study therefore is the difficulty in ascertaining the disease 
association with the haplotype combinations specific to the Punjabi cohort. 
Replication of the remaining SNPs in a larger cohort would certainly help to 
define the susceptibility haplotype for this population.  
 
The role of Calpain10 polymorphisms in the causation of type 2 diabetes remains 
debatable. The huge haplotype diversity between ethnic groups and the 
inconsistency in the results of association studies make it difficult to attribute 
causal effect. Despite evidence from animal and human studies suggesting a 
biological role for Calpains in various metabolic pathways, the exact mechanism 
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by which Calpain 10 influences the pathogenesis of type 2 diabetes remains 
unknown.  
 
 
7.5 Conclusion 
 
 
In the present study I found no association between SNP44 and the risk of 
diabetes while there was a suggestion that the ‘GG’ genotype at SNP43 may be 
associated with decreased risk. This relationship needs further verification in a 
larger independent cohort to determine whether the association is genuine or an 
artefact caused by the excess homozygosity for SNPs 43 and 44 observed in this 
population. 
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Chapter 8 
Common variants of the TCF7L2 gene are associated with 
increased risk of type 2 diabetes mellitus in a UK-based 
South Asian population 
 
 
8.1 Introduction 
 
 
The identification of the TCF7L2 gene marked a significant advancement in the 
search for type 2 diabetes genes(195).  Hitherto, success in the search for genes 
associated with type 2 diabetes was limited and with the exception of the PPARG 
and the KCNJ11 genes, studies involving most other genes were characterized by 
either lack of association or poor reproducibility.  Association between common 
polymorphisms within the transcription factor 7-like 2 (TCF7L2) gene and risk of 
type 2 diabetes was first reported by Grant et al in Icelandic, Danish and 
American cohorts (196). The microsatellite marker (DG10S478) in intron 3 within 
TCF7L2 was associated with a 1.5 to 2 times increased risk of type 2 diabetes and 
a population attributable risk of 21%. The study also reported association with 
SNPs as proxy markers of the microsatellite. The association between the SNPs 
identified by Grant et al and type 2 diabetes  was soon replicated in Amish (276), 
American (277), British (278) and Finnish (279) subjects and subsequently in 
many other populations with almost identical results(280). Two distinct features 
mark the discovery of the TCF7L2 gene polymorphisms. Firstly, the effect sizes 
reported with this gene have been the strongest reported so far compared with any 
other type 2 diabetes susceptibility gene. Secondly, there is consistency of 
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association in almost all ethnic groups studied supporting a role for this gene in 
the causation of type 2 diabetes.  
 
TCF7L2 (also known as TCF4) is a transcription factor and is an important part of 
the Wnt signalling pathway(281). Wnts are glycoproteins involved in the 
regulation of another protein, beta catenin. Their role was first described in 
relation to cancer of the colon(282). Activation of the Wnt receptor is followed by 
a series of reactions that prevent the degradation of beta catenin which then binds 
to a TCF protein in the nucleus to initiate transcription activity(281).  The Wnt 
signalling pathway has been shown to regulate myogenesis and adipogenesis and 
plays a vital role in beta cell proliferation and embryogenesis. The exact 
mechanism by which TCF7L2 increases susceptibility to diabetes is not clear but 
it is thought it may influence insulin secretion through GLP-1 activity(283;284). 
Given that the common variants associated with type 2 diabetes occur in non-
coding regions, it is possible that they may affect the expression of TCF7L2. 
 
Variants of TCF7L2 have been studied in three South Asian cohorts to date; these 
cohorts from western India(197), south India(198) and north Indian Khatri 
Sikhs(199) have all reported strong association with type 2 diabetes. The aim of 
this study was to replicate these findings and investigate the association between 
common polymorphisms within the TCF7L2 gene and type 2 diabetes in a well-
characterized UK-resident South Asian population of Punjabi ancestry, originating 
predominantly from the Mirpur area of Azad Kashmir, Pakistan. 
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8.2 Methods 
 
8.2.1 Patient selection and DNA extraction 
 
Selection of diabetes and non-diabetes control subjects has been described 
previously in chapter 6 (section 6.2.1) and the process of DNA extraction is the 
same as in chapter 6, section 6.2.2 
 
8.2.2 SNP selection and genotyping 
 
 
We genotyped four SNPs (rs7901695, rs7903146, rs11196205 and rs12255372) 
that showed association with type 2 diabetes in the study by Grant et al(196). 
Genotyping was carried out using TaqMan SNP Genotyping assays (as described 
in chapter 6, section 6.2.3) Approximately 20% of the samples were re-genotyped 
to estimate error rate, which was zero for all SNPs. 
 
8.2.3 Statistical analyses 
 
Genotype frequencies for each SNP were checked for Mendelian consistency 
using a X2 goodness-of-fit test. Alleles and genotypes were tested for association 
with type 2 diabetes using logistic regression. Association between the risk alleles 
and disease susceptibility was estimated using a multiplicative model consistent 
with the modelling used by Grant et al in the original report. Association between 
genotypes and continuous variables was tested using one way ANOVA. All 
statistical analyses were done using statistical software SPSS version 16.0 (SPSS 
Inc, Chicago IL). 
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8.3 Results 
 
The clinical characteristics of the diabetes and control subjects are the same as 
those shown in table 6.2, chapter 6.  
 
Genotype frequencies for all SNPs were in Hardy –Weinberg equilibrium except 
rs 12255372 which had an excess of homozygotes for both the major and minor 
alleles in the control group (p=0.02). The minor allele of each SNP was 
significantly associated with type 2 diabetes (Table 8.1) and this association 
persisted even after adjusting for age, gender and family history of diabetes.  
 
The strongest association was seen for the variants rs7903146 and rs11196205, 
with an allelic OR of 1.31 (95% CI 1.11 – 1.56, p=1.96×10-3) and 1.30 (1.11-1.54; 
p=1.1x10-3) respectively. For most variants, the risk of type 2 diabetes mellitus 
among minor allele homozygotes was greater than that among heterozygotes, 
consistent with previous suggestions by Grant et al for a multiplicative model of 
inheritance.  
 
The relationship between phenotypic characteristics and risk variants is 
summarized in table 8.2. No significant association between the phenotypes and 
the risk allele was observed for any of the four SNPs. However, a trend towards 
lower BMI and age at diagnosis was observed with homozygosity for the minor 
alleles for SNPs rs7903146 (TT) and rs7901695 (CC ).   
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SNP Allele 
Diabetic 
subjects 
F 
Control 
subjects 
F 
Genotype 
Diabetic 
subjects 
n (%) 
 
Control 
subjects 
n (%) 
 
Allelic OR 
(95% CI) 
Het OR 
(95% CI) 
Hom OR  
(95% CI) 
 T 0.65 0.71 TT 362 (43.7) 226 (51.7) 1.29 (1.09 - 1.54) 1.31 (1.02 - 1.68) 1.65 (1.12 - 2.44) 
rs7901695   
 
 
CT 355 (42.9) 169 (38.7)    
 C 0.35 0.29 CC 111 (13.4) 42 (9.6) p = 3.60 × 10-3 p = 0.032 p = 0.012 
 C 0.64 0.71 CC 352 (42.5) 222 (51.4) 1.31 (1.11 - 1.56) 1.37 (1.07 - 1.76) 1.66 (1.13 - 2.44) 
rs7903146    CT 360 (43.5) 166 (38.4)    
 T 0.36 0.29 TT 116 (14.0) 44 (10.2) p = 1.96 × 10-3 p = 0.014 p = 9.74 × 10-3 
 G 0.53 0.59 GG 229 (27.5) 159 (36.5) 1.30 (1.11 - 1.54) 1.46 (1.12 - 1.89) 1.65 (1.18 - 2.30) 
rs11196205    CG 417 (50.2) 199 (45.6)    
 C 0.47 0.41 CC 185 (22.3) 78 (17.9) p =1.10 × 10-3 p = 5.29 × 10-3 p = 3.33 × 10-3 
 G 0.68 0.73 GG 382 (46.8) 241 (55.4) 1.26 (1.05 - 1.51) 1.43 (1.11 - 1.83) 1.37 (0.92 - 2.05) 
rs12255372    GT 346 (42.3) 153 (35.2)    
 T 0.32 0.27 TT 89 (10.9) 41 (9.4) p = 3.60 × 10-3 p = 5.23 × 10-3 p = 0.127 
Table 8.1 : Allele frequencies (F) and genotype frequencies for all the four SNPs. Genotype odds ratio calculated compared with 
homozygotes for common allele; het OR= odds ratio for heterozygous genotype, hom OR= odds ratio for homozygous minor allele 
genotype.
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Table 8.2:  Relationship between the phenotypic characteristics and genotypes for all 4 TCF7L2 SNPs
SNP Genotype Age at diagnosis 
(years) 
Mean (SD) 
BMI 
(kg/m2) 
Mean (SD) 
Waist 
 Circumference (cm) 
Mean (SD) 
HbA1c (%) 
Mean (SD) 
Triglycerides 
(mmol/L) 
Mean( SD)  
HDL 
(mmol/L) 
Mean (SD) 
rs 7901695 
 
 
 
 
 
 
 
TT 
 
TC 
 
CC 
51.9 (12.0) 
 
51.3 (12.2) 
 
49.3 (12.6) 
 
28.2 (4.6) 
 
28.3 (4.8) 
 
27.8 (4.5) 
101.8 (11.6) 
 
101.9 (11.0) 
 
100.9(11.4) 
8.3 (1.9) 
 
8.2 (1.7) 
 
8.3 (2.1) 
2.6 (2.3) 
 
2.7 (1.8) 
 
2.6 (1.7) 
 
1.3 (0.5) 
 
1.3 (0.5) 
 
1.2 (0.3) 
rs 7903146 
 
 
 
 
 
 
CC 
 
CT 
 
TT 
51.8 (12.0) 
 
51.6 (12.1) 
 
49.4 (12.6) 
 
 
28.3(4.6) 
 
28 .3(4.8) 
 
27.8 (4.5) 
101.9 (11.0) 
 
101.6 (11.1) 
 
101.0 (11.4) 
8.3 (1.9) 
 
8.3 (1.8) 
 
8.4 (2.1) 
2.6 (2.4) 
 
2.6 (1.8) 
 
2.7 (1.7) 
 
1.3 (0.5) 
 
1.3 (0.5) 
 
1.2 (0.3) 
rs 11196205 
 
 
 
 
 
 
GG 
 
GC 
 
CC 
51.6 (11.0) 
 
51.6 (12.0) 
 
50.6 (12.0) 
28.4 (4.8) 
 
28.2 (4.6) 
 
28.8 (4.5) 
101.8 (11.8) 
 
101.8 (11.2) 
 
101.2 (11.8) 
8.2 (1.9) 
 
8.3 (1.8) 
 
8.4 (2.0) 
2.7 (2.7) 
 
2.5 (1.7) 
 
2.7 (1.7) 
 
1.3 (0.5) 
 
1.3 (0.5) 
 
1.2 (0.3) 
rs 12255372 
 
 
 
GG 
 
GT 
 
TT 
51.9 (12.0) 
 
51.2 (12.0) 
 
50.4 (12.0) 
28.5 (4.7) 
 
28.0 (4.7) 
 
28.7 (4.6) 
102.2 (11.5) 
 
101.4 (11.0) 
 
100.6 (11.6) 
 
8.3 (1.9) 
 
8.3 (1.8) 
 
8.3 (2.1) 
2.6 (2.3) 
 
2.6 (1.8) 
 
2.6  (1.8) 
1.3 (0.5) 
 
1.3  (0.5) 
 
1.3 (0.3 ) 
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8.4 Discussion 
 
The results from the present study provide important confirmation that variants of 
the TCF7L2 gene are strongly associated with type 2 diabetes in populations of 
South Asian origin, with similar effect sizes to those seen in white Caucasian 
populations (196;277-279;285). In the study by Grant et al, two of the four 
variants included in this study (rs 7903146 and rs 12255372) were shown to have 
the strongest associations (OR 1.54 and 1.52 respectively). Studies in British 
(278), Amish (276), Finnish (279) and American populations (277) have also 
confirmed similar associations. Although the frequency of the risk allele ‘T’ for 
SNP rs7903146   was lower in the Finnish population, the overall effect size was 
comparable to other studies (279). Some of the only exceptions are in Pima 
Indians where the risk allele frequencies were surprisingly low (0.08 and 0.01 for 
rs 7903146 and rs 12255372 respectively)(286) and in the Saudi population where 
no association was found(287).The relationship between the variants of TCF7L2 
and type 2 diabetes was investigated previously in three South Asian cohorts. In a 
South Asian cohort from Western India, Chandak et al reported association with 
three variants, with the strongest association with the rs12255372 variant (197). 
Bodhini et al studied a south Indian population and reported similar results(198). 
Replication of four of the six original SNPs described by Grant et al in Khatri 
Sikhs by Sanghera et al found associations with all four variants, but the strongest 
association was with the variant rs10885409 (199). This is different to the 
findings of our study in which the strongest associations were seen with 
rs7903146 and rs11196205. The fact that different variants show strongest 
associations in different South Asian subgroups would suggest that the 
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contribution of these risk variants in different populations is different or, more 
likely, that none of the variants are true susceptibility determinants but are 
markers of risk alleles elsewhere in the region of the TCF7L2 gene. Comparison 
of the odds ratios of the homozygous and heterozygous genotypes suggested our 
data were consistent with the multiplicative model proposed by Grant et al. 
Although our data also fits an additive model the small numbers of our cohort 
limit our ability to distinguish the true model of inheritance.  
 
Allele frequencies for rs7903146 in our Punjabi population were similar to those 
reported in earlier South Asian studies, whereas the minor allele of rs12255372 
appeared to be slightly more common in our cohort (32% in diabetes and 27% 
non-diabetes subjects) than in the south Indian and western Indian cohorts (23% 
and 19% respectively in the study by Bodhini et al, 30% and 22% respectively in 
the study by Chandak et al) but less than in Khatri Sikhs (37 % and 33% 
respectively).However, as the genotype frequencies for rs12255372 were not in 
Hardy-Weinberg equilibrium in our control group, it was not possible to 
accurately establish the effect size of this SNP.  To establish if the minor 
departure from Hardy-Weinberg equilibrium was due to an error in genotyping, 
all samples were re-genotyped for rs12255372 using the same technique but with 
fresh reagents. Furthermore all minor allele homozygotes in the control group 
were genotyped by RFLP, using primers designed with the web-based tool SNP 
Cutter (288) and the enzyme Tsp509 ( Note: This part of the analysis was 
performed by Dr. S Rees, Research Scientist in our group) . Neither method 
revealed any inconsistencies with the initial genotyping. It seems likely, therefore, 
that the departure from Hardy-Weinberg equilibrium is purely due to chance 
sampling.  
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Phenotypic characteristics associated with the risk alleles have been examined in 
previous studies. Although there have been reported associations with BMI and 
waist circumference, these have been inconsistent (196-198;286). In this cohort, a 
trend towards lower BMI was observed with the homozygous genotype of the risk 
allele for rs7901695 and rs7903146 variants but this was not statistically 
significant. There was also a borderline association between age at diagnosis and 
homozygous genotypes of the risk allele for variants rs7901695 and rs7903146. 
These results are different to the findings of Chandak et al and Bodhini et al who 
did not find any association between BMI or waist hip ratios and the risk variants 
(197;198) but consistent with the findings of Grant et al (196) and indicate that 
the TCF7L2 variants may increase the risk of diabetes independently of BMI and 
the carriers of the risk alleles may be more likely to develop diabetes early. Both 
Chandak et al and Bodhini et al reported associations with increased fasting and 2 
hour blood glucose values and the risk allele ‘T’ at rs 12255372(197;198). As 
neither fasting nor 2 hour glucose values were measured in this cohort, this 
relationship could not be verified. 
 
The identification of the TCF7L2 variants represents a major milestone in the 
search for type 2 diabetes genes(289). The fact that these associations have been 
replicated in several ethnic groups with similar effect size suggests these 
polymorphisms play an important role in the pathogenesis of type 2 diabetes. This 
assumption is further supported by data from the Diabetes Prevention Program 
showing that individuals who possess the risk variants of  TCF7L2 were more 
likely to progress from impaired glucose tolerance to  diabetes.(290) Over 
expression of TCF7L2 has also been associated with decreased glucose-stimulated 
insulin secretion, suggesting it may play a role in pancreatic insulin response. 
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(283). There is some evidence to suggest that TCF7L2 variants directly affect 
GLP-1 activity(284;291;292). However, other studies have shown that GLP-1 
levels are unaffected in carriers of TCF7L2 risk alleles(293). Rather it is more 
likely that these variants may affect GLP-1-stimulated insulin secretion. More 
functional studies are clearly needed to understand the pathways by which the risk 
variants of TCF7L2 influence insulin secretion. 
 
 
8.5 Conclusion 
 
 
 In conclusion, the results of this study add to the rapidly expanding body of 
evidence that implicates TCF7L2 as an important risk factor for type 2 diabetes in 
multiple ethnic groups. 
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Chapter 9 
Summary, criticisms and future research 
 
 
9.1 Introduction 
 
 
There is growing evidence from clinical trials to suggest that intensive risk factor 
management is essential to minimize the consequences of diabetes and its 
complications. Implementing the findings of these trials, especially in an 
ethnically diverse population with differing cultural, religious and economic 
needs, is particularly challenging. Integrated models of health care may be able to 
overcome some of these difficulties. The United Kingdom Asian Diabetes Study 
was set up to investigate if a culturally sensitive enhanced care package tailored to 
the needs of the South Asian population would improve the risk factors and 
eventually outcomes in individuals with diabetes. Although the main objective of 
the trial was to evaluate the effectiveness of the integrated care package, the scope 
of such a large study obviously extends beyond that. In this thesis I have 
presented a comparison of cardiovascular risk factors between South Asian and 
white European ethnic groups, the outcomes after 2 years of intervention in the 
former population and investigated the role of several common genetic 
polymorphisms in determining the risk of diabetes in a South Asian cohort of 
Punjabi ancestry. 
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9.2 Ethnic comparison of risk factors at baseline 
 
 
The contribution of ethnicity to overall cardiovascular risk remains a contentious 
issue. Data from several groups suggest that traditional risk factors alone do not 
explain the excess cardiovascular morbidity and mortality in South Asians while 
others suggest that the increased susceptibility is due to the excess burden of 
known risk factors. The data presented in chapter 3 suggests that while there are 
significant differences in risk profiles, the effect of ethnicity itself appears to be 
small. Interestingly, the most notable effect was on HbA1c. As HbA1c can be 
modified by several factors, it is difficult to draw any firm conclusions from these 
results. Nevertheless, the fact that it remained significant despite adjustments for 
all confounders (including treatment and duration of diabetes) is interesting. 
Difficulties in achieving tight glycaemic control in South Asians has been 
reported in earlier studies and the precise reasons for this need further attention. 
Another important observation of this study is that for any age group above the 
age of 45, the predicted risk of cardiovascular disease is significantly higher in 
South Asians than in white Europeans. Other groups have also reported similar 
results, suggesting that South Asians have a greater propensity for cardiovascular 
disease at a younger age. Whether interventions in South Asians should therefore 
start at an earlier age is worth consideration. A major criticism of this study would 
be that it is observational and therefore would limit our ability to draw definite 
conclusions. Also, it could be argued that the white Europeans who chose to 
participate in the study were more motivated and may not be entirely 
representative of the background population. Despite these limitations the findings 
of this study are highly relevant and highlight the disparities in disease risk and its 
management between the ethnic groups.  
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9.3 Enhanced care intervention 
 
 
A key feature of this thesis is the outcomes of the two year enhanced care 
intervention. The results of this study are presented in chapter 4. The definitive 
UKAD study involved a larger cohort and had a longer follow-up period than in 
the pilot study. Despite the additional resources, the intervention failed to 
demonstrate additional benefits in the enhanced care group. The obvious question 
is why did the intervention not have the expected effect? The lack of success of 
the UKADS intervention is likely to be due to several rather than a single factor. It 
is also likely that there was some degree of interaction between these factors. 
Firstly, the intervention focussed primarily on the improvement in major risk 
factors and consequently, relied on adherence to treatment protocols. Although 
strict treatment algorithms were provided, implementation of these algorithms and 
appropriate initiation and titration of treatments depended to a large extent on 
health professional involvement. There were no direct measures of protocol 
adherence but the fact that only a small percentage of patients achieved the study 
targets suggests that the adherence to treatment protocol was poor. Secondly, there 
were many other components of the intervention that were difficult to measure. 
All patients received educational input and access to link workers was supposed to 
increase compliance. However, these components were not structured and may 
therefore have failed to deliver the desired results. Further, in a complex 
intervention many of these factors interact with each other making it difficult to 
ascertain the benefits of these components individually. Thirdly, there was a 
significant impact of the secular changes in UK primary care on the outcomes of 
the study. The introduction of the QOF initiative changed the prescribing habits 
and the focus of general practitioners resulting in improved care to diabetes 
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patients. This was evident from the proportion of people achieving the targets for 
blood pressure and cholesterol as set out in the QOF initiative. As the patients in 
the intervention, as well as those in the control group, benefited from this 
initiative, the effect of intervention itself was diluted. Finally, it is likely that some 
of the components of the intervention, such as education and lifestyle changes, 
may take a longer time to have an effect. Perhaps a longer period of follow-up 
rather than the two years is required to detect the benefits from these 
interventions.  
 
 
Despite the seemingly disappointing results there were some key messages from 
the study. Recruitment and participation of South Asians in clinical trials is 
generally considered difficult. The UKADS, however, showed that by engaging 
with the community using culturally sensitive measures it is possible to recruit 
and retain South Asians in clinical trials. During the course of the study, a greater 
proportion of patients in the intervention achieved the blood pressure and HbA1c 
targets and the prescriptions of ACE/ARBs and statins increased significantly. 
These findings suggest that even in this ‘difficult to treat’ population it is possible 
to achieve improvement in risk factors using strict treatment protocols and 
involvement of the health care professionals. The study also showed that there are 
huge variations in general practice and initiatives such as QOF are highly relevant 
in reducing some of these inequalities. 
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9.4 Genetic characterisation 
 
 
Another important part of my thesis is the genetic characterisation of the South 
Asian population with regard to assessing the role of common polymorphisms of 
the type 2 diabetes susceptibility genes. Although South Asians have one of the 
highest rates of type 2 diabetes, genetic studies in this population have until now 
been sparse. Further, considerable genetic heterogeneity within this population 
makes it difficult to generalize the observations made in specific ethnic sub 
groups. In chapters 6, 7 and 8 of my thesis I have presented the results of the 
genetic replication studies in this UK South Asian population for common 
polymorphisms of some of the type 2 diabetes susceptibility genes previously 
identified in white European populations. These include the PPARG, PPARGC1A, 
CAPN10 and TCF7L2 genes. Interestingly, a positive association with 
susceptibility to type 2 diabetes was found only with the polymorphisms of the 
TCF7L2 gene, while no clear conclusions could be drawn about the other genes.  
 
Two important conclusions can be drawn from the results of these studies. Firstly, 
genetics of type 2 diabetes is complex and involves the interaction of several 
genes with environment. The prevalence of these genetic variants and the 
haplotype combinations varies significantly between people of different 
ethnicities and the risk of disease can be further modified by the degree of 
environmental exposure. Understanding the contribution of the individual gene to 
the overall risk of type 2 diabetes can therefore prove to be difficult. Secondly, 
most susceptibility genes have only a modest effect on disease risk. The ability to 
detect true associations is therefore greatly limited if the cohort size is small. 
Smaller cohorts have been shown to yield false positive results or fail to show an 
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association. A more successful approach would be to study large populations 
and/or identify a gene that has a very large effect size, but such genes are unlikely 
to be found for type 2 diabetes.  
 
An obvious criticism of the studies presented in this thesis therefore is that the 
cohort sizes were too small to detect any true associations. The sample sizes 
included in the genetic analysis were small and in particular the number of non 
diabetic control subjects was low. Small cohort sizes have been reported to yield 
false positive and false negative results and the sizes of our cohorts had to be 
taken into account while interpreting the results of these studies. Based on the 
results of all the studies reported in this thesis, we estimate that to detect a true 
association with our cohort sizes we will need to study polymorphisms with an 
effect size equal to greater than 1.6. At the time of writing this thesis the 
recruitment of South Asians with type 2 diabetes and also non-diabetic controls 
was in progress. Completion of this project should allow replication of the studies 
in larger cohorts. Another criticism is that the control samples used in my studies 
were recruited predominantly from the community and as such in some subjects 
only random and fasting blood sugars were used to define ‘normal glucose 
tolerance’. Given the high prevalence of diabetes in this community, it is likely 
that a proportion of these subjects would have varying degrees of impaired 
glycaemia leading to inconclusive results. Non-availability of additional data 
(such as biochemistry and anthropometric data) in a proportion of subjects also 
limited the ability to detect associations between genetic variants and phenotypic 
characteristics. Similarly none of the studies had data on physical activity or diet 
and therefore it was not possible to adjust for these effects when examining the 
relationship between the SNPs and the genotypes. A further problem encountered 
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during the study was the deviation of genotype distribution from that expected 
under Hardy-Weinberg equilibrium. This had an impact on my ability to detect 
genotypic associations with disease by distorting the observed genotype 
frequencies in one or both study groups. It is unclear why these deviations 
occurred, although repeat genotyping showed that they were unlikely to be due to 
genotyping errors. It is possible that consanguinity in the Mirpuri population 
could explain the greater than expected degree of homozygosity at some loci, 
although we would not expect the rate of first-cousin marriages to differ between 
the diabetic and control groups. As such, this is not a satisfactory explanation for 
the loci that deviated from Mendelian consistency in the control group only. 
Despite these limitations the results of these studies provide initial insights into 
the genetic susceptibility of a population previously not well studied. 
 
 
9.5 Recommendations for future work 
 
 
Health care delivery to people of South Asian ethnicity remains a considerable 
problem. The results from the UKAD study suggest that while some progress has 
been made in this area there are still considerable challenges. Like most studies 
there are several questions that remain to be answered.  Both the pilot study and 
the definitive study highlighted the difficulties in achieving tight glycaemic 
control. The reasons for this need to be fully understood and barriers to insulin 
therapy need to be explored. A key factor of type 2 diabetes management is the 
health professional-patient interaction. The UKADS results suggest that better 
outcomes can be achieved with greater health professional involvement but 
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whether such results can be sustained in the long term needs to be investigated. 
Similarly other models of integrated health care with increased focus on patient 
education can be developed based on the UKADS experience.  
 
Although our understanding of the role of genetics in type 2 diabetes has 
improved significantly in recent years, there are still major challenges to 
overcome in our understanding of the genetic basis of type 2 diabetes. Genetic 
studies looking for associations have largely used diabetes as a dichotomous 
variable. Such an approach may have limitations particularly as some of those 
classified as ‘normal’ may go on to develop diabetes at a future time. The genetics 
studies in subjects in the Diabetes Prevention Program and the Diabetes 
Epidemiology: collaborative analysis of diagnostic criterion in Europe 
(DECODE) study have looked at progressive degrees of dysglycaemia (Normal 
glucose tolerance, Impaired Glucose tolerance and Diabetes) and such an 
approach could be considered in future studies.  
 
Despite the high prevalence of diabetes, the scarcity of genetic studies in South 
Asians is disappointing. Establishing genetic resources involving larger well-
characterised South Asian cohorts is essential to understanding the differences 
between ethnic groups in pathogenesis and disease susceptibility. This could lead 
to the development of new therapies to tackle the disease more effectively in this 
ethnic group. 
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Appendix 4 
All chemicals mentioned in this appendix come from Sigma Aldrich (Poole, UK), 
unless otherwise stated. 
 
A1.1. DNA extraction reagents 
Reagent A: 
10mM  Tris.HCl (pH 8.0) 
320mM Sucrose 
5mM  MgCl2 
1%  Triton X-100 
Made up in distilled water and stored at 4°C. 
 
Reagent B: 
400mM Tris.HCl (pH 8.0) 
60mM  EDTA 
150mM NaCl 
1%  sodium dodecyl sulphate (SDS) 
The above solutions were diluted in distilled water and stored at room 
temperature. 
 
TE buffer: 
10mM   Tris.HCl (pH 8.0) 
0.1mM  EDTA 
The above solutions were diluted in distilled water, autoclaved and stored at room 
temperature. 
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